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Abstract 
Coronary heart disease is a major cause of morbidity and mortality worldwide. 
Percutaneous coronary intervention (PCI) has become the most widely used 
method of coronary artery revascularisation. The use of stents to hold open 
atherosclerosis induced arterial narrowing has significantly reduced elastic recoil 
and acute vessel occlusion following balloon angioplasty. However, bare metal 
stents have been associated with in-stent restenosis attributed to vascular 
smooth muscle cell (VSMC) hyperplasia and excessive neointimal formation. The 
resultant luminal renarrowing may manifest clinically with the return of 
symptoms such as chest pain or shortness of breath. The development of drug 
eluting stents has significantly reduced the incidence of in-stent restenosis (ISR). 
Unfortunately the antiproliferative medications used not only inhibit VSMC 
proliferation but also re-endothelialisation of the stented vessel. In addition, the 
drug impregnated polymer coating has been associated with a chronic 
inflammatory response within the vessel wall predisposing patients to stent 
thrombosis. Thus the identification of novel therapies which promote vessel 
healing without excessive proliferative or inflammatory response may improve 
long term outcome and reduce the need for repeated revascularisation.  
MicroRNAs (miRs) are short (18-25 nucleotide) non-coding RNAs acting to 
regulate gene expression. By binding to the 3’untranslated region of mRNA they 
act to fine tune gene expression either by mRNA degradation or translational 
repression. Originally identified in coordinating tissue development microRNAs 
have also been shown to play important roles coordinating the inflammatory 
response and in numerous cardiovascular diseases. MiR-21 has been identified in 
human atherosclerotic plaques, arteriosclerosis obliterans and abdominal aortic 
aneurysms. In addition, its up regulation has been documented in preclinical 
models of vascular injury. 
This study sought to identify the role of miR-21 in the development of ISR. 
Utilising a small animal model of stenting and in vitro techniques, we sought to 
investigate its influence upon VSMC and immune cell response following 
stenting.  
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The refinement of a murine stenting model within the Baker laboratory and the 
electrochemical dissolution of the metal stent from within harvested vascular 
tissues significantly improved the ability to perform detailed histological 
analysis. In addition, identification of miRNAs using in situ hybridisation was 
achieved for the first time within stented tissue.  
Neointimal formation and ISR was significantly reduced in mice in which miR-21 
had been genetically deleted. In addition, neointimal composition was found to 
be altered in miR-21 KO mice with reductions in VSMC and elastin content 
demonstrated. Importantly, no difference in re-endothelialisation was observed. 
In vitro analysis demonstrated that VSMCs from miR-21 KO mice had both 
reduced proliferative and migratory capacity following platelet derived growth 
factor stimulation. Molecular analysis revealed that these differences may, at 
least in part, be due to de-repression of programmed cell death 4 (PDCD4). 
PDCD4 is a known miR-21 target within VSMCs implicated in the suppression of 
proliferation and promotion of apoptosis. Unfortunately, initial attempts at 
antimiR mediated knockdown of miR-21 in vivo, failed to produce a similar 
change in the suppression of ISR.  
Furthermore, a significant alteration in macrophage polarisation state within the 
neointima of miR-21 WT and KO mice was noted. Immunohistochemical staining 
revealed a preponderance of anti-inflammatory M2 macrophages in KO mice. 
Analysis of bone marrow derived macrophages from miR-21 KO mice 
demonstrated an increased level of the peroxisome proliferation activating 
receptor-γ (PPARγ) which facilitates M2 polarisation. Importantly, significant 
alterations in numerous pro-inflammatory cytokines, which also have mitogenic 
effects, were also found following genetic deletion of miR-21.  
In Summary, this is the first study to look at miRs in the development of ISR. 
MiR-21 plays an important role in the development of ISR by influencing the 
proliferative response of VSMCs and modulating the immune response following 
stent deployment. Further attempts to modulate miR-21 expression following PCI 
may reduce ISR and the need for repeat revascularisation while also reducing the 
risk of stent thrombosis. 
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1 Introduction. 
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1.1 Global burden of Cardiovascular Disease 
1.1.1 Epidemiology 
Cardiovascular disease (CVD) is leading cause of death worldwide, responsible 
for the deaths of over 17 million people per year. It is expected that by 2030 
over 23 million deaths per year will be attributable to cardiovascular disease, an 
increase of over one third (Wong, 2014). In addition, over the last decade a 
global shift in total burden of coronary heart disease away from high-income 
western societies towards middle- and low-income countries has been observed 
(Wong, 2014) 
Coronary heart disease (CHD) and cerebrovascular disease account for the 
majority of deaths due to CVD; approximately 45% and 35% respectively (Wong, 
2014). Other diseases contributing to total cardiovascular mortality figures 
include valvular heart disease, non-ischaemic cardiomyopathy, endocarditis, 
myocarditis, channelopathies, congenital heart disease, peripheral vascular 
disease, aortic aneurysms, subarachnoid and intracerebral haemorrhage.  
Throughout the UK, deaths due to cardiovascular disease fell by over 40% 
between 2000 and 2010, for both men and women (Nichols et al., 2014). Two 
common clinical presentations of coronary heart disease are acute myocardial 
infarction and angina. The most recent available CHD data for Scotland show 
that across all ages the reported incidence of acute myocardial infarction was 
154 and 66 per 100,000 population, for men and women respectively (BHF, 
2014). Additionally the incidence of angina was 48.6 and 37.7 per 100,000 
population, for men and women respectively (BHF, 2014). 
Despite improvements in morbidity and mortality, CHD continues to place a 
major burden on health at both an individual and societal level. The cost to the 
NHS of CHD alone is estimated to be £1.8 billion per year with an equal split in 
spending between primary and secondary care (BHF, 2014). Coronary heart 
disease is also thought to cost the UK economy a further £3 billion per year in 
loss of productivity and on top of that a further £1.7 billion is lost in informal 
care of those with coronary heart disease (BHF, 2014). 
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1.2 Risk Factors for Coronary Disease 
Current understanding of the causes of coronary heart disease is derived from 
large epidemiological studies commenced over 50 years ago. Seen by many as 
the first important epidemiological study into cardiovascular disease the 
Framingham Heart Study was initiated in the middle of the 20th century by Dr 
Thomas R Dawber (Wong and Levy, 2013). Funded by the National Heart Institute 
its goal was to understand the growing burden of cardiovascular disease 
observed in the USA within the early 20th century (Wong and Levy, 2013). 
Recruiting over 5200 participants from the Framingham District in Massachusetts, 
these participants aged between 30 and 62 year old were followed on a biannual 
basis with data collected by history, examination and laboratory analysis (Kannel 
et al., 1961). After 6 years follow up Kannel et al described several “Factors of 
Risk” associated with the development of coronary heart disease including male 
gender, increasing age, elevated cholesterol and hypertension (Kannel et al., 
1961). Later observations from the Framingham study also documented that 
those with diabetes had a two to three fold increased risk of developing 
ischaemic heart disease (Kannel and McGee, 1979). Interestingly, determining an 
association with smoking proved more difficult, requiring the pooling of data 
with that of the Albany Cardiovascular Health Centre (Doyle et al., 1962). Other 
large epidemiological data sets have confirmed the above findings from the 
Framingham study (Stamler et al., 1986).  
The INTERHEART study was undertaken to determine whether the traditional risk 
factors previously identified in western Caucasian populations were applicable to 
other ethnic populations across the world at the beginning of the 21st century 
(Yusuf et al., 2004). This case-control study involving almost 30,000 people 
across 52 countries identified 9 modifiable risk factors associated with 
myocardial infarction including: smoking, an abnormal lipid profile, diabetes 
mellitus, abdominal obesity, psychological stress, low fruit and vegetable 
consumption, regular alcohol intake and low levels of physical exercise (Yusuf et 
al., 2004). Taken together these risk factors were found to account for around 
90% of the risk of developing an acute myocardial infarction (Yusuf et al., 2004).  
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1.3 Arterial wall structure  
Arteries are composed of three major components: endothelial cells (EC), VSMCs  
and extracellular matrix (ECM). ECM is composed of collagen, elastin and 
glycosaminoglycans (GAGs) (Stevens, 1999). These components are arranged in 
three distinct layers forming concentric circles. The layer adjacent to the vessel 
lumen is the intima (tunica intima) comprised of a single layer of endothelial 
cells resting upon a basement membrane. Immediately underlying this basement 
membrane is a fenestrated layer of ECM called the internal elastic lamina (IEL). 
This represents the inner most layer of the vessel media (tunica media). The 
media is comprised of layers of VSMCs and elastic fibres. A further layer of 
connective tissue called the external elastic lamina (EEL) demarcates the outer 
edge of the media (Stevens, 1999). The adventitial layer (tunica adventitia) 
surrounds the media and is comprised of connective tissue within which nerve 
fibres and network of small blood vessels called the vaso vasorum are located. 
The vaso vasorum supplies oxygen and other nutrients to the adventitia and 
outer portion of the media while the inner portion of the media and intima 
receive nutrients from the luminal blood by the process of diffusion (Stevens, 
1999).  
1.4 Atherosclerosis 
Atherosclerosis is a chronic inflammatory condition characterised by the 
deposition of lipids and inflammatory mediators within the wall of affected large 
and medium sized arteries (Ross, 1999). Over time these deposits undergo 
dynamic changes resulting in vessel fibrosis and calcification. Atherosclerotic 
lesions occur at multiple sites along the arterial tree being particularly common 
in the coronary arteries as well as the aorta, carotid, renal and iliac arteries. 
They demonstrate preponderance for sites exposed to non-laminar blood flow 
and low sheer stress such as the inner curves of arterial bends, branch points 
and bifurcations (Ross, 1999).  
Several large histological studies have systematically characterised different 
atherosclerotic lesions leading the American Heart Association (AHA) to produce 
a histological classification system. Last updated in 2000 this classification 
system is significantly simplified from earlier versions, (Figure 1-1 ;(Stary, 2000). 
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In particular it was noted that the morphological changes do not necessarily 
follow a well defined sequence as suggested in previous versions. The AHA 
classification acknowledges the heterogeneity of lesions, the non-linear 
progression of lesions through different histological sequences and the dynamic 
remodelling processes that occur within individual lesions after they become 
atheromatous plaques (type IV lesions). The caps of type IV lesions may thicken 
with layers of VSMCs and ECM overlying the lipid pools within the necrotic core 
(type V lesions) or become thinned and erode. Alternatively, the necrotic cores 
may undergo calcification or fibrosis giving rise to type VII and VIII lesions, 
respectively.  
 
 
Figure 1-1. American Heart Association Classification of Atherosclerotic Lesion 
Development and Evolution. Reproduced with permission from Herbert C. Stary Arterioscler 
Thromb Vasc Biol. 2000;20:1177-1178. Copyright American Heart Association. 
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1.4.1 Lesion Development 
Endothelial dysfunction, as determined by loss of endothelial-dependent 
vasodilation, due to the relative reduction in nitric oxide (NO) and an abundance 
of reactive oxygen species (ROS) such as superoxide anion, predates 
atherosclerosis development in healthy individuals in the presence of traditional 
risk factors such as smoking, hypertension and hypercholesterolaemia (Pagano et 
al., 1995, Forstermann et al., 1994, Celermajer et al., 1994). In addition to, and 
as a result of endothelial dysfunction low density lipoprotein (LDL) cholesterol is 
deposited within the sub-endothelial layer of the vessel wall, forming fatty 
streaks also known as intimal xanthoma. The resultant imbalance of NO : ROS 
and oxidisation of LDL induces endothelial activation, nuclear factor kappa B 
(NFκB) signalling and the expression of adhesion molecules, cytokines, 
chemoattractants and growth factors (Smith et al., 1995, Quinn et al., 1987). 
These chemical mediators facilitate the transmigration of inflammatory cells 
including monocytes, T and B cells into the forming plaque (Pritchard et al., 
1995).  
Once recruited into the fatty streaks, monocytes proliferate and differentiate 
becoming macrophages. Within the forming plaques macrophages become 
polarised by responding to various environmental triggers in order to alter their 
gene expression and hence functional capability. A multitude of polarisation 
states have been identified in different subpopulations of macrophages, some 
peculiar to atherosclerosis (Wolfs et al., 2011). The most common fate of 
infiltrating macrophages, in response to macrophage colony stimulating factor 
(M-CSF), is to become foam cells (Irvine et al., 2009). Through the expression of 
both scavenger receptors and cluster differentiation 36 (CD36), macrophages 
take up oxidised LDL (oxLDL) (van Tits et al., 2011). These lipid laden foam cells 
further potentiate the release of pro-inflammatory cytokines (Kunjathoor et al., 
2002). Eventually foam cells undergo apoptosis and necrosis with the resultant 
release of their lipid stores into the vessel wall (Crisby et al., 1997). Together 
with cell debris these lipid pools coalesce forming a necrotic core of 
thrombogenic material (Stary, 2000). 
Cytokines and growth factors liberated from inflammatory cells promote the 
dedifferentiation of VSMCs into a synthetic phenotype, before migrating and 
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proliferating within the forming plaque, Figure 1-2 (Sasu and Beasley, 2000, 
Sundaresan et al., 1995, Pidkovka et al., 2007). VSMCs are the cell type 
primarily responsible for the formation of the fibromuscular cap (Ross, 1999). 
During lesion development they migrate towards the luminal surface of the 
plaque secreting ECM, Figure 1-2. Transforming growth factor beta (TGFβ) 
secreted by numerous cell types including T cells is thought to be important in 
stimulating cap development (Lutgens et al., 2002).  
 
 
Figure 1-2. Development of an atherosclerotic lesion. A, Endothelial dysfunction and 
activation with expression of adhesion molecules allowing immune cell attachment. B, Fatty 
streaks initially consisting of lipid-laden foam cells, T cells and VSMCs. C, Development of a 
necrotic core with overlying fibromuscular cap. D, Plaque thinning and rupture resulting in 
intraplaque haemorrhage and superimposed thrombosis. Reproduced with permission from 
Ross, N Engl J Med 1999; 340:115-126, Copyright Massachusetts Medical Society.  
A B
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1.4.2 Plaque Instability and Intraplaque Haemorrhage 
Dynamic remodelling of the fibrous cap as a result of increased inflammatory 
cell infiltrate and liberation of enzymes such as matrix metalloproteases results 
in cap thinning (Gough et al., 2006). This process leaves the cap vulnerable to 
fissuring and erosion of the endothelial surface (Galis et al., 1994). Cap rupture 
with exposure of thrombogenic material to luminal blood results in thrombus 
formation both within the plaque and on its surface, Figure 1-3 (van der Wal et 
al., 1994). This process may result in rapid plaque expansion and clinically the 
development of an acute coronary syndrome. 
  
 
Figure 1-3. Rupture of thin-cap atheroma with thrombus. Healing with resultant constrictive 
remodelling and luminal stenosis. Reproduced with permission from Jacob Fog Bentzon et 
al. Circulation Research. 2014;114:1852-1866. Copyright American Heart Association. 
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1.5 Clinical Manifestations of Coronary Heart Disease  
The two major clinical manifestations of coronary heart disease are angina 
pectoris and myocardial infarction. Both may result in chest pain classically 
described as a tightness or heaviness across the chest, which may radiate to the 
left arm and or jaw.  
1.6 Management of Coronary Heart Disease  
1.6.1 Management of Angina 
Angina is caused by a fixed stenosis of one or more coronary arteries which limits 
blood flow and hence oxygen supply to the myocardium. Usually self-limiting, 
angina is commonly relieved with rest. Following diagnosis made usually on the 
basis of history and non-invasive testing, initial management of stable angina 
should focus on risk factor reduction through health related behaviours such as 
weight loss, physical exercise and smoking cessation. Pharmacological 
management can be divided into 3 categories: 
1. Drugs used to prevent or treat angina attacks by reducing myocardial 
oxygen demand such as short and long acting nitrates, beta-blockers, 
calcium channel antagonists (Montalescot et al., 2013). 
2. Antiplatelet drugs used to prevent acute coronary syndromes (myocardial 
infarction and unstable angina) such as aspirin or clopidogrel (Yusuf et al., 
2001)  
3. Drugs used to modify risk factors and reduce disease progression including 
HMG CoA reductase inhibitors (Statins) and medication used to treat 
hypertension (Montalescot et al., 2013). 
Failure to adequately control anginal symptoms with medications commonly 
necessitates further investigation by angiography and possibly revascularisation. 
Indications for revascularisation published by the European Society of Cardiology 
are presented in 
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Table 1. Revascularisation methods available include percutaneous coronary 
intervention with the use of balloon angioplasty with or without the use of stents 
(see section 1.7) and coronary artery bypass grafting (CABG). Coronary artery 
bypass grafting involves either mobilisation of one or both internal mammary 
arteries from the internal surface of the thoracic cavity and creating an 
anastomosis with it to the diseased coronary artery beyond the stenosis. 
Alternatively, the long saphenous veins from the leg or radial arteries can be 
harvested and used as bypass conduits. 
The decision to undertake one revascularisation strategy over another is 
determined by several factors including risk stratification to predict surgical 
mortality, location and complexity of disease, presence of diabetes and 
existence of adequate surgical targets (Head et al., 2012). 
 
 
Table 1-1.!Indications for revascularisation in patients with stable angina. 
CAD = coronary artery disease; LAD = left anterior descending coronary artery; LV = left 
ventricular. a With documented ischaemia. Reproduced from Windecker et al European 
Heart Journal (2014) 35, 2541–2619. Copyright European Society of Cardiology. 
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1.6.2 Management of Myocardial Infarction 
Myocardial infarction occurs following superficial erosion and rupture of the 
fibrous cap as discussed in section 1.4.2. Exposure of the circulating blood to the 
prothrombotic ECM and lipid-filled necrotic core quickly results in thrombus 
formation, myocardial cell death and the release of cardiac troponin into the 
blood. In addition to chest pain, patients commonly complain of shortness of 
breath and may have features of autonomic disturbance such as sweating, 
tachycardia, bradycardia, hypo or hypertension, nausea and vomiting. Initial 
management of myocardial infarction includes the administration of opiate 
analgesia, nitrates, dual antiplatelet agents such as aspirin and ticagrelor or 
clopidogrel (Wallentin et al., 2009, Yusuf et al., 2001). In addition, patients 
should be anticoagulated with low molecular weight heparin or fondaparinux 
(Yusuf et al., 2006, Cohen et al., 1997).  
Myocardial infarctions are commonly divided according to whether ST segment 
elevation is observed or not on the electrocardiogram (ECG). It should be noted 
that ST elevation represents the presence of an occlusive thrombus and 
mandates urgent referral to a percutaneous coronary intervention (PCI) centre 
for emergency PCI (Authors/Task Force et al., 2014). Primary PCI involves 
reopening of the vessel using an over the wire balloon catheter and subsequent 
stent deployment. The use of thrombolytic therapy is largely historical as it has 
been shown to be inferior to primary PCI therapy (Andersen et al., 2003). 
Thrombolysis is now only considered in those greater than 2 hours from a PCI 
centre (Widimsky et al., 2000). 
For patients presenting with a Non ST elevation MI urgent angiography is only 
indicated in the presence of cardiogenic shock or following resuscitation in the 
event of cardiac arrest (Authors/Task Force et al., 2014). Early risk stratification 
should be conducted to identify high-risk patients who would benefit from 
invasive management in addition to optimal medical therapy (Authors/Task 
Force et al., 2014). 
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1.7 Coronary Angiography and Intervention 
The first cardiac catheterisation in human was carried out in 1929 when Werner 
Forssmann catheterised the right side of his own heart using a urinary catheter 
introduced via his antecubital fossa (King, 1998). However, it was almost 30 
years before Mason Sones performed the first selective coronary angiogram, 
accidentally during an elective aortogram (Ryan, 2002). Despite the increasing 
use of coronary angiography to guide surgical revascularisation it took until 1977 
before Andreas Gruntzig conducted the first percutaneous transluminal balloon 
angioplasty (Gruntzig, 1978).  
The initial success of balloon angioplasty was moderated by the immediate 
complications of acute vessel occlusion, elastic recoil, dissection and 
thrombosis. In addition, over time negative remodelling resulted in return of 
clinical symptoms and need for either repeat procedures or CABG. The 
introduction of metallic stents in the 1980s resulted in the reduction in acute 
vessel closure following balloon angioplasty (Sigwart et al., 1987). The initial 
self-expandable stents were soon superseded by balloon expandable stents, 
found to produce superior long term angiographic results (Serruys et al., 1994, 
Fischman et al., 1994). 
Despite preventing acute vessel occlusion due to elastic recoil and dissection, 
the placement of stents mandated the use of dual antiplatelet therapy to 
prevent stent thrombosis. In addition, over a longer time course renarrowing 
within the stented segment caused by overactive tissue healing was noted in 20 -
30% of cases (Carrozza et al., 1992). In the early 2000’s the development of drug 
eluting stents (DES), metallic stents coated in a polymer impregnated with 
antiproliferative drugs, resulted in a significant reduction in ISR development 
(Morice et al., 2002). Despite improvements in stent technology, polymers and 
antiproliferative drugs, real world occurrence of ISR with DES use may be as high 
as 10% (Kastrati et al., 2006). Given that in the UK last year over 90,000 PCI 
procedures were performed ISR represents a significant clinical problem (BHF, 
2014).   
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1.8 In-stent Restenosis 
1.8.1 Definition 
Angiographically ISR has been defined as the loss of ≥ 50% of the vessel lumen 
within the stent or up to 5 mm beyond either stent edge (Mehran et al., 1999). 
Clinically significant ISR requires both the presence of the angiographic finding 
of ≥ 50% luminal stenosis and either,  
1. A history of recurrent angina, 
2. Objective evidence of ischaemia either at rest or during non-invasive 
functional testing, or  
3. Objective evidence of impaired blood flow during invasive investigation 
(eg. Fractional flow reserve (FFR) <0.80) 
One early study of 288 ISR lesions in almost 250 patients proposed a 
classification system based on angiographic pattern observed, Figure 1-4. 
Investigators were able to demonstrate that target vessel revascularisation was 
more common with increasing grades of ISR. In addition they demonstrated that 
previously documented ISR and the presence of diabetes were also associated 
with higher grades of ISR (Mehran et al., 1999).  
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Figure 1-4. Classification of in–stent restenosis. Focal ISR ≤10mm divided into 4 subtypes. 
Diffuse ISR >10mm. Reproduced from (Mehran et al., Circulation 1999: 100; 1872-1878). 
Copyright American Heart Association.  
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1.8.2 Contributing factors in the development of ISR 
Numerous reports have been published documenting factors associated with ISR 
development and can broadly be divided into three categories: patient, lesional 
and procedural factors. One of the most commonly reported patient related 
factors is the presence of diabetes mellitus, in particular if treated with insulin 
(Kornowski et al., 1998, Abizaid et al., 1998). The fact that insulin is a potent 
mitogen known to stimulate VSMC growth may account for this observation 
(Stout et al., 1975). Hypertension and peripheral vascular disease have also been 
associated with increased incidence of ISR (Agema et al., 2004). However, 
current smoking, hyperlipidaemia and gender have not (Agema et al., 2004). 
Lesion characteristics, which predispose to ISR development include long or 
complex lesions or those present in small calibre vessels (Kastrati et al., 2006). 
Procedural risk factors include the use of BMS, multiple stents and under 
expansion of the stent resulting in malaposition against the vessel wall (Kastrati 
et al., 2006). Interestingly the use of intravascular ultrasound which would 
detect malaposition has been associated with reduction in ISR development 
(Kasaoka et al., 1998). The use of high pressure inflation has itself not been 
associated with increased ISR unless the stent is oversized resulting in deep 
vessel injury (Gunn et al., 2002). Indeed the severity of vessel injury has been 
directly correlated with size of neointima and degree of stenosis (Schwartz et 
al., 1992). In addition, stent geometry has been found to significantly impact on 
the development of ISR with increasing stenosis directly related to several 
factors including degree of strut protrusion, inter-strut distance, medial bowing, 
strut depth, angular burden and strut thickness (Kastrati et al., 2001, Garasic et 
al., 2000). Concordantly, increasing the number of struts per cross sectional area 
produces a polygon with a greater number of sides, alleviating many of these 
stent geometry related factors and reducing ISR (Dean et al., 2005). 
1.8.3 Pathophysiology of in-stent restenosis 
Following stent placement normal tissue healing results in the coverage of stent 
struts with a thin layer of neointima composed of VSMCs, ECM and a single layer 
of endothelial cells lining the vessel lumen (Virmani and Farb, 1999, Costa and 
Simon, 2005). It should be noted that the healing process and extent of luminal 
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renarrowing represents a continuum from incomplete strut coverage to total 
vessel occlusion due to neointimal hyperplasia (Joner et al., 2006).  
The process of ISR development involves a complex series of events over time 
often referred to as a “cellular and molecular cascade”, delineated by an early 
inflammatory response followed by a late proliferative phase (Chaabane et al., 
2013). The iatrogenic endothelial disruption, denudation and medial rupture 
which occur as a result of stenting exposes blood to the underlying thrombogenic 
vessel components. Deposition of inflammatory aggregates composed of 
platelets, fibrin and leucocytes occurs around stent struts and overlying areas of 
vessel damage have been identified from human pathological samples (Mickelson 
et al., 1996). In various porcine and canine, balloon injury and stenting models 
up regulation of adhesion molecules on the surface of activated platelets (P-
selectin and integrin glycoprotein IIb/IIIa), ECs, VSMCs (vascular cell adhesion 
molecule-1 (VCAM-1), Intercellular adhesion molecule-1 (ICAM-1), E selectin), 
neutrophils and macrophages (macrophage1 antigen-1 (MAC-1)) increases 
inflammatory cell binding (Neumann et al., 1996, Kornowski et al., 1998, Kim et 
al., 2001). This process is also aided by the release of cytokines from EC and 
VSMCs including monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 
(IL-8) (Roque et al., 2002). Early canine and porcine balloon injury studies 
suggested a direct correlation between degree of vessel inflammation and 
neointimal size (Schwartz et al., 1992). Additionally, significant differences in 
the inflammatory response were identified between balloon injury and stenting 
in rabbits and pigs (Rogers et al., 1996, Welt et al., 2000). Balloon injury results 
in a short lived increase in MCP-1 and IL-8 peaking at between 4 and 8 hours and 
returning to baseline shortly after (Welt et al., 2000). Elevation of MCP-1 and IL-
8 were found to be more pronounced and still increased at 14 days after stenting 
(Welt et al., 2003). In addition, cellular composition of the forming neointimal 
also varied between the two rabbit injury models (Welt et al., 2003). Balloon 
injury induced a neutrophil predominant infiltrate, which peaked at day 3 and 
returned to baseline by day 6. In addition to an early neutrophil response, 
stenting produced a profound increase in monocyte / macrophage infiltration, 
which continued to rise by day 14 (Welt et al., 2003). Interestingly, blockade of 
the MCP-1 receptor c-c chemokine receptor type 2 (CCR2) in primates reduced 
ISR following stenting while blockade of cluster differentiation 18 (CD18) 
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reduced neointimal hyperplasia (NIH) in balloon injury (Horvath et al., 2002). 
This confirmed not only the importance of inflammation in neointima 
development but also the relative importance of neutrophils and macrophages 
with respect to different injury modalities. In addition, use of liposomal 
alendronate to produce a systemic but transient depletion of monocytes / 
macrophages in a hypercholesterolaemic rabbit model also reduced ISR 
(Danenberg et al., 2003).  
In conjunction with the loss of anti proliferative factors including nitric oxide 
(NO) and heparin sulphate proteoglycans, growth factors such as platelet derived 
frowth factor (PDGF) and fibroblast derived growth factor (FGF) are released 
from a variety of cells including neutrophils, macrophage and VSMCs during this 
early inflammatory period (Chaabane et al., 2013, Daemen et al., 1991). During 
ISR development these potent mitogens act on VSMCs to dedifferentiate and 
begin migrating into the neointima (Ferns et al., 1991). Through receptor 
tyrosine kinases they activate several signalling cascades including the ras / raf / 
mitogen activated protein kinase (MAPK) pathway (Graf et al., 1997, Eguchi et 
al., 1996). The net effect of these signalling cascades is the down regulation of 
cyclin dependent kinase inhibitor p27Kip1 which in turn drives the VSMC through 
the G1/S phase check point inducing VSMC proliferation and migration (Polyak et 
al., 1994, Sun et al., 2001). In addition, growth factors, cytokines and vasoactive 
compounds including angiotensin II (AngII) and endothelin 1 induce these 
dedifferentiated VSMCs to secrete ECM (Daemen et al., 1991). VSMCs also play a 
significant role in the remodelling of this ECM scaffold over time by secreting 
proteolytic enzymes including matrix metalloproteases (MMPs) (Johnson et al., 
2011, Cho and Reidy, 2002). Re-endothelialisation is the final step in the healing 
process, through release of NO and Prostacyclin (PGI2) endothelial cells inhibit 
further VSMC, proliferation, migration and ECM synthesis (Jeremy et al., 1999, 
Peiro et al., 1995). Complete re-endothelialisation may take 12 months or longer 
in humans (Joner et al., 2006).  
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1.9 Animal Models of In-stent Restenosis 
Much of our understanding of the molecular mechanisms underlying ISR 
development has been extrapolated from numerous small animal non-stenting 
vascular injury models including air desiccation, wire, filament, ligation and 
balloon injury (Kumar and Lindner, 1997, Lindner et al., 1993, Fishman et al., 
1975). However, it has become clear that different injury methods, not least 
stenting, produce different and distinct molecular and cellular responses. Thus 
researchers have endeavoured to design more complex models, which more 
accurately replicate the vascular response to stenting. Initial stenting models 
utilised large animals including dog, pigs and primates (Geary et al., 1996, 
Roubin et al., 1987, Steele et al., 1985). Importantly the size of these animals 
allowed the use of human stents, wires and balloons. However, several problems 
including cost and difficulty in handling has limited their use. In addition to the 
considerations mentioned above, the ability to manipulate the mouse genome 
has driven researchers to develop several murine stenting models.  
The first published murine stenting model was based on previously developed 
vein grafting and aortic allograft models (Dietrich et al., 2000, Zou et al., 1998). 
Using an over the balloon method a stainless steel stent was deployed in the 
thoracic aorta of a euthanised mouse (Ali et al., 2007). The stented vessel was 
subsequently interposition grafted into the carotid artery of a recipient mouse. 
Plastic cuffs were used to facilitate the construction of vascular anastomosis at 
each end of the graft (Ali et al., 2007). This model demonstrated stenting 
produces a significantly greater injury response than balloon injury alone. In 
addition, greater ISR was found in  apolipoprotein E (ApoE) -/- mice compared to 
wild-type (WT) controls (Ali et al., 2007). Despite the success of this model it is 
not without its criticisms. The use of two mice per procedure increases the 
number of animals needed and a high degree of surgical skill is required. In 
addition, disruption of the vaso vasorum around the stented aorta may increase 
vessel wall anoxia, altering the response to injury.  
In response to criticism noted above, the three subsequently developed murine 
stenting models have all utilised a single animal per procedure. Chamberlain et 
al developed a self expanding nitinol stent, which was deployed in the infra 
renal aorta (Chamberlain et al., 2010). Noted complications included 
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haemorrhage and hind limb paralysis, which occurred in over half of the animals 
used following femoral artery vascular access (Chamberlain et al., 2010). In 
addition, nitinol stents are not currently used in clinical practice.  
Rodriguez-Menocal et al also developed an infra renal aortic stenting model 
(Rodriguez-Menocal et al., 2010). This model appears more clinically relevant 
due to the use of an over the balloon stent. However, vascular access was 
obtained via a direct incision to the infra renal aorta and likely contributed to 
the very high fatal haemorrhage rate described (Rodriguez-Menocal et al., 
2010). 
More recently a carotid artery direct stenting model has been published. This 
model used a self expanding nitinol stent. Following tissue harvesting, such 
profound vessel damage was observed that interpretation of the resultant 
histology was almost impossible (Simsekyilmaz et al., 2013). In addition, to the 
use of a non-clinically relevant stent the carotid artery of a mouse does not 
contain a vaso vasorum which has been shown to play an important role in 
vascular remodelling following injury (Gabeler et al., 2002).  
While none of these models is without criticism, they are important in assisting 
our understanding of the molecular mechanisms involved in ISR. Of note the only 
model to be repeatedly utilised is that described by the Channon laboratory, (Ali 
et al., 2007, Douglas et al., 2012, Douglas et al., 2013). 
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1.10 Vascular Smooth Muscle Phenotype 
Vascular smooth muscle cells present within the tunica media of the vessel wall 
are highly differentiated cells, which primarily function to maintain vessel wall 
integrity and regulate vessel tone (Owens et al., 2004). In addition, in response 
to numerous environmental stimuli they display considerable plasticity, being 
able to change their phenotype between a contractile or quiescent state to that 
of a synthetic phenotype also known as a proliferative phenotype (Owens et al., 
2004). 
Healthy, mature, differentiated VSMCs within the vessel wall display a 
predominantly contractile phenotype possessing an elongated spindle shape. 
They have also been shown to express elevated levels of contractile proteins 
including smooth muscle α-actin, smooth muscle myosin heavy chain (SM MHC), 
smooth muscle 22 alpha (SM22α) and calponin among others (Li et al., 1996, 
Miano et al., 1994). Another key feature of contractile VSMC is their low 
proliferation rate. In contrast de-differentiated VSMCs display a synthetic 
phenotype exhibit an epithelioid shape as well as demonstrating increased 
proliferative and migratory capacity, Figure 1-5 (Miano, 2010). As suggested by 
their name, synthetic VSMCs contain copious amounts of rough endoplasmic 
reticulum and are the main cell type responsible for ECM generation (Miano, 
2010). It is interesting to note that proliferation of VSMC need not necessarily 
involve complete phenotypic switch to an extreme de-differentiated phenotype.  
Environmental stimuli directing VSMC phenotype are known to include growth 
factors, cytokines, ECM interactions and mechanical stretch (Davis-Dusenbery et 
al., 2011b). Interestingly, both chemical and mechanical injury influences 
VSMCs, inducing a de-differentiated phenotype, which plays a role in 
atherosclerosis, vein graft failure and ISR as, discussed in section 1.8.3.  
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Figure 1-5. Vascular smooth muscle cell phenotype regulation. A, Multiple stimuli capable of 
modulating VSMC phenotype. Contractile phenotype demonstrates elongated shape with 
elevated expression of contractile genes and low proliferation rate. Synthetic phenotype 
characterised by increased migratory and proliferative capacity. Adapted from Davis-
Dusenbery et al. Arterioscler Thromb Vasc Biol. 2011;31:2370-2377. Reproduced with 
permission. 
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1.11 MicroRNAs 
In 1993 two groups studying the temporal control of Caenorhabditis elegans (C. 
elegans) development published their findings that lin-4 was a non protein 
coding gene producing a 22 nucleotide long single stranded ribose nucleic acid 
(RNA) molecule (Lee et al., 1993, Wightman et al., 1993). They demonstrated 
that through complimentary binding in an antisense manner to the 3’ 
untranslated region (3’UTR) of lin-14 messenger RNA (mRNA), translation and 
hence protein levels were temporarily suppressed (Wightman et al., 1993, Lee et 
al., 1993). Initially thought to be peculiar to C. elegans it took a further 7 years 
before a second example (let 7) was identified again in C. elegans (Reinhart et 
al., 2000). However, shortly afterwards let-7 was identified in Drosophila and 
various mammals including humans (Pasquinelli et al., 2000).  
Many more regulatory RNA molecules have since been discovered with the same 
mechanisms of generation and action. These short RNAs have been termed 
microRNAs (miRNAs) in order to distinguish them from other classes of regulatory 
RNAs such as short inhibitory RNAs (siRNAs), and PIWI interacting RNAs (piRNAs) 
(Bartel, 2004). MiRNAs are short 19 - 25 nucleotide non-coding RNA molecules 
found in plants, insects and animals, which function to post-transcriptionally 
regulate the translation of messenger RNA (Bartel, 2004). Over 1000 miRNAs 
have been identified in the human genome and are thought regulate around 30% 
of all protein coding genes (Friedman et al., 2009). Interestingly, significant 
homology in miRNAs is observed across animal species. MiRNAs can have 
numerous targets often repressing multiple genes at different points in the same 
biological pathway. Conversely multiple miRNAs may be able to target the same 
mRNA. Across numerous biological processes including development miRNA - 
mRNA networks exist to fine tune protein expression (van Rooij et al., 2012). In 
addition, miRNAs have been identified to play important roles in almost every 
disease including cancer and cardiovascular disease (van Rooij and Olson, 2012). 
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1.11.1 Biogenesis  
1.11.1.1 Transcription 
MiRNAs have been described in various genomic locations, including the introns 
of previously identified protein coding genes where they may be positioned on 
either the sense or antisense strand. In addition, depending on splice variations 
of the protein coding gene, miRNAs may be located within an exon (Rodriguez et 
al., 2004). If running in the sense orientation to the protein coding gene, miRNAs 
may be transcribed as part of the protein coding mRNA transcript under the 
control of the host promoter (Baskerville and Bartel, 2005). Alternatively, it has 
been demonstrated that intronic miRNAs may be transcribed under the control 
of their own distinct promoter (Cai et al., 2004). MiRNA-21 being an example 
which can be transcribed under the control of both its own promoter and that of 
the protein coding gene in which is resides (Ribas et al., 2012, Cai et al., 2004, 
Fujita et al., 2008, Loffler et al., 2007). Many miRNAs are located within 
intergenic regions far from known protein coding genes and may be transcribed 
singly or as clusters (Bartel, 2004). Clustered miRNAs are commonly transcribed 
under the control of one promoter (Bartel, 2004). In addition clustered miRNAs 
are often family members possessing significant homology and regulating the 
same genes or pathways (Friedman et al., 2009). MiRNA promoters have been 
shown to possess the same transcription response elements as protein coding 
genes (Loffler et al., 2007). 
The majority of miRNAs are believed to be transcribed by RNA polymerase II (Lee 
et al., 2002). Primary miRNAs (Pri-miRNAs) can be 1kb or longer and most are 
noted to be methyl G capped at their 5’ end and contain polyadenylation signals 
at their 3’ terminus, Figure 1-6 (Cai et al., 2004).  
1.11.1.2 Nuclear Processing 
Following transcription the pri-miRNA containing the stem loop hairpins are 
processed within the nucleus by the RNaseIII endonuclease Drosha which is part 
of a larger microprocessor complex also containing a DiGeorge Critical Region 8 
(DGCR8) and the DEAD box RNA helicases p68 and p72, Figure 1-6 (Lee et al., 
2003). This Drosha / DGCR8 microprocessor cleaves the stem loop from its 
primary transcript to form a pre-miRNA molecule 65 to 100 nucleotides in length 
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which importantly has a 2 nucleotide overhang on its 3’ end (Lee et al., 2003). 
Enhanced Drosha/DGRC8 processing of pri-miRNA transcripts has been 
documented in response to both TGFβ and  bone morphogenic protein 4 (BMP4) 
stimulation. The induction of receptor specific SMAD interaction with the p68 
component of the microprocessor complex has been shown to promote 
stabilisation of the Drosha / DGCR8 interaction, increasing pri-miR-21 processing 
(Kang et al., 2012, Davis-Dusenbery and Hata, 2011). Additionally, the tumour 
suppressor p53 has been shown to increase the processing of anti-proliferative 
miRNAs including miR-143 and miR-145 (Suzuki et al., 2009). It should be noted 
that for miRNAs transcribed as part of a longer protein coding mRNA, splicing 
does not need to occur before the miRNA is processed by Drosha/DGCR8. In 
addition, pri-miRNA processing does not negatively impact on the preliminary 
mRNA (pre-mRNA) to undergo spicing into mature mRNA (Kim and Kim, 2007). 
1.11.1.3 Transportation across the Nuclear Membrane 
The resulting preliminary miR (pre-miR) hairpin product is exported from the 
nucleus into the cytoplasm by an active process involving Exportin-5 and Ran-
GTP. The importance of the 3’overhang for Exportin-5 recognition has previously 
been demonstrated. Interestingly, having the pre-miR base ends of equal length 
reduced export from the nucleus (Zeng and Cullen, 2005). Additionally, binding 
to Exportin-5 has been shown to protect the pre-miR from nuclear degradation, 
Figure 1-6 (Zeng and Cullen, 2004).  
1.11.1.4 Cytoplasmic Processing and Maturation 
Once in the cytoplasm the pre-miRNA is then recognised by Dicer, a second 
RNaseIII endonuclease. Dicer, which contains helicase activity and two RNase 
binding domains, cleaves the loop from the pre-miRNA creating a second 3’ 
overhang (Lee et al., 2002). This imperfect RNA duplex 19-25 nucleotides long 
was initially denoted miRNA:miRNA* referring to the active or guide miRNA stand 
involved in mRNA regulation and the star (or passenger) strand of RNA which was 
thought to have no function and to be degraded by the cellular apparatus. 
However, recent studies have shown that both strands may be biologically active 
(Bang et al., 2014). Thus, newer nomenclature commonly uses the suffixes -5p 
or -3p dependent on which side of the stem loop they are generated from.  
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Once cleaved by Dicer the mature duplex is unwound and the appropriate guide 
strand selected for loading into the Argonaute (Ago) protein (Bartel, 2009). 
Along with other co-factors such as TAR RNA-binding protein (TRBP), this 
Argonaute protein and mature miRNA form the microRNA induced silencing 
complex (miRISC) (Bartel, 2009). In humans four different Argonaute proteins 
present in humans each containing a PIWI-Argonaute-Zwillie (PAZ) domain which 
binds the 3’ end of the miRNA, a MID domain binding the 5’ end and an central 
P-element induced wimpy testes (PIWI) domain (Song et al., 2004). Argonaute 
proteins are responsible for facilitating mRNA translational repression (Pillai et 
al., 2005). Ago2 is the only Argonaute protein containing endonuclease activity 
within its PIWI domain (Lima et al., 2009). 
1.11.1.5 MiRNA mechanisms of action 
Nucleotide residues 2 - 8 at the 5’ end of the miRNA, known as the “seed 
sequence” are primarily responsible for the binding of the guide miRNA to the 
3’UTR of target mRNA, inhibiting translation (Bartel, 2009). Perfect 
complementarity of the miRNA seed and 3’UTR in the presence of Ago2 is likely 
to induce cleavage of the mRNA and thus prevent translation. However, 
imperfect seed sequence complementarity, in conjunction with the binding of 
other residues outwith the seed sequence to the 3’UTR is more commonly 
observed. This results in translation repression, possibly by interfering with the 
initiation of translation through blockade of the eukaryotic initiation factor (eIF) 
4E - mRNA interaction (Humphreys et al., 2005). Despite direct cleavage of 
mRNA by Ago2 being an uncommon event a reduction in target mRNA levels are 
commonly observed (Guo et al., 2010). This has been attributed to the miRISC 
directing the mRNA target towards intracellular p-bodies where they are 
deadenylated, uncapped and degraded, Figure 1-6 (Wu et al., 2006, Eulalio et 
al., 2009).  
Although the majority of miRNA - mRNA interactions occur at the 3’UTR of the 
mRNA notable exceptions have been discovered. Several miRNAs including miR-
134, miR-296 and miR-470 have been shown to suppress the translation of key 
regulatory genes involved in stem cell differentiation through binding to target 
sequences within their coding sequence rather than 3’UTR (Tay et al., 2008). 
Additionally, miR-10a has been demonstrated to upregulate cellular protein 
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synthesis by binding to the 5’UTR of several ribosomal proteins increasing their 
translation (Orom et al., 2008).  
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Figure 1-6. miRNA Biogenesis Pathway. The primary transcripts of miRNAs, pri-miRNAs, are 
transcribed from individual miRNA genes, introns host genes, or polycistronic clusters. The 
RNaseIII Drosha cleaves the pri-miRNA into a pre-miRNA. Pre-miRNAs are exported from 
the nucleus by exportin 5. Within cytoplasm, another RNaseIII, Dicer cleaves the pre-miRNA 
forming a miRNA:miRNA* (miRNA-5p:mRNA-3p) duplex. Mature miR is loaded in to RISC 
complex containing Argonaute protein and henceforth negatively regulates gene expression 
by either translational repression or mRNA degradation. RISC – RNA induced silencing 
complex. ORF - open reading frame. Reproduced with permission, Van Roiij Circ Res. 
2011;108:219-234. Copyright American Heart Association. 
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1.12 Expression of microRNAs are essential for 
development 
Lin-4 and let-7, the first two identified miRNAs initially were shown to play an 
important role in C. elegans development. By suppressing translation of their 
respective mRNA targets lin-14 and lin-41 they facilitated normal progression 
through the larval phase of development (Lee et al., 1993). The necessary role 
of miRNAs in the development of vertebrates has since been documented. In 
Zebra fish embryos, genetic deletion of Dicer demonstrated that normal 
development appeared to occur during the first week post fertilisation, while on 
day 8 growth arrest was noted and most were dead by the end of the second 
week (Wienholds et al., 2003). A notably elevated level of pre-miR26a was 
demonstrated and mature let-7 found to be absent, implying that alternative 
processing pathways were not facilitating miR maturation within the embryos 
(Wienholds et al., 2003). Interestingly, knockdown of Dicer produced an earlier 
phenotype than that of genetic deletion attributed to the concomitant 
suppression of maternal Dicer (Wienholds et al., 2003). Importantly, post 
mortem examination revealed general growth arrest rather than a single organ 
defect suggesting a global role of miRNAs in development (Wienholds et al., 
2003). Another group independently identified that in mice complete absence of 
Dicer was lethal at embryonic day 7.5 (E7.5) immediately prior to gastrulation 
(Bernstein et al., 2003). They attributed their findings to the depletion of stem 
cells from the blastocyst as a consequence of their premature terminal 
differentiation (Bernstein et al., 2003). 
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1.13 MicroRNA expression and cardiovascular 
development 
Several studies have looked at the importance of miRNAs in the development of 
different vascular tissues. Within the heart, genetic deletion of Dicer in mice, 
while not being embryonically lethal did result in death within 4 days of birth 
(Chen et al., 2008). Hearts from these mice demonstrated the virtual absence of 
mature miRNAs, dilated cardiomegaly, left ventricular mural thrombi and 
myofibril disarray (Chen et al., 2008). However, Dicer deletion did not affect 
cardiomyocyte proliferation but did affect expression of contractile proteins 
including myosin heavy chain and α-tropomyosin (Chen et al., 2008). 
Interestingly, analysis of human hearts with dilated cardiomyopathy revealed a 
significant reduction in Dicer at the time of left ventricular assist device 
implantation, a finding which was reversed upon functional recovery (Chen et 
al., 2008). Another study of targeted postnatal Dicer deletion in cardiomyocytes 
using a tamoxifen–inducible Cre recombinase approach demonstrated similar 
findings with structural and electrical remodelling in juvenile and adult mice (da 
Costa Martins et al., 2008). 
Within vascular endothelial cells, both Drosha and Dicer knockdown using siRNA 
have demonstrated the importance of miRNAs in cardiovascular development. In 
vitro analysis demonstrated that endothelial sprout formation was reduced when 
either RNaseIII was knocked down (Kuehbacher et al., 2007). However, only 
Dicer knockdown impaired human umbilical vascular endothelial cell (HUVEC) 
migration (Kuehbacher et al., 2007). Using nude mice, researchers 
subcutaneously implanted matrigel plugs containing siRNA transfected HUVECs. 
As with the in vitro migration experiment this demonstrated only Dicer inhibition 
reduced angiogenesis (Kuehbacher et al., 2007). These findings confirmed 
previously published work, which had used similar Dicer knockdown strategies to 
demonstrate alterations in the expression of several key regulators of 
angiogenesis (Suarez et al., 2007). Further work using a postnatal inducible EC 
Dicer deletion approach demonstrated Dicer to be essential for post natal 
angiogenesis and that the effects on EC proliferation, migration and angiogenesis 
was likely as a result of miR-17-92 cluster inhibition (Suarez et al., 2008). 
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An essential role for miRNAs in VSMC development has also been elucidated. 
Conditional Dicer deletion in VSMC was noted to be embryonically lethal 
between E15.5 and E16.5 as a result of subcutaneous and intracerebral 
haemorrhage (Albinsson et al., 2010, Pan et al., 2011). Detailed analysis 
revealed Dicer deletion resulted in blood vessels which were thin walled, dilated 
and lacking VSMCs. Myography of umbilical arteries revealed impaired 
contractile response to both potassium chloride (KCl) and calcium stimulation 
(Albinsson et al., 2010). Histological analysis of the elastic lamellae also 
revealed profound fragmentation (Albinsson et al., 2010). In addition, VSMCs 
from the KO mice revealed reduced proliferative capacity and a reduction in 
VSMC specific gene expression including, smooth muscle α-actin, calponin and 
myosin heavy chain 22 (MYH22) (Pan et al., 2011). These findings show that, not 
only are miRNAs essential for VSMC proliferation but that they are also involved 
in VSMC differentiation. Postnatal deletion of Dicer in VSMC has subsequently 
been shown to result in vascular remodelling, reduced blood pressure and 
contractile function in resistance vessels (Albinsson et al., 2011). 
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1.14 Role of MicroRNAs following Vascular Injury 
While microRNAs are essential for normal development and maintenance of 
homeostasis they have also been implicated in numerous disease states. From 
infectious and autoimmune diseases to cancer and notably cardiovascular 
disease their aberrant expression often results in the induction of maladaptive 
molecular and cellular responses (Small and Olson, 2011, Schee et al., 2012, Zhu 
et al., 2012). MicroRNAs have been shown to be dysregulated in numerous 
cardiovascular diseases including myocardial infarction, hypertension, dilated 
cardiomyopathy, atherosclerosis, cardiac allograft vasculopathy, aneurysm 
formation, vein graft failure and in the development of in-stent restenosis 
following percutaneous coronary intervention (Small and Olson, 2011, van Rooij 
and Olson, 2012, O'Sullivan et al., 2011).  
Different MiRNAs have been shown to promote either a contractile or synthetic 
VSMC phenotype. In addition, following vascular injury their dysregulation 
facilitates the transitioning towards a synthetic phenotype. Several microRNAs, 
which are known to influence VSMC phenotype, are discussed below, Table 1-2. 
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Table 1-2. Summary of VSMC miRNA Expression Following Vascular Injury.  
 
Legend. PTEN, phosphatase and tensin homologue. PDCD4, programmed cell death 4. 
TPM1, tropomyosin-1, KLF, Kruppel-like factor. PKCε, protein kinase C epsilon. PDGF-Rα, 
platelet derived growth factor receptor alpha. Sp-1, specificity protein-1. Cdc42, cyclin 
dependent kinase 42. NOR1, neuron derived orphan receptor 1.  
  
miRNA Expression
after1Injury
Biological1
Effect
mRNA1
target
Reference
miR$21 Increased Pro$synthetic4/4
pro$contractile
PTEN
PDCD4
TPM1
c$Ski
Ji et4al42007,
Maegdefessel
et4al42012,
McDonald4et4
al42013, Lin4et4
al42009, Song4
et al42012,4
Wang4et4al4
2012,4Wang4et4
al42011,4Li4et4
al42014
miR$2214/ 222 Increased Pro$synthetic p27,4p57 Liu4et4al42009,
Davis4et4al4
20094
miR$1434/4145 Decreased Pro$contractile KLF4,4KLF5,4Elk$
1,4PKCε,4PDGF$
Rα,4Fascin4
Cheng et4al4
2009,4Cordes
et4al42009,4
Quintavalle et4
al42010.
miR$133a Decreased Pro$contractile Sp$1,4Moesin Torella et4al4
2011
miR$195 Decreased Pro$contractile4/4
anti4
inflammatory
Cdc42 Wang4et4al
2012b
miR$663 Decreased Pro$contractile JunB Li4et al42013c
miR$638 Decreased Pro$contractile NOR1 Li4et4al42013b
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1.14.1 miR-21 (Pro-synthetic and Pro-contractile) 
MicroRNA-21 is located on human chromosome 17q23.1. An intronic miRNA, its 
stem loop is located within the 11th intron of the transmembrane proten 49 
(TMEM49) gene also known as vacuole membrane protein 1 (VMP1) (Cai et al., 
2004). This transmembrane spanning protein localised to the endoplasmic 
reticulum has been implicated in the initiation and regulation of autophagy: the 
process of cell organelle degradation, which serves to maintain cell survival 
during periods of cellular stress or starvation (Calvo-Garrido et al., 2008). In 
addition, it has also been implicated in the resistance of some cancers including 
pancreatic cancer to chemotherapeutic agents (Gilabert et al., 2013). Several 
groups have demonstrated that miR-21 can be transcribed independently from 
the protein coding host gene through a distinct promoter. Three overlapping 
promoter regions have been proposed and while it is acknowledged to span much 
of the 10th intron of the protein coding host gene no conclusive agreement upon 
its size has yet been reached (Cai et al., 2004, Fujita et al., 2008, Loffler et al., 
2007). The primary transcript of miR-21 has been shown, like messenger RNA 
molecules, to be both 5’ capped and 3’ polyadenylated (Cai et al., 2004). 
MiRNA-21 is processed as described in section 1.11.1 with pre-miR-21 containing 
72 nucleotides its mature form being 22 nucleotides in length with the sequence 
5’-UAGCUUAUCAGACUGAUGUUGA-3’. Mature miR-21 is derived from the 5’ end 
of the pre-miR hairpin giving it the suffix -5p (miR-21-5p) (Asangani et al., 
2008). Throughout the remainder of this thesis it shall be denoted as miR-21 
unless there is a specific need to distinguish it from the passenger (star) strand 
where the terms miR-21-5p and miR-21-3p will be used, respectively. 
Initially described as an “oncomir” due to its ubiquitous over-expression and 
deleterious function in many cancers, two studies have highlighted its 
importance in patients with vascular disease. MiRNA-21 has been shown to be up 
regulated in both the intima and serum of patients with Arteriosclerosis 
Obliterans as well as within atherosclerotic plaques (Li et al., 2011, Raitoharju 
et al., 2011). 
Conflicting reports as to whether miR-21 promotes either a contractile or 
synthetic VSMC phenotype following vascular injury have been published. De-
differentiated synthetic VSMCs demonstrate greatest miR-21 expression while 
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others have demonstrated up regulation of miR-21 is necessary for TGFβ to 
induce a contractile phenotype (Ji et al., 2007, Davis et al., 2008). More 
recently, the miR-21 targeting of tropomyosin-1 (TPM1), a contractile protein 
regulating the calcium-dependent interaction of actin and myosin, induced cell 
elongation (a contractile feature) while concurrently inducing an increase in 
proliferation and migration; two classic features of synthetic VSMCs (Wang et 
al., 2011). Thus it would appear that the effect of miR-21 in VSMCs phenotype 
are complex and may depend on their origin, the disease process and mRNA 
target. 
Regardless of which VSMC phenotype miR-21 induces, its up regulation has been 
demonstrated consistently in multiple injury models. The following sections 
discuss the effects of miR-21 up regulation in relation to mRNA targets. 
1.14.1.1 Phosphatase and tensin homolog  
One of the earliest published studies investigating miR-21 in vascular injury 
utilised a rat carotid artery balloon injury model (Ji et al., 2007). Investigators 
demonstrated that 7 days following injury miR-21 was up regulated over 6 fold. 
This elevation persisted at day 14, before returning to baseline by day 28 (Ji et 
al., 2007). Investigators found a significant reduction in neointimal formation by 
applying a miR-21 antagomiR containing poloxamer gel to the adventitial surface 
of the carotid vessel at the time of balloon injury. Two reasons given for this 
finding are a reduction in cellular proliferation as evidenced by significantly 
fewer 5-Bromo-2’-deoxyuridine (BrdU) positive cells within both the vessel 
neointimal and media. Secondly a significant increase in apoptosis was observed 
within the developing neointima upon miR-21 knockdown (Ji et al., 2007). In 
vitro analysis demonstrated elevated miR-21 expression within de-differentiated 
VSMCs cultured in 10% serum. In addition, the in vitro effects of knockdown on 
proliferation and apoptosis were in keeping with those found in vivo (Ji et al., 
2007).  
Further analysis revealed that in vitro over expression of miR-21 using an 
adenovirus vector in VSMCs, resulted in reduced phosphatase and tensin homolog 
(PTEN) protein expression and an increase in the anti apoptotic protein B-cell 
lymphoma-2 (Bcl-2) (Ji et al., 2007). The increase in Bcl-2 is likely an indirect 
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downstream signalling effect. Concordant with the observed reduction in PTEN, 
an increase in phosphorylated Akt was also demonstrated. PTEN is a previously 
validated target of miR-21, which acts to block the growth factor-mediated 
activation of Akt by phosphoinositide-3-kinase (PI3K) (Meng et al., 2007). As a 
result of PTEN inhibition, Akt-mediated activation of mammalian target of 
rapamycin (mTOR) increases with consequent increases in proliferation and 
reduced apoptosis (Meng et al., 2007). 
Further evidence of the importance of PTEN inhibition by miR-21 was 
documented in two mouse models of abdominal aortic aneurysm (AAA) 
development. As aneurysms developed following porcine pancreatic elastase 
(PPE) or AngII infusion a parallel increase in miR-21 expression was observed 
(Maegdefessel et al., 2012). Systemic over expression of miR-21 using a lentiviral 
vector induced PTEN down regulation at both mRNA and protein levels 
(Maegdefessel et al., 2012). In addition, miR-21 over expression was associated 
with a reduction in aneurysm expansion attributed to increased VSMC 
proliferation and a decrease in apoptosis within the aortic wall (Maegdefessel et 
al., 2012). Interestingly, a single tail vein injection of antimiR-21 at 10 mg/kg 
appeared sufficient to block miR-21 for up to 14 days, increase PTEN expression 
and produce aneurysm expansion. In human samples of AAA, miR-21 and PTEN 
levels were found to be dysregulated in the same manner as occurred in the 
experimental mouse models (Maegdefessel et al., 2012). 
Using these murine aneurysm animal models, researchers also assessed the 
effect on inflammatory cytokine production as a consequence of miR-21 and 
PTEN modulation. They demonstrated MCP-1 and IL-6 were elevated upon miR-
21 over expression (Maegdefessel et al., 2012). This is in keeping with previous 
reports that PTEN deficiency in the setting of a murine carotid artery ligation 
results in increased inflammatory cytokine and NIH production (Furgeson et al., 
2010). 
Another key study confirming the conservation of miR-21 / PTEN axis across 
species assessed multiple vein-grafting models in mice, pigs and humans 
(McDonald et al., 2013). Vein grafts in all three species demonstrated an 
increase in miR-21. This was confirmed to be present in all three layers of the 
vein graft with co-localisation identifying up regulation in VSMCs, macrophages 
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and myofibroblasts. Genetic deletion of miR-21 in a mouse model of 
interposition grafting demonstrated an 81% reduction in NIH development 
(McDonald et al., 2013). Grafting between miR-21 KO and WT mice 
demonstrated that the graft genotype was key to reduction of NIH rather than 
that of the recipient. In addition, ex vivo antimiR-21 treatment of human 
saphenous vein grafts demonstrated a de-repression of several previously 
validated targets including PTEN (McDonald et al., 2013).  
1.14.1.2 Programmed cell death 4 
Programmed cell death 4 (PDCD4) is a tumour suppressor protein known to 
inhibit the initiation of mRNA transcription by binding eIF4A (Yang et al., 2003). 
In addition, it is also known to inhibit the activity of AP-1 and initiate apoptosis 
(Liu et al., 2010). 
In vitro investigation by two independent groups using different injury methods 
have demonstrated PDCD4 is an important target of miR-21 in rodent VSMCs. 
Firstly, chemical injury with hydrogen peroxide was shown to increase miR-21 
expression, concomitantly repressing PDCD4 expression and reducing apoptosis. 
Using luciferase reporter assays they confirmed PDCD4 to be a miR-21 target. In 
addition, they demonstrated miR-21 modulation using pre-miR and antimiR 
strategies repressed and de-repressed PDCD4 expression which resulted in a 
reduction and increase in apoptosis, respectively (Lin et al., 2009). 
Interestingly mechanical stretch has been shown to induce a biphasic response in 
miR-21 expression within murine VSMCs (Song et al., 2012). Researchers 
demonstrated that while moderate stretch reduced miR-21 expression, excessive 
stretch produced the opposite effect. A reduction in PDCD4 was observed with 
excessive stretch while miR-21 inhibition restored PDCD4 levels. At a cellular 
level apoptosis was observed following excessive stretch and this was 
exacerbated further by miR-21 inhibition (Song et al., 2012). This implies miR-21 
up regulation is a protective mechanism inhibiting apoptosis following 
mechanical injury.  
Conformation that miR-21 targets PDCD4 in vivo was demonstrated in a rat iliac 
balloon injury model (Wang et al., 2012a). This study implicated miR-21 induced 
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PDCD4 inhibition in both reducing apoptosis and increasing proliferation. Using 
antagomiR applied to the adventitial surface of the ballooned iliac artery a 
reduction in NIH was observed. In vitro PDCD4 knockdown using siRNA 
ameliorated the reduction in cell proliferation observed with miR-21 inhibition 
(Wang et al., 2012a).  
Taken together these studies involving the miR-21 / PDCD4 axis show its 
importance in regulating apoptosis and proliferation following vascular injury.  
1.14.1.3 Tropomyosin 1 
Arteriosclerosis obliterans is progressive vascular disorder characterised by 
progressive vascular occlusion due to uncontrolled VSMC hyperplasia. MicroRNA 
dysregulation was observed in human samples of patients with arteriosclerosis 
obliterans. In particular an almost eight fold increase in miR-21 was identified 
within VSMCs (Wang et al., 2011). This increase in miR-21 was associated with a 
reduction in tropomyosin (TPM1), a contractile protein found in VSMCs, which 
regulates the calcium-dependent interaction of actin and myosin (Wang et al., 
2011). TPM1 was confirmed as a target of miR-21 by luciferase reporter assay. 
Careful in vitro analysis using siRNA and antagomiR strategies revealed PDGF-
induced VSMC stimulation of proliferation and migration was mediated by an 
increase in hypoxia inducible factor alpha (HIF-α), which in turn stimulated the 
expression of miR-21 (Wang et al., 2011). Researchers were unable to identify a 
HIFα response element within the miR-21 promoter and it remains unclear as to 
the exact mechanism of this interaction (Wang et al., 2011).  
Down regulation of TPM1 by miR-21 was associated with VSMC elongation (Wang 
et al., 2011). The VSMCs elongation implies the presence of a contractile 
phenotype despite the increase in proliferation and migration which are two key 
features of a synthetic phenotype (Wang et al., 2011). 
1.14.1.4 c-Ski 
c-Ski is a protein found within VSMC which primarily acts to increase cell cycle 
inhibitor p27 and p21 (Li et al., 2013a). Following balloon injury in a rat model 
miR-21 increase was accompanied by c-Ski reduction and increased proliferation 
(Li et al., 2014). Conformation that c-Ski is a miR-21 target was conducted by 
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luciferase reporter assay. Utilising a miR-21 mimic strategy c-Ski was down 
regulated in A10 cells a rat derived cell line of VSMCs. Over expression of c-Ski in 
the presence of miR-21 mimic inhibited proliferation. Researches demonstrated 
the miR-21 mimic reduced both p21 and p27, the effects of which were reversed 
by c-Ski over expression (Li et al., 2014). These data show c-Ski is a miR-21 
target in the setting of vascular injury. 
Taken together the above studies demonstrate the up regulation of miR-21 in 
response to a variety of different types of vascular injury. Through careful miR-
21 and target manipulation they demonstrate that miR-21 actively participates 
in the healing response promoting proliferation, migration and preventing 
apoptosis.   
 
1.14.2 miR-221/222 (Pro-synthetic) 
Encoded as a miRNA cluster on the X chromosome, miR-221 and miR-222 have 
the same seed sequence (Davis et al., 2009). Their expression has been 
demonstrated in human blood vessels, in particular VSMCs although expression in 
the endothelium has been documented (Nicoli et al., 2012). Both miR-221 and 
miR-222 appear co-expressed within the systemic circulation while in pulmonary 
artery smooth muscle cells (PASMCs) their differential expression has also been 
noted (Davis et al., 2009). They primarily function to promote a synthetic VSMC 
phenotype with the up regulation of miR-221 in particular shown to coincide 
with a reduction in contractile VSMC markers including calponin and SM22 (Davis 
et al., 2009). 
In cultured VSMCs stimulation with PDGF induced miR-221 and miR-222 
expression in a dose-dependent manner (Davis et al., 2009). Both were also up 
regulated within the carotid artery following balloon injury. In situ hybridisation 
and co-localisation with smooth muscle α-actin demonstrated this increase 
occurred in VSMCs (Liu et al., 2009).  
Knockdown strategies using antimiRs successfully inhibited both miRs in vitro 
and in vivo, when administered systemically. The resulting decrease in 
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proliferation indicates miR-221 and miR-222 exert a positive effect on VSMC 
proliferation (Liu et al., 2009). 
Not only did PDGF stimulation of VSMCs induce miR-221 and miR-222 but a 
reduction in p27 and p57 was also found. Both of these cell cycle inhibitors are 
predicted targets of miR-221 and miR-222 (Liu et al., 2009). 3’UTR luciferase 
reporters confirmed miR-221 and miR-222 binding. In culture, loss of function 
experiments demonstrated that inhibition of both miRs increased p27 and p57. 
De-repression of p27 and p57 was confirmed in vivo by locally applying antimiR-
222 to the vessel wall at time of angioplasty. In addition to de-repression of 
these targets a reduction in proliferating cells was also observed within the 
vessel wall (Liu et al., 2009). 
 
1.14.3 miR-143/145 (Pro-contractile) 
MiR-143 and miR-145 are both markers and promoters of the contractile VSMC 
phenotype (Boettger et al., 2009). Located on human chromosome 5 (mouse 
chromosome 18), miR-143 and miR-145 together compose a bicistronic cluster, 
co-transcribed as part of the same pri-miR (Rangrez et al., 2011). During 
embryonic development they are first expressed in the developing heart at E7.5 
before peaking at E9.5 and can no longer be detected in ventricular myocardium 
by E16.5. In addition, at E11.5 miR-143 and miR-145 are both highly expressed 
within the developing great vessels before becoming evident in blood vessels of 
all developing organs (Cordes et al., 2009). Postnatally miR-143 and miR-145 
have been shown to be expressed within the media of blood vessels in particular 
within VSMCs (Cheng et al., 2009).  
1.14.3.1 miR-143 and miR-145 as markers and modulators of a 
contractile phenotype 
Evidence confirming, in vitro and in vivo, that miR-143 and miR-145 are markers 
of a pro-contractile phenotype has been published by several groups (Boettger et 
al., 2009, Cheng et al., 2009, Davis-Dusenbery et al., 2011a, Hutcheson et al., 
2013, Xin et al., 2009). Culture of primary VSMCs demonstrated high initial levels 
of miR-145 expression, which was noted to fall over time as cells de-
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differentiated into a synthetic state (Boettger et al., 2009, Cheng et al., 2009). 
The addition of PDGF, a known inducer of a synthetic phenotype, to freshly 
isolated VSMCs accelerated the reduction in miR-145 expression and fall in 
markers of contractile phenotype (Cheng et al., 2009). In vivo, balloon injury of 
the carotid artery in rats is known to induce VSMCs towards a synthetic state 
prior to proliferation and migration (Clowes and Clowes, 1986). A concomitant 
reduction in miR-143 and miR-145 following balloon injury has also been 
demonstrated (Cheng et al., 2009). Interestingly, other models of vascular injury 
including carotid ligation, transverse aortic constriction and atherosclerosis in 
ApoE -/- mice, have also demonstrated reduction in miR-143 and miR-145 (Elia 
et al., 2009, Cordes et al., 2009). Concordant with these findings, human 
samples taken from patients with AAA demonstrated a reduction in both miRs 
compared to aortic samples from healthy controls has been demonstrated (Elia 
et al., 2009). 
Loss and gain of function studies using sIRNAs and premiRs were subsequently 
utilised to determine whether miR-143 and miR-145 plays a role in VSMC 
phenotype modulation in vitro. miR-145 knockdown augmented PDGF mediated 
de-differentiation in vitro with a resultant decrease in smooth muscle markers 
α-actin and calponin (Cheng et al., 2009). The addition of premiR-145 to VSMCs 
cultured in the presence of PDGF inhibited their de-differentiation and 
maintained the expression of VSMC markers smooth muscle α-actin and calponin 
(Cheng et al., 2009).  
In vivo, locally administered adenovirus mediated up regulation of miR-143 and 
miR-145 demonstrated a reduction in NIH and an increase in smooth muscle cell 
markers within the vessel wall 7 days after balloon injury (Cheng et al., 2009). 
Lenti-miR-145 has also been demonstrated in a carotid artery ligation model to 
increase VSMC differentiation markers including calponin and smooth muscle α-
actin (Cordes et al., 2009).  
1.14.3.2 miR-143 and miR145 knockout studies 
Several groups have independently generated miR-143 KO, miR-145 KO or miR-
143/145 combined KO mice. Analysis of their phenotype demonstrated structural 
changes within the vascular tree including thinning of the aorta and femoral 
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arteries. However, changes in ECM have been conflicting in miR-143/145 KO 
mice, with some reporting extended areas of ECM degradation while others have 
found VSMCs encased in thick layers of ECM (Elia et al., 2009, Xin et al., 2009). 
Additionally, these mice demonstrated no change in cell number but an increase 
in the presence of de-differentiated VSMCs as evidenced by an increase in rough 
endoplasmic reticulum suggesting the presence of a synthetic state (Elia et al., 
2009, Xin et al., 2009). VSMCs from KO mice have also been noted to have 
disorganised actin fibres and no cytoskeletal stress fibres (Xin et al., 2009). 
The effect of miR-143 and miR-145 KO on NIH formation is complex and not fully 
understood. Two groups have reported spontaneous neointimal lesions in aged 
mice, which initially comprised of VSMCs but over time the accumulation of 
macrophage and amorphous type I collagen was also observed (Boettger et al., 
2009, Elia et al., 2009). These lesions occurred in the presence of a normal lipid 
profile and exhibited a predilection for the femoral arteries rather than the 
aorta (Boettger et al., 2009). Given that miR-143 and miR-145 over expression in 
the setting of vascular balloon injury has been shown to reduce NIH it would be 
expected that genetic deletion may result in increased lesion size. However, it 
has been reported that carotid ligation in WT mice produced a thick neointima, 
while in miR-143 KO, miR-145 KO and miR-143/145 combined KO mice a 
significant reduction in NIH was observed (Xin et al., 2009). In particular, almost 
no neointima was formed in either the miR-145 KO or the double knockout mice. 
Interestingly, a 50% mortality rate was observed following carotid ligation in 
miR-145 KO mice which was attributed to stroke secondary to systemic 
hypotension and likely failure of cerebral blood flow auto-regulation (Xin et al., 
2009). The reasons underlying the counterintuitive results observed in KO mice 
remain unclear but could be due to a combination of factors. Firstly, genetic 
deletion may induce compensatory responses in other miRs or cell signalling 
pathways, which are not present following temporary knockdown or over 
expression. Thus, the blood vessels are already abnormal at the time of injury. 
Additionally, as hypertension is known to promote NIH and ISR the profound 
hypotension observed in KO mice may limit lesion development (Meguro et al., 
2000). Interestingly, only one of the three groups, which used different methods 
to independently generate miR-143 KO and or miR-145 KO mice, actually 
conducted vascular injury experiments in these mice. Comparing lesion 
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formation across all three colonies as well as the effect of in vivo knockdown 
may help explain the reduction in NIH with absence of this bicistronic cluster.  
In summary, miR-143 and miR-145 are highly expressed in VSMCs where they act 
to maintain a contractile phenotype. Further work is required to understand the 
complex and seemingly contradictory findings between in vitro and in vivo 
manipulation of these miRs. 
 
1.14.4 miR-133a (Pro-contractile) 
miR-133a is another miRNA shown to promote a contractile phenotype in VSMCs. 
While two copies of miR-133a are present, each clustered with a copy of miR-1, 
only miR133a is found in VSMCs. miR-133a is found abundantly in quiescent 
VSMCs but is reduced when they are stimulated to proliferate by either growth 
factor stimulation or mechanical injury (Torella et al., 2011). ERK1/2 activation 
by the ras / MAPKinase pathway has been attributed to this down regulation of 
miR-133a (Torella et al., 2011).  
The over expression of miR-133a, using a premiR, in VSMCs stimulated with 10% 
FCS reduced proliferation significantly implying this miRNA plays an active role 
in maintaining quiescence. 
In VSMCs two predicted miR-133a targets, specificity protein 1 (SP-1) and moesin 
have been validated using 3’UTR luciferase reporter assays as well as by gain and 
loss of function experiments. SP-1 is a transcription factor shown previously to 
be up regulated following vascular injury, while moesin is known to play a role in 
VSMC migration (Torella et al., 2011).  
In vivo, adenovirus mediated over expression of miR-133a was accomplished at 
time of balloon injury by local administration to the vessel wall. This resulted in 
SP-1 and moesin down regulation as well as reduction in NIH development 
(Torella et al., 2011). This suggests miR-133a acts to inhibit VSMC proliferation 
and migration maintaining a contractile phenotype. 
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1.14.5 miR-195 (Pro-contractile) 
Oxidised LDL is known to stimulate proliferation and migration of VSMCs (Zettler 
et al., 2003). Researchers investigating the mechanisms underlying this effect in 
HASMCs identified numerous miRNAs dysregulated upon oxLDL exposure (Wang et 
al., 2012b). MiR-195, highly expressed in human arterial smooth muscle cells 
(HASMCs) compared to ECs and macrophages was significantly down regulated by 
oxLDL treatment. In vitro, augmentation of miR-195 expression using premiR-195 
was shown to reduce oxLDL-induced proliferation and migration. Conversely, 
knockdown of miR-195 increased the migratory effects of oxLDL on HASMCs 
(Wang et al., 2012b).  
By comparing protein coding gene microarray data following stable miR-195 over 
expression with bioinformatic target prediction programmes several putative 
targets were identified. Of these, cell division cycle 42 (Cdc42), a RhoB GTPase 
implicated in cell growth, proliferation and migration was confirmed as a target 
using 3’UTR luciferase reporter constructs (Wang et al., 2012b). Importantly, 
knockdown of Cdc42 using shRNA had the same negative effect on oxLDL treated 
HASMC proliferation as miR-195 overexpression (Wang et al., 2012b).  
In vivo, a reduction in miR-195 expression within the vessel wall was confirmed 
following balloon injury. Over expression of miR-195 by intra-arterial infusion of 
an adenovirus expressing miR-195 reduced not only Cdc42 but also NIH (Wang et 
al., 2012b).  
Interestingly, miR-195 also had an inhibitory effect on IL-1β, IL-6 and IL-8 pro- 
cytokine expression from HASMCs stimulated with oxLDL (Wang et al., 2012b). 
These pro-inflammatory cytokines have been shown to stimulate VSMC 
proliferation (Chamberlain et al., 2006, Ikeda et al., 1991).  
Taken together these data implicate miR-195 in promoting a quiescent anti-
inflammatory phenotype within VSMCs. Consequently, manipulation of miR-195 
may not only have a role in treatment of atherosclerosis but also in preventing 
NIH and ISR following balloon angioplasty and stent placement, respectively. 
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1.14.6 miR-663 (Pro-contractile) 
MiR-663, first noted to be up regulated within ECs following oscillatory shear 
stress also plays a role in regulating the inflammatory process within these cells 
(Ni et al., 2011). In addition, its increased expression in head and neck cancers 
promotes tumour growth and invasion (Yi et al., 2012). More recently miR-663 
has been identified as a novel phenotypic marker in VSMCs, with an increase in 
expression upon the induction of a contractile phenotype by either exposure to 
differentiation medium or trans-retinoic acid (Li et al., 2013c). Conversely upon 
stimulation with PDGF, miR-663 expression was significantly reduced. 
MiR-663 over expression using an adenovirus vector was sufficient to increase 
VSMC differentiation markers, including SM22α, calponin and myosin heavy chain 
11 (MYH11), in both quiescent and pro-synthetic states. Furthermore, a gain of 
function approach also reduced VSMC proliferation and migration while 
knockdown with anti-miR-663 had the opposite effect (Li et al., 2013c).  
The transcription factor JunB, comprising one half of the heterodimer activator 
protein 1 (AP-1) (Jun/Fos), has been validated as a miR-663 target. AP-1 is an 
important regulator of VSMC proliferation and migration, the down regulation of 
which is key to the suppressive effect of miR-663 on both proliferation and 
migration. In vivo, miR-663 over expression in a mouse carotid artery ligation 
model reduced NIH development by over 60%. This effect was attributed to a 
reduction in proliferating cells as evidenced by lower proliferating cell nuclear 
antigen (PCNA) positive stained cells and suppression of JunB (Li et al., 2013c). 
Thus not only is miR-663 a marker of VSMC differentiation but it actively 
modulates their phenotype. In addition, its over expression following vascular 
injury may be of therapeutic benefit in reducing NIH development.  
1.14.7 miR-638 (Pro-contractile) 
The pro-contractile miR-638 is abundantly expressed in VSMCs contributing to 
the expression of differentiation markers including smooth muscle α-actin and 
calponin (Li et al., 2013b). Stimuli known to induce a dedifferentiated 
phenotype significantly reduce the expression of miR-638 in both human aortic 
and pulmonary artery SMCs. Selective blockade of individual PDGF-induced 
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signalling cascades have shown that the MAPK / ERK1/2 pathway is responsible 
this down regulation. Conversely, miR-638 expression is increased within VSMCs 
when cultured in media promoting a contractile phenotype (Li et al., 2013b).  
In order to determine that miR-638 plays an active role in VSMC biology, gain 
and loss of function approaches have shown that the augmentation and 
inhibition of miR-638, by in vitro administration of premiR-638 and siRNA, 
reduced and increased proliferation, respectively. Using a scratch assay it has 
also been demonstrated that miR-638 inhibits migration of HASMCs. In addition, 
its inhibition by antimiR promoted migration, in vitro (Li et al., 2013b). 
Researchers confirmed neuron-derived orphan receptor 1 (NOR1), a component 
of the orphan nuclear receptor NR4A, which stimulates the expression of cyclin 
D1, as a target of miR-638 in HASMCs. MiR-638 over expression reduced NOR1 
and cyclin D1 expression, inhibiting cell cycle progression from G1 into S phase. 
Interestingly NOR1 over expression could partially reverse the inhibitor effect of 
miR-638 on VSMC proliferation and migration (Li et al., 2013b).  
While the data strongly suggests miR-638 promotes a contractile phenotype, 
limiting VSMC proliferation and migration, its effect on the development of NIH 
and ISR in vivo remains to be evaluated.  
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1.15 The role of microRNAs in macrophage function 
following vascular injury 
Macrophages are pivotal cellular components of the innate immune system. Not 
only do they play an important role in immunity, combating invading pathogens 
through phagocytosis and antigen presentation, but they have also been shown 
to have an important role initiating inflammation and organ development, 
including haematopoiesis (Sica and Mantovani, 2012). They also play an 
important role in the resolution of inflammation and tissue repair (Mantovani et 
al., 2013). In addition, their activity has been associated with various disease 
states including autoimmunity, neoplasia, neurodegenerative and cardiovascular 
disease (Leitinger and Schulman, 2013, Lucas et al., 2010, Mantovani and Locati, 
2013).  
In order to perform the diverse number of roles required of them, macrophages 
alter their phenotype in response to environmental cues (Davis et al., 2013). 
Such cues include but are not limited to colony stimulating factors, growth 
factors, lipids and cytokines (Mosser and Edwards, 2008). The resultant 
phenotypic transformation induced by altered gene expression is referred to as 
polarisation, the two extremes of which are commonly referred to as classically 
(M1) polarised macrophages or alternatively (M2) polarised macrophages (Mosser 
and Edwards, 2008). Classical polarising stimuli include lipopolysaccharide (LPS) 
and interferon gamma (IFNγ), which upon toll-like receptor (TLR) stimulation 
results in an increased expression of pro-inflammatory cytokines, major 
histocompatibility complex (MHC) class II and nitric oxide synthase 2 (NOS2) via a 
combination of signal transduction and transcription factor 1 (STAT1), IRF5 and 
NFκB signalling (Tugal et al., 2013). M1 macrophages play an important role in 
combating bacterial and viral infection as well as in the development of 
atherosclerosis (Robbins et al., 2013, Leitinger and Schulman, 2013).  
Alternative polarisation is commonly induced by IL-4, IL-10 and IL-13 
stimulation, which via STAT3 and STAT6 pathways promote the expression of 
arginase 1 (Arg1), peroxisome proliferator activator receptor gamma (PPARγ), 
CD206, resistin-like α (Retnla) and chitinase 3-like 3 (Chi3l3) also known as YM-1 
(Tugal et al., 2013, Szanto et al., 2010, Raes et al., 2002, Odegaard et al., 
2007). M2 macrophages can be further divided into a variety of subclasses (Ho 
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and Sly, 2009). They are known to play a role in combating helminth infection, 
wound healing, tissue remodelling, various cancers and the development of 
atopy (Mantovani and Locati, 2013, Lucas et al., 2010, Guiducci et al., 2005).  
Macrophage polarisation represents a phenotypic continuum, which has been 
demonstrated to be reversible both in vitro and in vivo (Guiducci et al., 2005, 
Davis et al., 2013). The recognition that microRNAs, including let-7c and miR-
125a-5p, can dynamically influence polarisation has added further complexity to 
the determination of macrophage phenotype (Banerjee et al., 2013b, Banerjee 
et al., 2013a).  
Macrophages have been implicated in the development of several cardiovascular 
diseases including atherosclerosis, aneurysm formation and cardiac allograft 
vasculopathy (Moore et al., 2013, Blomkalns et al., 2013, Kitchens et al., 2007). 
Importantly, macrophages rather than neutrophils have also been shown to play 
a pivotal role in arterial remodelling and the development of NIH following 
stenting (Welt et al., 2000, Rogers et al., 1996). Despite recognition that 
microRNAs are up regulated within various forms of vascular disease, there is a 
relative paucity of data regarding their role within macrophages following 
vascular injury. However, it is likely that there are common processes observed 
across the spectrum of cardiovascular disease, which can be extrapolated to this 
particular setting. Several microRNAs implicated in macrophage function have 
been shown to be up regulated within atherosclerotic plaques and macrophages 
following oxLDL exposure (Wolfs et al., 2011, Leitinger and Schulman, 2013). Of 
these miRNAs miR-21, miR-155, miR-146a and miR-125a-5p have been more 
closely examined as discussed below. 
1.15.1 miR-21 
Several studies have already demonstrated the complex role played by miR-21 in 
regulating the immune response. Within endothelial cells oscillatory shear stress 
has been shown to upregulate miR-21 expression, which via NFκB activation 
increased endothelial activation and adhesion molecule expression (Zhou et al., 
2011). Following vascular injury it is likely that this contributes significantly to 
the recruitment of immune cells including T-cells and macrophages.   
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A pro-inflammatory role within T-cells has been described by independent 
groups showing miR-21 enhances pro-inflammatory cytokine release including IL-
12, TNFα, IFNγ and MIP-2 (Ando et al., 2013, Shi et al., 2013). In addition, the 
genetic deletion of miR-21 and resultant immunosuppressive effect, 
demonstrated improved survival in a mouse model of colitis (Shi et al., 2013).  
Conflicting reports of the action of miR-21 within macrophages have been 
published. Using an immortalised macrophage cell line investigators have found 
that miR-21 suppresses LPS / TLR4 induced inflammation, reducing IL-6 and 
enhancing IL-10 production through the targeting of PDCD4 a pro-inflammatory 
protein also known to promote apoptosis (Sheedy et al., 2010). Conversely, miR-
21 itself has been demonstrated to activate intracellular TLR7 and TLR8 due to 
its GU-rich motif, resulting in an increase in pro-inflammatory cytokines 
including TNFα and IL-6 (Fabbri et al., 2012). The later finding suggests miR-21 
may induce an M1 polarisation state, which is known to promote NIH 
development following vascular injury (Lavin et al., 2014). Furthermore, miR-21 
has been shown to inhibit M2 polarisation by targeting of STAT3 (Wang et al., 
2015).  
The contradictory findings presented above suggest the exact role played by 
miR-21 in immune regulation is complex and may be determined by the timing 
and context in which it is expressed. Whether the expression and action of miR-
21 within macrophages is important in the development of NIH and ISR remains 
to be investigated.  
 
1.15.2 miR-155 
Located on human chromosome 21 within the B-cell integration cluster gene, 
miR-155 is highly expressed within haemopoietic cells. Not only has this miRNA 
been demonstrated to play a role in haemopoiesis and immune function its 
dysregulation has been documented in viral infections, cancer, and 
cardiovascular disease (Wei et al., 2013, Sethupathy et al., 2007, Cai et al., 
2012). 
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In vitro characterisation of miR-155 within bone marrow-derived macrophages 
revealed it to be up regulated 120-fold following M1 polarisation (Cai et al., 
2012). In addition, by blocking its action, M1 macrophages could be repolarised 
towards an M2 phenotype. The converse was found upon over expression within 
M2 macrophages. Interestingly within tumour associated macrophages which 
exhibit an M2-like phenotype, low levels of miR-155 were also found (Cai et al., 
2012). 
Conflicting reports exist as to whether miR-155 is pro- or anti-inflammatory 
(Donners et al., 2012, Cai et al., 2012). However, the most consistent and 
compelling evidence is for a pro-inflammatory and pro-atherogenic action. 
Observational data has shown miR-155 along with tumour necrosis factor alpha 
(TNFα) to be highly expressed within atherosclerotic lesions taken not only from 
ApoE -/- and LDLR -/- mice but also human plaques. Minimally modified LDL, LPS 
and IFNγ have been shown via TLR4 stimulation to induce the expression of miR-
155 (Nazari-Jahantigh et al., 2012, Du et al., 2014). A positive correlation 
between miR-155, TNFα and IL-6 has also been demonstrated. In addition, 
lentiviral mediated over expression of miR-155 was associated with an increase 
in TNFα release (Du et al., 2014).  
Furthermore, by knocking out miR-155, a reduction in pro-inflammatory cytokine 
release as well as an increase in cholesterol efflux from macrophages was 
demonstrated (Du et al., 2014). Further support of a pro-inflammatory, pro-
atherogenic role for miR-155 was derived from experiments in ApoE -/- miR-155 
-/- double knockout mice (Nazari-Jahantigh et al., 2012, Du et al., 2014). These 
mice were found to have smaller atherosclerotic lesions with a reduction in lipid 
and macrophage accumulation. Investigators demonstrated that miR-155 targets 
B-cell lymphocyte 6 (Bcl-6) and suppressor of cytokine signalling-1 (SOCS-1), two 
known repressors of cytokine release (Nazari-Jahantigh et al., 2012, Du et al., 
2014). They elegantly demonstrated that the absence of miR-155 results in Bcl-6 
target de-repression, which in turn suppresses pro-inflammatory cytokine 
release including MCP-1 expression (Nazari-Jahantigh et al., 2012, Du et al., 
2014). Genetic deletion of miR-155 has also been demonstrated to reduce 
CD11+/Ly6Chi cells, thought to be precursors of M1 macrophages important in 
developing atherosclerotic lesions and possibly in ISR (Du et al., 2014).  
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With respect to vascular injury, miR-155 -/- mice have been demonstrated to 
produce less NIH following carotid artery ligation (Zhang et al., 2014). Notably, 
this study did not demonstrate that the reduction in vascular injury response was 
mediated by the absence of miR-155 specifically from macrophages. However, 
bone marrow transplantation from miR-155 -/- mice into ApoE -/- mice 
demonstrated a reduction in both atherosclerotic lesion size and in NIH 
development following partial carotid artery ligation (Nazari-Jahantigh et al., 
2012). Given the methodology used in the later study it can be inferred that 
within leukocytes miR-155 is important in promoting the development of NIH. 
Indeed it is likely that this effect is, at least in part, mediated by its expression 
in macrophages.  
Taken together these findings suggest by influencing macrophage biology 
including polarisation, cholesterol handling and release of mitogenic cytokines 
miR-155 may play an important role in the development of NIH and ISR. 
 
1.15.3 miR-146a 
MiR-146a has been found within human atherosclerotic plaques and has been 
shown to be up regulated following vascular injury (Ji et al., 2007, Raitoharju et 
al., 2011). While recent reports have suggested a role for miR-146a in 
modulating VSMC phenotype by targeting KLF4, initial studies of this miR focused 
on its influence upon the innate immune system (Sun et al., 2011). Within 
monocytes and macrophages the expression of miR-146a is induced by TLR 
activation and has been found to be NFκB transcription factor dependent (Yang 
et al., 2011). MiR-146a is up regulated within these cells following exposure to 
oxLDL (Chen et al., 2009). Interestingly, miR-146a acts to reduce oxLDL 
accumulation and the release of several cytokines, which have been implicated 
in neointimal development, including IL-6, IL-8 and CCL2 (Chen et al., 2009). 
Further work would be required to determine whether the inhibition of foam cell 
formation and release of pro-migratory and pro-proliferative cytokines by miR-
146a play an important role in limiting the development of neoatherosclerosis 
and ISR following stenting.    
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1.15.4 miR-125a-5p 
Not only has miR-125a-5p been implicated in the regulation of macrophage 
polarisation, it has also been shown to be up regulated following oxLDL exposure 
(Chen et al., 2009). Similar to miR-146a, miR125a-5p inhibition has been shown 
to increase lipid uptake by macrophages. De-repression of oxysterol binding 
protein-related protein 9 (ORP9), a protein that plays an important role in lipid 
metabolism and transport, has been implicated in the action of miR-125a-5p 
(Chen et al., 2009).  
In addition, miR-125a-5p appears to have an anti inflammatory role in 
suppressing the release of IL-2, IL-6, TNFα and TGFβ (Chen et al., 2009). Given 
the influence of miR125a-5p on macrophage polarisation, lipid metabolism and 
cytokine expression it would appear reasonable to suggest this miRNA may play a 
role in NIH and ISR development. However, direct evidence is lacking and further 
work would be required to confirm this hypothesis. 
 
Taken together it is clear that numerous miRNAs are important in regulating 
macrophage function within cardiovascular disease. However, it is also clear that 
further investigation is required to fully elucidate their role within macrophages 
following vascular injury.   
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1.16 Aims 
In-stent restenosis remains a significant clinical burden to patents, resulting in 
the return of clinical symptoms. Despite significant advances in stent design, 
polymers and anti-mitogenic medications, ISR still occurs in up to 5% of deployed 
stents. In addition, the need for prolonged used of dual antiplatelet agents to 
prevent in stent thrombosis puts patients at risk of major haemorrhage. Thus, 
there is a need to develop novel therapies to prevent ISR, reducing the need for 
repeat revascularisation and to lower the bleeding risk associated with long term 
dual antiplatelet use. Numerous microRNAs have been found to influence either 
VSMC proliferation or inflammation, two key pathologies associated with ISR. 
MicroRNA 21 has been implicated in regulating both. Thus this thesis shall 
investigate the role of miR-21 in the development of ISR by; 
1. Reproducing a small animal model of stenting  
2. Investigating the potential role played by miR-21 within VSMCs during the 
development of ISR, using a variety of gain and loss of function 
approaches. 
3. Investigating the potential role of miR-21 in macrophage phenotype and 
function in the development of ISR. 
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1.17 Hypotheses 
1. MiR-21 is likely to play an important role in facilitating the development 
of ISR. 
2. The deleterious actions of miR-21 on ISR development is likely to be 
multifactorial; 
a. Through the promotion of VSMC proliferation and migration.  
b. Through alteration of the inflammatory response in particularly 
within macrophages the dominant cell type involved in ISR. 
3. Blocking the actions of miR-21 through genetic deletion and or 
pharmacological knockdown may reduce the development of ISR. 
4. Genetic overexpression of miR-21 may increase the development of ISR. 
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2 Methods 
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2.1 Animals 
Four groups of mice were used. C57BL6 mice (Charles River, Maidstone, UK), 
miR-21 wild type (WT) mice miR-21 Knock-out (KO) mice and miR-21 Transgenic 
(Tg) over expressing mice (Gift from Eric Olsen, University of Texas 
Southwestern, USA)(Hatley et al., 2010). Mice gifted from Professor Olsen’s 
Laboratory were created on a C57BL6 parent strain, which had been crossed 
with SJLB6 mice. The pre-miR-21 sequence was deleted in mice to create MiR-21 
KO mice using homologous recombination using standard loxP and CAG-Cre 
methods as described previously (Patrick et al., 2010). Deletion of pre-miR-21 
was not associated with disruption of TMEM49 gene expression as evidenced by 
reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) (Patrick 
et al., 2010). All mice were fed a diet of standard chow and had free access to 
water. Male mice aged 18-22 weeks, weighing between 25 and 30 g were used 
for in vivo experiments. Cells isolated from male mice aged between 8 and 12 
weeks were used for in vitro experiments. All animal work was conducted under 
Home Office licence and in accordance with the Animals Scientific Procedures 
Act (1986). 
2.2 Genotyping 
The genotype of all miR-21 WT, KO and Tg miR-21 over expressing mice was 
confirmed prior to inclusion in all studies as outlined below. 
2.2.1 DNA Extraction 
Ear notches from mice were obtained by staff from biological services when 
numbering animals as per institutional protocol. Samples were stored at -20oC 
until deoxyribose nucleic acid (DNA) was ready to be extracted using QIAamp 
DNA mini kit (250) (cat. 51306) (Qiagen, Manchester, UK) as per manufacturer’s 
protocol. Briefly, mechanical and biological tissue lysis was conducted by adding 
180 µL of ATL buffer, 20 µL of Proteinase K and one 3 mm tungsten carbide bead 
(cat. 69997) (Qiagen, Manchester, UK) to each sample. Samples were then 
shaken vigorously in a TissueLyser (Qiagen, Manchester, UK) for 2 min at 25 Hz 
and repeated once. Samples were then left overnight in a water bath at 55oC. 
The following day 400 µL of AL buffer : ethanol (1:1) mixture was added to 
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samples containing tissue lysates and vortexed for 15 s. Buffered lysates were 
then added to a QIAamp mini spin column containing a silica membrane and 
centrifuged at 8000 revolutions per minute (rpm) for 1 min. During 
centrifugation DNA present within the lysates binds to the silica membrane while 
proteins and any other contaminants including divalent ions which interfere with 
PCR are passed through and were discarded. Samples were washed with two 
further buffers AW1 and AW2 to remove any residual contaminants by 
centrifugation for 1 min at 8000 rpm and 13200 rpm respectively. The QIAamp 
spin column was then placed in a clean 1.5 mL Eppendorf and 50 µL of nuclease 
free water added. The column and Eppendorf were spun at 8000 rpm for 1 min 
to elute the DNA bound to the silica membrane. This was repeated by placing 
the sample back into the column which was spun again to ensure maximal DNA 
elution. Samples were stored at -20oC prior to PCR amplification. 
2.2.2 Polymerase Chain Reaction for microRNA-21 WT and KO 
Mice 
DNA isolated from ear notches of miR-21 WT and miR-21 KO mice were amplified 
by PCR using a Promega Green GoTaq-Flexi polymerase kit (Promega, 
Southampton, UK). Each 25 µL reaction was prepared using: 5xGoTaq Flexi 
Buffer (5 µL), magnesium chloride (MgCL2) 25 mM (3 µL), dNTPs 10 mM (0.5 µL), 
miR-21 forward primer 10 µM 5’-GGGCGTCGACCCGGCTTTAACAGGTG-3’ (1µL), 
miR-21 reverse primer 10µM 5’-GGGCGTCGACGATACTGCTGCTGTTACCAAG -3’ 
(1µL) (Exiqon, Vedbaek, Denmark), nuclease free dH2O (12.875 µL), Taq 5 U/µL 
(0.125 µL) and genomic DNA 1 in 5 dilution (1.5 µL). The cycling conditions used 
were as follows: 95oC for 2 min (enzyme activation) followed by 35 cycles of 
95oC for 15 s (DNA denaturation), 62.5oC for 35 s (primer binding) and then 72oC 
for 30 s (primer extension). The PCR products were separated by gel 
electrophoresis within 2% Agarose/ Tris/Borate/EDTA (TBE) gel. The amplicons 
(miR-21 WT 469 base pairs (bp), miR-21 KO 330 bp) were identified by size in 
comparison against a 100 bp ladder run simultaneously, Figure 2-7. 
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Figure 2-7. MiR-21 colony genotyping. Gel electrophoresis following PCR of ear samples 
taken from mice of miR-21 KO colony. From left, Lane 1 100 bp ladder. Lanes 2-5, samples 
from four miR-21 WT mice (469bp amplicon). Lanes 6-9, samples from four miR-21 KO mice 
(330bp amplicon). 
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2.2.3 Genotyping of microRNA-21 Transgenic Overexpressing 
Mice 
Genotyping of miR-21 overexpressing mice was conducted by PCR and 
identification of the reporter enhanced green fluorescent protein (EGFP) gene 
present within the transgene construct, Figure 2-8(Hatley et al., 2010). PCR was 
conducted using the same kit as described in section 2.2.2. However 1 µL rather 
than 1.5 µL of genomic DNA was added to each reaction. The addition of extra 
nuclease free dH2O was used to maintain a total reaction volume of 25 µL. 
Primer sequences used were as follows EGFP forward 5’-
TCTTCTTCAAGGACGACGGCAACT-3’ and EGFP reverse 5’-
TGTGGCGGATATTGAAGTTCACCT-3’ (Exiqon, Vedbaek, Denmark). The cycling 
conditions used were: 95oC for 2 min (enzyme activation) followed by 32 cycles 
of 95oC for 30 s (DNA denaturation), 60oC for 30 s (primer binding) and then 72oC 
for 60 s (primer extension). The PCR product was 216 bp long and its presence 
identified by gel electrophoresis within 2% Agarose/TBE gel, Figure 2-9. 
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Figure 2-8. Schematic of Transgenic microRNA 21 Overexpression Construct. PCR 
conducted to determine presence or absence of reporter EGFP. Presence of EGFP signifies 
presence of miR-21 overexpressing construct. (IRES - Internal Ribosome Entry Site, EGFP – 
Enhanced Green Fluorescence Protein). Adapted from Hatley et al Cancer Cell 2010:18; 282 
– 293. Supplemental Figure 1. Reproduced with permission. 
 
 
Figure 2-9. MiR-21 Transgenic colony genotyping. Gel electrophoresis following PCR of ear 
samples taken from miR-21 transgenic mouse colony. The identification of EGFP (216 bp 
amplicon) present within the miR-21 overexpression construct, was used to identify Tg miR-
21 ++/+ mice. From Left, Lane 1 100 bp ladder. Lanes 2 and 3 EGFP present, Tg miR-21++/+ 
mice. Lanes 4 and 5 EGFP absent, WT miR-21 +/+ mice.  
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2.3 RNA and miRNA Extraction from Cells and Tissues 
Total and miRNA was extracted using the miRNeasy mini kit (Qiagen, 
Manchester, UK), including on-column DNAse (Qiagen, Manchester, UK) 
treatment to remove any DNA contamination, as per manufacturer’s 
instructions. Cells were washed in PBS to remove any residual media and lysed 
by the addition of 700 µL QIAzol lysis reagent. Lysates were vortexed to 
homogenize prior to the addition of 140 µL of chloroform. For tissues 1400 µL of 
QIAzol was added to an Eppendorf containing the tissue of interest along with 
two 3 mm tungsten carbide beads. Samples were then shaken vigorously in a 
TissueLyser (Qiagen, Manchester, UK) for 2 min at 25 Hz and repeated once. 
Tissue lysates were then divided equally between two Eppendorfs and 280 µL of 
Chloroform added to each. Chloroform facilitates separation of the sample. 
Protein remains in the lower organic phase and DNA partitions to the interphase 
while the RNA partitions to the upper aqueous phase. The sample was 
partitioned fully by centrifugation at 12,000 rpm for 15 min at 4ºC. The RNA 
containing aqueous phase was transferred to a fresh RNAse free Eppendorf and 
1.5 x volume of 100 % ethanol was added to facilitate binding to the RNeasy mini 
spin column. Samples were immediately added to the spin column and 
centrifuged at 8000 rpm for 15 s to bind the RNA to the spin column. Columns 
were washed with 350 µL of buffer RWT for 15 s and 8000 rpm and the flow 
through discarded. Digestion of residual DNA was performed by incubating the 
spin columns with DNAse for 15 min at room temperature. The column was again 
washed with 350 µL RWT buffer, followed by two washes of 500 µL RPE buffer by 
centrifugation at 8000 rpm for 15 s to remove any traces of salts from the 
sample. To dry, spin columns were placed in clean collection tubes and 
centrifuged at 13,200 rpm for 1 min. RNeasy spin columns were transferred to 
RNAse free Eppendorfs and RNA was eluted using 50 µL of RNAse free water and 
centrifugation at 8000 rpm for 1 min. This was repeated by placing the sample 
back into the column which was spun again to ensure maximal RNA elution. RNA 
samples were stored at -80ºC until use. 
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2.4 Quantification of RNA 
Total RNA was quantified using a NanoDrop 1000 Spectrophotometer 
(ThermoScientific, Loughborough, UK). The NanoDrop measures the 
concentration of nucleic acid in solution by exposing the sample to a pulse of 
light at 260 nm and then measuring the amount of light absorbed. The 
relationship between the absorbance and the concentration of the sample is 
based on the Beer-Lambert law: 
c=A/(Θ x l) 
Where: 
c= nucleic acid concentration (ng/µl) 
A= absorbance 
Θ= molar absorptivity (constant for given solution) 
l= path length of light passing through (constant for given instrument) 
 
The purity of the sample was assessed by calculating the ratio of absorbance at 
260 and 280 nm. A 260 / 280 ratio of <2.0 was accepted as pure. 
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2.5 Complementary Deoxyribonucleic Acid (cDNA) 
Synthesis 
mRNA extracted from cells was reverse transcribed to cDNA to allow for analysis 
of gene or miRNA expression via RT-qPCR. For both gene expression and miRNA 
cDNA synthesis two negative control reactions were prepared: one containing 
water instead of mRNA and the other containing no reverse transcriptase, the 
enzyme responsible for cDNA synthesis.  
2.5.1 Gene Expression 
mRNA extracted from cells was reverse transcribed to cDNA for gene expression 
analysis using the Taqman Reverse Transcription Reagents (Applied Biosystems, 
Warrington, UK) as per manufacturer’s instruction. Reverse transcription of RNA 
was conducted in 40 µL reactions containing: 10 x RT buffer (4 µL) 25 mM MgCl2 
(8.8 µL), 10 mM dNTPs (8 µL), 50 µM random hexamers (2 µL), 0.5 U/µL RNAse 
inhibitor (0.8 µL), 50 U/µL multiscribe reverse transcriptase (1 µL), 100 ng/mL 
RNA (10 µL) and dH2O (5.4 µL). Cycling conditions used were as follows: 25ºC for 
10 min (annealing), 48ºC for 30 min (reverse transcription), 95ºC for 5 min 
(inactivate reverse transcriptase). cDNA was stored at -20ºC. 
2.5.2 microRNA Expression 
miRNA was reverse transcribed to cDNA for the detection of miRNA using specific 
stem-loop reverse transcription primers as per the Taqman miRNA Reverse 
Transcription kit (Applied Biosystems, Paisley, UK). Reverse transcription of 
microRNA was conducted in 7.5 µL reactions containing: 100 mM dNTPs (0.075 
µL), 10 x RT buffer (0.75 µL), 5 x RT primer (1.5 µL), 0.25 U/µL RNase inhibitor 
(0.095 µL), 6.6 U/µL multiscribe reverse transcriptase (0.5 µL), dH2O (2.08 µL) 
and 2.5 µL of total RNA diluted to 2 ng/µL. The cycling conditions used were as 
follows: 16ºC for 30 min (anneal), 42ºC for 30 min (reverse transcription), 95ºC 
for 5 min (inactivate reverse transcriptase). cDNA was stored at -20ºC. 
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2.6 TaqMan® quantitative real-time polymerase chain 
reaction (qRT-PCR) 
TaqMan® qRT-PCR was used to quantify relative expression levels of genes or 
miRNAs of interest. TaqMan® assays contain forward and reverse primers specific 
to the target DNA sequence between which a probe can anneal. The probe is 
labelled with a reporter fluorophore at the 5’ end and a non-fluorescent 
quencher at the 3’ end, when intact the quencher suppresses fluorescent 
emission by the reporter. In the presence of target sequence the probe anneals 
and is then cleaved upon amplification of the target sequence by the forward 
and reverse primers. This produces separation of the quencher from the reporter 
and a fluorescent signal can be detected. Further reporter dye molecules are 
cleaved from their respective probes with each cycle, resulting in an increase in 
fluorescence intensity directly proportional to the concentration of the target 
product produced. Data is acquired whilst PCR is in the exponential phase and is 
measured when the reporter dye emission reaches a threshold, known as the 
cycle threshold (Ct). Results were normalised to a housekeeping gene, whose 
expression remains stable, to correct for any errors in RNA content. Results are 
shown relative to the experimental control using the -2∆∆Ct method described by 
Livak. (Livak and Schmittgen, 2001) 
2.6.1 Gene Expression 
For gene expression, qRT-PCR was performed using TaqMan® gene expression 
assays. Ten microlitre reactions were prepared for each sample containing: 2 x 
TaqMan® Universal MasterMix II (5 µL), probe (0.5 µL), RNAse free H2O (3 µL) and 
1.5 µL cDNA. Samples were run in technical duplicate on a 384 well plate. For 
each probe tested the negative reverse transcription control was run in addition 
to a water only control. qRT-PCR was performed in simplex using the 7900HT 
sequence detection system (Applied Biosystems) using the following cycling 
conditions: 50oC for 20 s, 95ºC for 10 min (enzyme activation), 40 cycles of 95ºC 
for 15 s (denaturing of cDNA) then 60ºC for 60 s (primer and probe annealing, 
primer extension). Three genes: Glyceraldehyde 3-Phosphate Dehydrogenase 
(GAPDH), 18S and TATA box binding protein (Tbp) were used as housekeepers for 
gene expression depending on which tissue RNA was initially extracted from. 
Table 2-3 lists the gene expression assays used.  
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Table 2-3. List of TaqMan Gene Expression Assays 
 
Gene Assay(ID RefSeq Gene(ID
GAPDH Hs02758991_g1 NM_001256799.1
18s Hs03003631_g1
Tbp Mm00446971_m1 NM_013684.3
Arginase1 Mm00475988_m1 NM_007482.3
YM@1 Mm00657889_mH NM_009892.2
PPARγ Mm01184322_m1 NM_011146.3
Retnla Mm00445109_m1 NM_020509.3
NOS2 Mm01309897_m1 NM_010927.3
STAT3 Mm01219775_m1 NM_213660.2
PTEN Mm00477208_m1 NM_008960.2
TIMP3 Rn00441826_m1 NM_012886.2
BMPR2 Mm00432134_m1 NM_007561.4
PDCD4 Mm01266062_m1 NM_011050.4
IL@12p35 Mm00434165_m1 NM_008351.2
PPARα Mm00440939_m1 NM_011144.6
CCL3 Mm00441259_g1 NM_011337.2
  85 
 
2.6.2 miRNA Expression 
Quantitative RT-PCR for miRNA expression was performed using miR probes 
complementary to the mature miRNA sequence. Expression of each miRNA was 
normalised to the housekeeper U6. For each sample a 10 µL reaction was 
prepared for each sample containing: 2x TaqMan® Universal MasterMix II (5 µL), 
probe (0.5 µL), RNAse free water (3.8 µL) and miRNA RT product (0.7 µL). Each 
sample was run in a 384 well plate in technical duplicate. Controls were 
performed as above and the experiment performed using the 79000HT sequence 
detection system as in section 2.6.1. Table 2-4 lists the TaqMan® assays used.  
 
Table 2-4. List of TaqMan miRNA Expression Assays 
 
  
miRNA Assay)ID
MIRBASE
ID
hsa$miR$21$5p 000397 hsa$miR$21$5p
mmu$miR$21$3p 002493 mmu$miR$21$3p
U6 Hs00984809_m1
NM_024598.3:
(NCBI:accession)
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2.7 Cell Culture 
2.7.1 Isolation and Culture of Murine Aortic Vascular Smooth 
Muscle Cells 
Male mice 8 - 12 weeks old were euthanized by rising CO2 concentration within a 
sealed chamber. Following confirmation of death the mice were placed supine 
on a sterile drape and perfused with sterile saline by ventricular puncture. The 
thoracic and abdominal aorta was harvested and all adipose and connective 
tissue carefully dissected off. The vessel was cut longitudinally and stored 
temporarily in serum-free media containing 1% penicillin/streptomycin and L-
Glutamine prior to transfer into aseptic conditions. Further vessel preparation 
was undertaken within a sterile tissue culture hood under laminar airflow. The 
vessel was removed from serum-free media, placed on a sterile petri dish and 
endothelial cells removed by gently rubbing the luminal surface with the plunger 
from a 1ml syringe. The aorta was dissected horizontally and longitudinally using 
a sterile scalpel blade before being resuspended in 400 µL of Amniomax C100 
basal cell media containing 15% Amniomax C100 growth supplement (Life 
Technologies, Paisley, UK). The explants were placed in a T25 tissue culture 
flask and incubated at 37oC with 5% CO2. Following adherence of aortic tissue to 
the flask surface, 2 mL of supplemented Amniomax media was added. Media was 
changed every 3 days for 1 week until VSMC outgrowth was observed, Figure 2-
10. Tissue explants were removed and cells washed twice with 3 ml of sterile 
phosphate buffered saline (PBS) and incubated at 37oC in 0.5 mL trypsin-
ethylenediamine tetra-acetic acid (0.05% trypsin, 0.02% EDTA) for approximately 
5 min or until the majority of the cells had detached from the flask and re-
plated into the same T25 flask (Passage 1, P1). Supplemented Amniomax media 
was added to neutralise the enzymatic activity of trypsin-EDTA Cells were grown 
to near confluence prior to changing media to Dulbecco’s Modified Eagle Media 
(DMEM) containing 20% (volume/volume [v/v]) fetal calf serum (FCS), 100 
international units (I/U)/mL penicillin, 100 µg/mL streptomycin and 2 mM L-
glutamine (Life Technologies, Paisley, UK). VSMCs were then trypsinised and 
plated into a T75 flask (P2) and after 24 h media was changed to final growth 
media of DMEM containing 10% FCS, 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 2 mM L-glutamine. VSMCs were further passaged when 80 - 90 
% confluent and were used for experiments between P4 and P6. 
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Figure 2-10 Aortic Vascular Smooth Muscle Cells growing out from aortic explants of mice 
at 7 days following harvest. A, WT mice. B, KO mice. Scale bar = 100 µm. 
A
B
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2.7.2 Cell Counting 
Cells were suspended in either Trypsin-Ethylenediaminetetraacetic Acid (EDTA) 
or Cell Dissociation Solution (Sigma Aldrich, Poole UK), centrifuged at 1500 rpm 
for 5 min and then resuspended in 1 mL of appropriate culture media. A cover 
slip was placed on a Bright Line Haemocytometer (Sigma Aldrich, Poole, UK) and 
20 µL of cell suspension placed across the chamber by capillary action. A light 
microscope was used to count the number of cells in each of four corner squares 
and the mean calculated. Each corner square represents a total volume of 0.1 
mm3 or 1x10-4 cm3. As 1 cm3 equals 1 mL the concentration of cells per ml can 
be calculated using the following equation: 
 Cells/mL = average cell count per square x 104 
The calculated cell concentration was then used to plate out cell at the required 
density. 
2.7.3 Proliferation Assay 
Murine VSMCs isolated and grown until passage 4 to 6 were trypsinised and 
counted as described in sections 2.7.1 and 2.7.2, respectively. Cells from miR-21 
WT and KO mice were seeded into 96 well plates at a density of 7x103 cells/well 
in DMEM with 10 % FCS and incubated overnight at 37ºC in the presence of 5% 
CO2. VSMCs were quiesced for 24 h by changing media to DMEM with 0.2% FCS, 
100 international units (I/U)/mL penicillin, 100 µg/mL streptomycin and 2 mM L-
glutamine. Following quiescence cell proliferation was stimulated by the 
replacement of media with media containing one of four experimental 
conditions: 10% FCS, PDGF-ββ (R&D Systems, Abingdon, UK) 10 ng/mL, PDGF-ββ 
20 ng/mL or PDGF-ββ 50 ng/mL. 0.2 % FCS was used as control. All experimental 
conditions were conducted in biological triplicate and technical duplicate. 
Experiments were terminated at 48 h.  
Proliferation of VSMCs was assessed using a commercially available 5-Bromo-2’-
deoxyuridine (BrdU) assay (Millipore, Livingstone, UK). BrdU, a thymidine 
analogue is incorporated into newly synthesized DNA strands of actively 
proliferating cells. The incorporation of BrdU can be detected immunologically 
thus allowing the assessment of cells using a colourimetric method for 
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determining the quantity of BrdU incorporation. The manufacturer’s protocol 
was followed as outlined. Five hours following the stimulation of quiesced cells 
under experimental conditions BrdU was added at a final concentration of 1:500 
from supplied stock. This allowed DNA repair to occur following changing of cell 
media without BrdU incorporation. After 48 h cell media was removed and cells 
washed twice with sterile PBS, followed by the addition of the supplied fixing 
solution to fix and partially denature DNA thus allowing immunological detection 
of BrdU. After 30 min the fixing solution was removed and cells washed with 
supplied wash buffer. The 96 well plate was then blotted dry and samples 
incubated with mouse anti-BrdU antibody for one hour at room temperature 
followed by further washing to remove unbound primary antibody. Samples were 
then incubated with goat anti-mouse IgG peroxidase conjugated antibody for 30 
min before unbound antibody was removed by washing. The plate was blotted 
dry prior to incubation with 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate for 
30 min in the dark. The absorbance of the blue product is directly proportional 
to the quantity of BrdU incorporated and was measured using a 
spectrophotometer microplate reader set at a dual wavelength of 450 / 550 nm. 
Absorbance readings from wells which did not have BrdU added were subtracted 
from experimental readings prior to further analysis. 
2.7.4 Migration Assay 
Scratch assay was utilised to assess cell migration (Liang et al., 2007). VSMCs 
isolated from miR-21 WT and KO mice as described in section 2.7.1 were seeded 
into 12 well plates at a density of 1x105 cells per well and grown in DMEM with 
10% FCS and incubated overnight at 37ºC in the presence of 5% CO2 until fully 
confluent. The cells were quiesced as described in section2.7.3. Horizontal lines 
were drawn on the under surface of each well to act as a reference for 
measurements. Three straight, scratches perpendicular to the reference lines 
were incised in the cell monolayer of each well using a sterile 200 µl pipette tip. 
Cellular debris was removed by gently washing cells once with 1 mL of sterile 
PBS. Cells were incubated with DMEM containing either 0.2% FCS, 10% FCS or 
PDGF-ββ 20 ng/mL. All experiments were run in biological triplicate and 
technical duplicate. Images of the scratch were taken at the same position in 
relation to the reference line in each well using a Nikon Eclipse TS1000 
microscope and imaged on QICAM Fast1394 camera (QImaging, Maidenhead, UK) 
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at 0, 6, 12 and 24 h. Image analysis was performed using Image pro software. 
The distance between wound edges were measured in 10 places and an average 
taken, Figure 2-11. Distance migrated between each time point was analysed. 
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Figure 2-11. . Migration Assay. Incised scratch and measurements between wound edges. 
Scale bar = 100 µm. 
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2.8 Murine Monocyte and Macrophages  
2.8.1 Isolation and Culture of Murine Bone Marrow Cells 
Male mice were euthanized as per section 2.7.1. Both hind legs from the 
acetabulum to foot were amputated, covering pelt removed and placed in serum 
free wash media (RPMI containing, 100 IU/mL penicillin, 100 µg/mL streptomycin 
and 2 mM L-glutamine) on ice prior to transfer into a tissue culture hood with 
laminar airflow. The intact tibia and femur from each leg were carefully isolated 
by removal of all muscle tissue. The epiphyses were removed to expose the bone 
marrow cavity and bone marrow flushed out into a petri dish using a 25 G 
needle. The wash media containing the bone marrow was then filtered through a 
70 µm cell strainer (BD biosciences, Oxford, UK). Cells were then spun at 1500 
rpm, 4oC for 5 min and the supernatant discarded. Red cells were removed by 
adding 2 mL of Red Blood Cell Lysing Buffer Hybri-Max™ (Sigma-Aldrich, Dorset, 
UK) for 2 min. The reaction was arrested by adding 12 mL of wash media and 
centrifuging cells as above. The supernatant was discarded and cells 
resuspended in macrophage growth media (RPMI containing 10% FCS, 100 IU/mL 
penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine). Cells were counted 
as described in section 2.7.2 and 2 million cells were plated into 10 cm petri 
dishes. Eight 10 cm petri dishes were obtained from each animal. In order to 
ensure the differentiation of bone marrow derived monocytes into macrophages 
Macrophage–Colony Stimulating Factor (M-CSF) (Peprotech) was added to each 
petri dish to ensure a final concentration of 50 ng/mL. Complete RPMI media 
containing 50 ng/mL M-CSF was changed every second day  
2.8.2 Polarisation of Bone Marrow Derived Macrophages 
Following 6 days of culture and differentiation from murine monocytes into 
macrophages (section 2.8.1), cell media was removed and cells washed with 
sterile PBS. Two mL of cell dissociation solution was added to each petri dish 
and cells gently scrapped off the bottom of the dish. Cell dissociation solution 
was removed by centrifuging cells at 1500 rpm at 4oC for 5 min then discarding 
supernatant and resuspending them in complete RPMI media without M-CSF. 
Macrophages were counted and plated into 6 well plates at 1 million cells per 
well and left overnight to adhere to culture plates. On day 7 macrophages were 
  93 
 
polarised by changing media for complete RPMI on its own (unstimulated control) 
or complete RPMI either containing LPS (from E.coli 0111:B4), 100 ng/mL, (Enzo 
Life Sciences, Exeter, UK) or IL-4, 2 ng/mL, (Peprotech, London, UK) to drive 
macrophages towards an M1 phenotype or M2 phenotype, respectively.  
Following 24 h of exposure to LPS or IL-4 the conditioned media from cells was 
harvested and stored at -80oC. In addition Macrophages were harvested for 
either flow cytometry immediately or cells lysed by the addition of QIAzol and 
stored at -80oC prior to RNA extraction as per section 2.3. 
2.8.3 Flow Cytometry 
Polarised murine Macrophages (described in section 2.8.2) were harvested by 
adding 500µL of cell dissociation solution to each well, gently scraping each well 
and transferring cells into an Eppendorf. Eight hundred microliters of Flow 
Assisted Cell Sorting (FACS) buffer, composed of standard PBS (pH 7.4) 
containing 2 % FCS and 2 mM EDTA, was added to each cell suspension before 
centrifugation at 12000 rpm for 5 min. Supernatant containing cell dissociation 
solution and FACS buffer was discarded. Cells were resuspended in 50 µL of FACS 
buffer containing Fc receptor block (CD16/CD32) at a final concentration of 
0.005 mg/mL (BD Pharmingen, Oxford, UK). Following incubation with Fc 
receptor block at 4oC for 15 min, 1 µL of fluorescent labelled antibodies were 
added to each tube depending on desired antigen staining. Three staining panels 
were used for all samples. 
Panel 1: F4/80 
Panel 2: F4/80, MHC II, TLR2, CD206, CD86 
Panel 3: F4/80, CD69, CD11c 
Table 2-5 contains the antibodies used and their fluorescent label. Following 
incubation of samples with appropriate antibodies for 30 min on ice and in 
darkness, 1 mL of FACS buffer was added and cells centrifuged at 12000 rpm for 
5 min. The supernatant was discarded and cells resuspended in 300 µL of FACS 
buffer prior to analysis using a BD FACS Canto™ II. (BD biosciences, Oxford, UK). 
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An unstained sample, samples stained with each individual antibody, and 
samples stained with all but one antibody were used as controls to facilitate 
calibration of the FACS machine. 
Table 2-5. FACS Antibodies. 
  
Supplier Antibody Clone
eBiosciences CD86,FITC GL1
F4/806antigen6APC,efluor6
780
BM8
MHC6Class6II,PE,CY7 M5/114.15.2
TLR2(CD282),PE 6C2
Biolegend CD206,APC C068C2
BD6biosciences CD11c,FITC HL3
CD696PerCP,Cy65.5 H1.2FE
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2.9 Luminex Assay 
Quantitative analysis of cytokines present within the conditioned media from 
miR-21 WT and KO polarised murine macrophages was conducted using a murine 
20-plex Luminex™ kit (Invitrogen, Paisley, UK, catalogue number 
LMC0006)(Goritzka et al., 2014). Cytokines measured simultaneously were FGF-
basic, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, 
IP-10, KC, MCP-1, MIG, MIP-1α, TNF-α and VEGF. 
The assay was conducted in accordance with manufacturer’s protocol. The 
principle of the assay is as follows. Polystyrene beads of 5.6 µm diameter 
conjugated with antibodies specific to one of the above cytokines are internally 
stained with a fluorophore of defined spectral property. The beads were added 
to samples of interest (in addition to controls and known standards of each 
cytokine) which had been placed in a 96 well filter bottom plate. Any cytokines 
of interest bound to the antibody covered beads immobilised on the floor of the 
plate.  
Following incubation the beads were then washed and cytokine specific 
biotinylated detector antibodies added which bound the immobilised protein. 
Excess unbound biotinylated antibodies were removed by washing.  
Streptavidin-R-Phycoerythrin conjugate was then added and allowed to incubate 
for 30 min following which excess reagent was removed by washing. The 
Streptavidin bound to the biotinylated detector antibodies associated with the 
immune complexes on the beads thus completed a four-layer sandwich, Figure 2-
12. 
The Luminex™ 100 plate reader was used to detect the spectral properties of the 
beads and the amount of associated R-Phycoerythrin (RPE) fluorescence, thus 
allowing the concentration of each cytokine to be determined. 
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Figure 2-12. Pictorial Representation of Luminex Assay. A, Antibody conjugated beads 
stained with fluorophore unique to each cytokine.  B, Analyte bound to antibody. C 
Biotinylated secondary antibody. D. Streptavidin-R-Phycoerythrin.  
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2.10  Conditioned Media Experiments  
VSMCs isolated from WT and KO mice as described in section 2.7.1 were plated 
out into 96 well plates at a seeding density of 7x103 cells per well, n=3 for each. 
The effect on VSMC proliferation was assessed by incubating quiesced VSMCs 
with 150 µL conditioned media from polarised WT and KO macrophages for 48 h. 
A proliferation assay using BrdU was conducted as described in section 2.7.3. 0.2 
% FCS and 10 % FCS were used as negative and positive controls, respectively.   
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2.11 Arterial Stenting and Grafting Operation 
The mouse stenting model described below is taken from Ali et al (Ali et al., 
2007). To reduce the risk of in stent thrombosis (IST) one week prior to surgery 
procedure each mouse had their drinking water supplemented with Aspirin 
(Boots, Byres Road) at a concentration of 300mg/L. Each procedure was carried 
out under sterile conditions and under direct microscopy. A donor mouse was 
selected and by intraperitoneal (IP) injection given an overdose of 
pentobarbitone (200mg/mL). The abdomen and thorax exposed anteriorly and 
thoracic cage was reflected superiorly to expose the heart. The right atrium was 
opened and the left ventricle perfused with 10ml of heparinised saline 
(10units/ml). The aorta was then exposed and the layer of adipose tissue 
dissected from its anterior surface. A small v-shaped incision was made in the 
aorta at the level of the diaphragm and a deflated 1.2 mm x 8 mm minitrek 
(Abbott Vascular, Paisley UK) coronary balloon catheter onto which a 1.25 mm 
long stainless steel stent had been hand crimped was passed retrogradely into 
the thoracic aorta. Using an Encore 26 Advantage Kit (Boston Scientific, 
Massachusetts USA) inflation device the coronary balloon was inflated and stent 
deployed at 10 atmospheres of pressure. After 30 s the balloon was deflated and 
removed leaving the stent in situ. The thoracic aorta from diaphragm to arch 
including stent was harvested using diathermy to cauterise and seal all 
intercostal vessels. The harvested stented aorta was stored in heparinised saline 
prior to interposition grafting into a recipient mouse of similar genotype.  
The recipient mouse was anaesthetised with a 1:1 mixture of midazolam and 
buprenorphine according to weight at a dose of 0.3 mg/kg, for each drug. The 
recipient mouse was placed supine on a heated mat and given supplemental 
oxygen via a nose cone for the duration of the procedure. Lack of a withdrawal 
reflex to pain was used to determine that an appropriate depth of anaesthesia 
was achieved. The ventral surface of its neck was shaved and cleaned with 
chlorhexidine before a 1 - 1.5 cm midline incision was made from the 
suprasternal notch extending superiorly. The right salivary gland was reflected 
laterally and wrapped in a saline soaked swab. The right sternocleidomastoid 
muscle was isolated, ligated with 6-0 silk suture, transected cranial to the 
suture and reflected infero-laterally in order to expose the right neurovascular 
bundle containing the right carotid artery. The common carotid was isolated and 
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separated from all surrounding fascia between the level of the thoracic cage and 
point of bifurcation into its internal and external branches. The common carotid 
was ligated and transected between two 7-0 silk sutures. Polyurethane cuffs 0.8 
mm diameter were threaded onto each side of the carotid and held in place with 
micro-haemostatic clips (Braun, UK) in order to maintain haemostasis while the 
7-0 sutures placed previously were removed. Each cut end of carotid was 
reflected over the corresponding cuff and held in place using 8-0 silk sutures. 
The stented graft was then flushed with saline to remove heparin and sleeved 
onto either end, before being secured in place using 7-0 silk sutures. The micro-
haemostatic clips were carefully removed, both anastomoses checked for 
haemostasis and vigorous pulsation seen within graft. Figure 2-13 summarises 
the key steps involved in the stenting operation. The graft was covered by 
replacement of the sternocleidomastoid muscle and salivary gland prior to 
closure of the skin with 5-0 vicryl suture. Animals were recovered following a 
subcutaneous injection of 1 ml of saline in a heated cage with close observation. 
If their recovery was prolonged or they showed signs of distress they were 
euthanized using a schedule one method. Animals were maintained on aspirin 
supplemented water until harvesting of the graft at day 28 post-operatively, 
although some animals were sacrificed immediately after grafting. At harvesting 
animals were euthanized using a schedule one method, the heart was then 
perfused with saline and the graft, aorta, contralateral carotid artery and heart 
were removed. Tissues were fixed for 12 h in 4% Paraformaldehyde (PFA). 
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Figure 2-13. : Stenting Procedure. A, Donor Aorta. B & C, Balloon catheter with stent in aorta 
deflated and inflated respectively. D, Deployed stent. E, Carotid of recipient everted and 
secured over plastic cuff. F Graft secured in situ. G, Distal clip released demonstrating 
retrograde filling of graft (arrow). H, Successful stented graft with pulsatile flow. 
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2.12 Tissue Processing 
Following fixation in 4% PFA the graft was stored in either PBS or 70% ethanol for 
at least 24 h prior to further processing.  
2.12.1 Electrolysis 
The graft was sectioned into three parts, proximal, stented and distal, Figure 2-
14. The stented section was immersed in PBS and a v-shaped incision made in 
the distal end of the tissue overlying a stent strut. The exposed stent loop was 
then mounted onto either a stainless steel spring from a ball point pen (Bic, 
Ryman Stationers Byres Road), copper or solid silver wire (gift from Nosrat 
Mirzai, Bioelectronics, University of Glasgow). The other end of the tissue was 
partially submerged in a 5% citric acid solution with 5% (w/v) sodium chloride. 
The stainless steel spring was suspended on the stainless steel stylet from a 
minitrek balloon catheter and threaded through a truncated 18 G needle, The 18 
G needle was used as a guide to maintain a central position of the stented tissue 
within the chamber, preventing its direct contact with the copper cathode. The 
stent and wire / spring were connected to the anode from a DC power source 
and the cathode submerged in the citric saline solution. Three to 12 Volts and 
0.1 mA were run across the circuit containing the stent ensuring that bubbles of 
gas were being released from the cathode. After between 5 and 30 min the stent 
had partially dissolved. Undissolved stent was either reconnected to the spring 
and the process repeated or carefully removed by manual dissection under 
microscopy. Figure 2-15 shows apparatus used for electrolysis of stented mouse 
tissue. 
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Figure 2-14. Schematic of Graft. Demonstrating gross dissection of graft to remove stented 
section for electrolysis. Plastic cuffs (blue), Stented graft (pink). Proximal and distal graft 
(yellow). 
  
Plastic Cuff
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Figure 2-15. Electrolysis Apparatus. A. DC power pack top left, bijou, connector leads and 
bottle containing electrolysis solution. B. Electrolysis chamber consisting of bijou, copper 
cathode and stainless steel spring. 
  
A
B
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2.12.2 Tissue Embedding 
All tissues, including those from which the stent had been dissolved, were stored 
in 70% ethanol prior to processing overnight in an automated Shandon Excelsior 
Tissue processor. Tissues were automatically submerged in increasing alcohol 
gradients followed by xylene then finally in molten wax. The exact processing 
series of gradients were as follows, 70% ethanol 30 min, 95% ethanol 30 min, 
absolute ethanol 30 min, absolute ethanol 30 min, absolute ethanol 45 min, 
absolute ethanol 45 min, absolute ethanol 1 hour, absolute ethanol/xylene 30 
min, xylene 30 min, xylene 30 min, wax 30 min, wax 30 min, wax 45 min and 
wax 45 min. Following processing tissues were embedded in paraffin wax blocks 
using a Shandon Histocentre 3. 
2.12.3 Tissue Sectioning 
Paraffin embedded tissue blocks were cooled to 4oC and cut into sections 
between 3 and 7 microns thick using a bench top microtome, Leica RM2235 
(Leica, Milton Keynes, UK). Tissue sections were floated on a Leica HI1210 water 
bath (Leica, Milton Keynes, UK) at 40oC containing 0.01% Tween20 prior to 
mounting on silanized glass slides (Thermo Scientific, Germany). Tissues were 
baked onto slides overnight at 60oC. 
  
  105 
 
2.13 Histochemical Staining 
2.13.1 Deparaffinisation and Rehydration  
Prior to all staining protocols tissues were deparaffinised and rehydrated by 
immersion in 2 x 5 min washes of Histoclear (ThermoScientific, UK) followed by 
graded concentrations of ethanol: 100%, 90%, 70% for 5 min each and maintained 
under running tap water for 5 min.  
2.13.2 Haematoxylin and Eosin 
Tissue sections were deparaffinised as above and slides placed in Harris 
Haematoxylin for 2 min, then rinsed in running tap water for 2 min prior to 
immersion in eosin for a further 2 min. Excess eosin was removed by tapping 
slides and tissue sections were then dehydrated in 90% ethanol 2 x 5 min washes, 
100% ethanol 2 x 5 min washes and finally Histoclear 2 x 5 min washes. 
Coverslips were mounted onto slides with DPX mount. 
2.13.3 Elastic Van Geison 
Following deparaffinisation using protocols documented above, tissue sections 
were placed in potassium permanganate (0.5% w/v) for 10 min then rinsed in 
running tap water for 5 min prior to immersion in oxalic acid (1% w/v) for a 
further 5 min. Slides were again rinsed in running tap water for 5 min, dipped in 
70% ethanol then immersed in Miller’s Stain (catalogue number 3511545) (VWR 
International Ltd, Lutterworth, UK) for 3 h. Slides were then removed, excess 
Miller’s stain tapped off and rinsed by immersing 5 times in 70% ethanol. The 
slides were then washed in distilled water for 5 min prior to counter staining in 
Van Geison’s solution for 10 min. 
2.13.4 Picro-sirius Red 
Deparaffinised and rehydrated tissues were immersed in Weigert’s Haematoxylin 
for 8 min to counterstain nuclei. Weigert’s haematoxylin was purchased as two 
separate solutions. Weigert’s Solution A (cat HS375) and Weigert’s Solution B 
(cat HS 380) (TCS Biosciences Ltd, Buckingham, UK) and mixed in equal 
quantities immediately prior to use. Slides were then washed for 10 min in 
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running tap water. A saturated aqueous solution of picric acid was made by 
adding 0.5 g Sirus Red (cat 365548) (Sigma-Aldrich, Dorset, UK) to deionised 
water until saturated. The slides were immersed in the picric acid solution. After 
90 min the slides were given 2 x 5 min washes in acidified water. Acidified water 
was made by adding 0.86 ml of glacial hydrochloric acid (HCl) to 1 litre of water 
giving a final concentration of 0.01 M. Slides were then tapped and blotted with 
tissue to remove as much excess water as possible before 2 x 5 min washes in 
absolute ethanol followed by 2 x 5 min in Histoclear. Coverslips were mounted as 
previously described. 
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2.14 Immunohistochemistry 
The following general protocol for immunohistochemical staining was followed 
for each antibody unless otherwise stated.  
2.14.1 Antigen Retrieval 
After deparaffinisation and rehydration, described previously, antigen retrieval 
was achieved by boiling the slides in a prewarmed citrate buffer (10 mM, pH 6) 
using a microwave. For cytoplasmic and nuclear staining 10 min and 20 min of 
microwaving were required respectively. Antigen retrieval was not required for 
MAC-2. Care was taken to top up citrate buffer at regular intervals to avoid 
tissues drying out. Tissue slides were allowed to cool slowly over 20 - 30 min at 
room temperature in order to minimise epitope refolding then placed under 
running tap water for 10 min. 
2.14.2 Quenching of Endogenous Peroxidases 
Slides were immersed in distilled water containing 3% H2O2 for 10 min at room 
temperature to block endogenous peroxidase activity and then rinsed for 10 min 
in running tap water. 
2.14.3 Blocking 
Tissue sections were encircled using a wax pen and non-specific staining was 
reduced by incubating tissue sections with blocking buffer for one hour. Blocking 
buffer was composed of phosphate buffered saline (PBS) containing 0.05% 
Tween20 plus 20% normal serum from the species in which the secondary 
antibody was raised. For YM-1 staining the blocking buffer also contained 5% 
bovine serum albumin (BSA). 
2.14.4 Primary and Secondary Antibody Incubation 
Blocking buffer was removed by tapping slides and the appropriate primary 
antibody or isotype matched IgG control applied. All primary antibodies were 
diluted in PBS containing 2% serum from the species in which the secondary 
antibody was raised. Following incubation overnight at 4oC in a humidified 
chamber excess primary antibody was removed with 2 x 15 min washes in PBS-T. 
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After washing sections with TBS they were then incubated with appropriate 
biotinylated secondary antibody diluted in PBS-T with 2% serum for 1 hour at 
room temperature.. Table 2-6 contains the different antibodies and the dilutions 
used. 
2.14.5 Antibody detection 
Excess unbound secondary antibody was removed by 2 x 15 min washes in PBS-T. 
Sections were then incubated with Extravidin-Peroxidase (cat E-2886 Sigma) 
diluted 1 : 200 in PBS-T. Staining was visualized using 3,3 diaminobenzidine 
(Vector Labs SK-4100) and nuclei were counterstained with Mayer’s 
haematoxylin for 30 s. 
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. Table 2-6. Immunohistochemistry Antibodies. 
Primary'
Antibody'
Supplier' Species'and'
Clonality'
Dilution' IgG'
control'
Secondary'
Antibody'
'
Dilution' Blocking'
Serum'
Anti<Alpha'
Smooth'
Muscle'
Actin'
Abcam!
(ab5694)!
Rabbit!
Polyclonal!
IgG!
1!in!200! Normal!
Rabbit!IgG!
control!
Invitrogen!
(10500C)!
Goat!anti@
rabbit!
Vector!Labs!
(BA@1000)!
1!in!200! Normal!
Goat!
Serum!
Vector!
Labs!(S@
1000)!
PCNA' Abcam!
(ab2426)!
Rabbit!
Polyclonal!
IgG!
1!in!200! Normal!
Rabbit!IgG!
control!
Invitrogen!
(10500C)!
Goat!anti@
rabbit!
Vector!Labs!
(BA@1000)!
1!in!250! Normal!
Goat!
Serum!
Vector!
Labs!(S@
1000)!
CD31'
(PECAM)'
Histonova!
(SZ31)!
Rat!
Monoclonal!
IgG!
1!in!20! Rat!IgG2a!
BD!
Pharminge
n!(559073)!
Rabbit!anti@
rat!Vector!
Labs!(BA@
4000)!
1!in!200! Normal!
Rabbit!
Serum!
Vector!
Labs!(S@
5000)!
MAC<2' Cedarlane!
(CL8942AP)!
Rat!
Monoclonal!
IgG!
1!in!5000! Rat!IgG2a!
BD!
Pharminge
n!(559073)!
Rabbit!anti@
rat!Vector!
Labs!(BA@
4000)!
1!in!200! Normal!
Rabbit!
Serum!
Vector!
Labs!(S@
5000!
YM<1'(Anti<
Chitinase<3'
like'Protein'
3)'
Abcam!
(ab93034)!
Rabbit!
Polyclonal!
IgG!
1!in!500! Normal!
Rabbit!IgG!
control!
Invitrogen!
(10500C)!
Goat!anti@
rabbit!
Vector!Labs!
(BA@1000)!
1!in!200! Normal!
Goat!
Serum!
Vector!
Labs!(S@
1000)!
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2.15 In situ Hybridisation  
Tissue section cut to 7 µM and baked onto silanized slides at 60 °C overnight 
were deparaffinised and rehydrated as described previously.  
2.15.1 Unmasking and Deproteinating Sections 
Sections were placed in freshly prepared 0.1% DEPC for 1hr then transferred 
them into DEPC-treated 10 mM sodium citrate buffer, pH 6, and heated in a 
microwave for 10 min. The samples were then allowed to cool for 15 min at 
room temperature prior to washing in PBS for 1 min. Slides were immersed in 0.2 
M HCl for 20mins then washed in DEPC-treated PBS 2 x 5 min and further 
immersed in 0.3% Triton-X in DEPC treated PBS for 10 min. Slides were then 
washed again with DEPC-treated PBS 3 x 5 min and then prewarmed (37oC) 
proteinase K (10ug/mL in DEPC-treated PBS) applied to each section in a 
humidified chamber at 37oC. After 20 min, sections were rinsed with DEPC-
treated PBS 2 x 5 min and fixed in 4% PFA in DEPC treated PBS for 10 min at 
room temperature.  
2.15.2 Hybridisation 
Fifty to 100 µL of hybridisation buffer (50 % deionised formamide, 4 x standard 
saline citrate (SSC), 2.5 % Denhardt’s solution, 0.245 µg/mL salmon sperm DNA, 
0.2 mg/mL yeast transfer RNA, 0.025 % SDS and 0.1 % DIG-blocking reagent 
(Roche) was placed on each section and a cover slip added. Slides were placed in 
a sealed, humidified, RNase free box at hybridisation temperature for 1 hour 
(miR-21 52°C, scramble 58°C). Probe was then diluted in hybridisation buffer 
(1.6 µL probe per 1mL hybridisation buffer, final conc. 40 nM) and heated to 
95°C to linearise and then chilled on ice. Twenty-five to 50 µL of probe was 
added per slide and covered with a coverslip and incubated overnight at 
hybridisation temperature in the humidified RNAse free box wrapped in saran 
wrap. 
2.15.3 Stringency washing  
Coverslips were gently removed with 5 x SSC before being washed in 1 x SSC at 
hybridisation temperature for 20 min then in 0.2 x SSC at hybridisation 
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temperature for 20 min. Slides were then further washed at room temperature 
in 0.2 x SSC for 5 min while being gently agitated on a shaker and finally washed 
in 1 x DEPC-treated PBS at room temp for 5 min on a shaker. 
2.15.4 Immunological detection 
Sections were incubated with blocking buffer (0.5% blocking reagent (Roche), 
10% heat inactivated goat serum, 0.1% Tween, 1 x PBS) for one hour prior to 
overnight antibody incubation (1 : 500) anti-Dig-AP Fab (Roche) in blocking 
buffer + 10 % heat inactivated goat serum in humidified chamber at 4°C. The 
following day sections were given 3 x 5 min washes in PBS-Tween20 (0.05%) 
followed by 3 x 10 min washes in AP buffer 100 mM Tris HCL pH 9.5, 100 mM 
NaCl, 0.1% Tween 20). BM Purple AP (Roche) + 2 mM Tetrazolium (1000 x 
inhibitor) was then added to each section protected from light and left at room 
temperature until colour development (8 - 48 h). Slides were then given 3 x 5 
min washes in PBS-T, rinsed for 5 min in running tap water, mounted with 
aqueous mounting solution and edges sealed with clear nail varnish (Boots, Byres 
Road UK) 
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2.16 Image Analysis 
2.16.1 Image Acquisition and Analysis 
Images of tissue sections obtained with QCapture software were taken using a 
Qimaging Micropublisher 3.3 RTV camera with mounted on an upright Olympus 
BX 40 microscope. Both morphometry and staining analysis was conducted using 
ImagePro software. Figure 2-16 demonstrates morphological analysis in a stented 
section with a large neointima. Figure 2-17 shows an example of staining 
quantification within the area of interest used for all stains except re-
endothelialisation, which was calculated as a percentage of luminal 
circumference. Prior to image acquisition and analysis, slides were anonymised 
by removing all identifiable information and the allocation of random numbers 
by an independent researcher from within the Baker group. Following analysis 
the genetic identity of the samples was unblinded in order that conclusions 
could be drawn from the data obtained. 
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Figure 2-16. Example of Morphological Analysis. Measurements highlighted in yellow including total vessel, luminal, medial and neointimal areas.  
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Figure 2-17. A, Area of interest (neointima) highlighted in green. B &C, Areas of staining highlighted (red) and quantified as percentage of total area of 
interest
A CB
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2.17 Statistical analysis 
Data is presented as mean ± SEM unless otherwise stated. In vivo experiments 
were conducted from n = 3 – 12 animals per group. In vitro experiments were 
conducted in biological triplicate on three independent occasions except for 
Luminex assay, which was conducted once.  
All statistical analysis was carried out using GraphPad Prism 4. Data was assessed 
for normality. Parametric data was analysed by Student’s t-test when comparing 
two groups or one way ANOVA with Bonferroni’s correction for multiple testing 
when comparing more than two groups. A p value <0.05 was considered 
significant.  
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3 Refinement of the Mouse Model of ISR and Stent 
Electrolysis 
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3.1 Introduction 
Vascular disease is a complex pathological process involving the interaction, 
proliferation and migration of multiple cell types including inflammatory cells, 
endothelial cells, smooth muscle cells and fibroblasts among others (Ross, 1999). 
Additionally, a significant role is played by cytokines, growth factors and 
proteases released from these cell types which act in both an autocrine and 
paracrine fashion (reviewed in (Ross, 1999).  
Adding further to the complexity of vascular pathology is that rather than being 
a single process it has become clear vascular disease is a heterogeneous group of 
pathologies, several of which are iatrogenic in their aetiology. Thus vascular 
disease encompasses a group of conditions including native vessel 
atherosclerosis, arteriosclerosis obliterans, cardiac allograft vasculopathy, vein 
graft neointimal hyperplasia and in-stent restenosis (Mehran et al., 1999, 
Motwani and Topol, 1998, Mancini et al., 2003).  
The accurate and relevant replication of such a complex pathology in vitro is not 
possible; hence many studies of vascular pathology involve in vivo investigations 
using animal models (Waksman et al., 2012). Indeed many different animal 
models have been developed to mimic the variety of vascular pathologies noted 
above. Models of restenosis have been developed in several different species 
including large animals such as dog, pig, rabbit and non-human primates (Roubin 
et al., 1987, Ragosta et al., 1994, Ialenti et al., 2011, Geary et al., 1996). These 
models are attractive due to the comparable size of the target artery with 
human coronary arteries. However, none perfectly replicate human disease and 
have other associated problems. Dogs do not easily develop atherosclerosis and 
exhibit only a mild reaction upon balloon angioplasty or stenting (Roubin et al., 
1987, Schwartz et al., 1994).  
While rabbits can develop atherosclerosis when placed on high fat diets, many of 
the injury models use a two stage process involving air desiccation or balloon 
abrasion prior to angioplasty; thus calling into question how well they actually 
replicate human disease (Wilensky et al., 1995, Ragosta et al., 1994). In addition 
the neointima formed in rabbits following stenting contains a large proportion of 
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foam cells, which is not seen in human vessels following stenting (Feldman et 
al., 2000).  
The porcine single injury model of angioplasty and stenting is well utilised and 
produces a significant neointimal lesion proportional to the degree of injury in 
both the carotid and coronary arteries (Steele et al., 1985, Schwartz et al., 
1990, Ialenti et al., 2011). While the neointimal lesion formed resembles that in 
humans, with a high proportion of VSMCs present, the degree of injury inflicted 
is far greater than that seen in clinical practice. However, due to thrombotic 
complications observed in pigs they are, like humans, maintained on dual 
antiplatelet therapy following percutaneous intervention (Ialenti et al., 2011).  
Non-human primate models are rarely utilised despite their close evolutionary 
link due to cost, the long period required for atherosclerosis development and 
difficulties with animal handling (Geary et al., 1996).  
Small animal models of vascular injury have been far more widely used to study 
the development of NIH as they are cheap, easy to undertake and allow 
consistent lesion generation. The 1970s saw the earliest small animal models of 
vascular injury being developed with rat carotid arteries being subjected to air 
desiccation along their luminal surface, producing endothelial denudation and 
subsequent NIH (Fishman et al., 1975). The lack of clinical relevance with the air 
induced injury model resulted in the development of two other models. Firstly, a 
balloon injury model was developed whereby a balloon catheter was passed into 
the common carotid via a branch of the external carotid and inflated three times 
(Clowes and Clowes, 1986). This not only denuded the vessel lumen but also 
damaged the vessel media eliciting a large neointimal hyperplastic response. In 
order to dissect out the relative contributions of platelet aggregation, 
thrombosis and medial injury to the development of neointimal hyperplasia a 
third model of vascular injury was devised. By passing a 5/0 nylon monofilament 
along the luminal surface of the carotid artery three times, almost complete 
endothelial denudation could be achieved (Fingerle et al., 1990). This produced 
a smaller neointimal response than observed with balloon injury due to sparing 
of internal elastic lamina and VSMCs within the vessel media from damage. 
Unfortunately, while the above models of vascular injury have been well utilised 
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they have failed to fully reveal the molecular mechanisms underlying NIH 
following vessel injury.  
Attracted by the huge number of transgenic and knockout mouse strains 
available, researchers have developed several mouse models of vascular injury. 
These have allowed scientists to elucidate the contribution from individual cells, 
cytokines, growth factors and proteases to the development of NIH (Ikeda et al., 
1991, Zimmerman et al., 2002). With the exception of carotid artery ligation 
these models, including wire or filament injury, electrical injury, and adventitial 
cuff placement have been directly adapted from the rat or other animal species 
(Moroi et al., 1998, Lindner et al., 1993, Hui, 2008, Kumar and Lindner, 1997, 
Carmeliet et al., 1997). Despite the wealth of knowledge gained from these 
mouse models they still do not accurately mimic human disease.  
The routine use of stents, coronary artery bypass grafting and increasing 
prevalence of heart transplantation within clinical practice has pushed 
researchers to develop more clinically relevant small animal models. Many of 
these more complex models mimicking specific clinical situations have 
intentionally been developed in mice. Indeed models of vein grafting and cardiac 
allograft vasculopathy were the next to be successfully developed. Almost a 
decade after the publication of the first mouse vein grafting model and seven 
years after the publication of the first allograft vasculopathy model a stenting 
model was finally developed which could be used in mice. This first stenting 
model, developed in the Channon laboratory, is based on the carotid 
interposition grafting models mentioned above (Ali et al., 2007). A small custom 
made stent is deployed within the aorta of a donor mouse and then grafted into 
the carotid artery of a recipient mouse using plastic cuffs to aid the creation of 
vascular anastomoses.  
Despite the development of several murine stenting models histological analysis 
remains challenging due to the inability to cut tissues containing metal stents on 
standard microtomes. Although tissue resin embedding can be undertaken, 
cutting requires the use of a diamond tipped saw and laborious polishing of 
sections, disrupting the tissue architecture (Watt et al., 2013). In addition, in 
depth immunohistochemical analysis cannot be undertaken due to the inability 
of antibodies to penetrate the resin (Malik et al., 1998, Torgersen et al., 2009). 
  120 
 
These obstacles have limited the widespread use of such stenting models and our 
knowledge of the molecular mechanisms underlying ISR development. 
3.2 Aims 
1. To introduce to our lab the mouse model of stenting pioneered in the 
Channon Laboratory Oxford.  
2. To develop a reliable method of electrochemical dissolution of the metal 
stent ex vivo and allow the in-depth characterisation of neointimal 
content by immunohistochemistry. 
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3.3 Results 
3.3.1 Replication and Complications of the Stenting Model 
The in vivo stenting model developed by the Channon laboratory (Ali et al., 
2007) was successfully replicated but not without difficulty mainly due to the 
high degree of surgical skill required. The highest mortality was encountered 
during the early stages of this study when attempting recovery surgery but by 
the end of the complete study programme all cause mortality in recipient mice 
had decreased to 4% within the final cohort (n = 50).  
The in vivo procedure was initially undertaken in 50 mice (25 donors and 25 
recipients). Two recipient mice suffered carotid rupture, 10 mice could not be 
recovered due to anastomotic failure. All were schedule one culled while under 
general anaesthesia. Two died of anaesthetic overdose. Of those recovered two 
mice were culled by schedule one method at day 1 and day 6 due to poor 
condition and visible distress. At post mortem one was found to have graft 
thrombosis the other a neck abscess. Nine animals were successfully recovered 
and stented grafts harvested at 28 days post operatively. All of these successful 
operations were undertaken towards the end of the operating list. Of the 9 
animals surviving to 28 days, 2 grafts were found to have occluded. Examination 
of the occluded grafts showed in-stent thrombosis likely due to under 
deployment of the stent resulting in malaposition with the vessel wall. 
Inspection of tissue sections revealed concentric layers of thrombus interspersed 
with inflammatory cells. In some grafts infiltration of thrombus by VSMCs was 
observed. Figure 3-18 shows graft thrombosis and thrombus architecture. Figure 
3-19 demonstrates macrophage staining within a thrombosed graft. 
Complications observed were divided into early (peri-operatively and up to 1 day 
post-operatively) and late (>1 day postoperatively). Early complications included 
minor haemorrhage, major haemorrhage and death under anaesthesia. Minor 
haemorrhage was usually due to capillary rupture during tissue manipulation and 
was treated with direct manual pressure using gauze or a cotton bud. Major 
haemorrhage, either from failure to maintain haemostasis during carotid 
manipulation or failure of either anastomosis, commonly resulted in death. 
Where haemostasis could not be regained and death due to major haemorrhage 
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was deemed inevitable cervical dislocation was used to humanely kill the 
animal. Another early complication of surgery was death due to overdose of 
anaesthesia resulting from additional doses of injectable anaesthetics being 
administered intra-operatively in an attempt maintain an appropriate depth of 
anaesthesia for the duration of the operation. This complication was initially 
abrogated by the use of supplemental oxygen with additional doses and 
eventually completely eliminated by the reduction in operation duration from 1 
hour 20 minutes to 30 minutes. Late complications also included haemorrhage, 
usually due to a persistent small leak, stroke due to graft thrombosis with 
embolisation and rarely infection.  
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Figure 3-18. Graft Thrombosis. A, Harvested graft with thrombus visible underlying stent. B, 
Thrombosed stented section demonstrating malaposition of stent against vessel wall (H&E) 
10x. C, In-Stent Thrombosis stained with picro-sirus red showing the gradual build-up of 
thrombus in layers encroaching on the vessel lumen 10x. * - Stent strut location, Arrow - 
thrombus, Arrowhead – media. Scale bar = 100 μm. Representative sections from n=1. 
A
B C
*
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Figure 3-19. Macrophage Staining. A, B, C and D, Total macrophage staining with MAC-2. 
Macrophages present within the adventitia and within layers of thrombus (D dotted line). 
E,F,G and H, Alternatively activated macrophages predominate around stent struts and are 
less populous within adventitia. (Inserts-IgG control). Positive staining represented by 
brown colour. Boxes in panels A and E represent areas of higher magnification depicted in 
other panels. Scale bar = 100 μm. Representative sections from n=1. 
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3.3.2 Optimisation of Stent Electrolysis Protocol and Staining 
Following fixation in 4% PFA, electrochemical dissolution of the metallic stent to 
allow tissue sectioning was undertaken as described in Chapter 2. The five main 
variables requiring optimisation were the: 
1. Containment apparatus. 
2. Solution used in the electrolysis process.  
3. Solution in which tissues were stored. 
4. Electrodes/connection.  
5. Voltage delivered by the DC power pack.  
 
3.3.2.1 Containment Apparatus 
Initially a 500 mL plastic mineral water bottle was used as the containment 
vessel and successfully dissolved a bare metal stent (Driver 3.0 x 24 mm, 
Medtronic) that was not encased in tissue. Progressively smaller containment 
vessels were investigated until a 5 mL bijou was found optimal. This allowed for 
more accurate mounting, easier manipulation and better visualisation of murine 
tissue. In addition, precise alteration of fluid level and conformation of a 
conducting circuit by the identification of ionic stream and gaseous bubble 
production was facilitated using a bijou.  
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3.3.2.2 Solution used in electrolysis process 
Three citric acid/sodium chloride solutions were investigated at differing weight 
to volume concentrations, 1% (w/v), 5% (w/v) and 10% (w/v). All were found to 
complete the electrical circuit when bare metal electrodes were used. However, 
only the solutions above 1 % were found to conduct well when tissue samples 
were tried. Thus a solution of citric acid 5% (w/v) and sodium chloride 5% (w/v) 
pH 2, with 50:50 relative proportion of each chosen for all further work.  
3.3.2.3 Storage solution for tissue 
Standard lab protocol suggests storage of tissue in either PBS or 70% ethanol 
following fixation. Tissues stored in PBS allowed conduction to take place with 
bubbles of gas formed at the copper cathode but a stream of metallic ions was 
not observed. Examination of the stented tissue after 10 minutes revealed the 
stent remained almost completely intact and that any degradation of the stent 
occurred randomly across the stent. Stented tissues stored in 70% ethanol for at 
least 24 hours showed more complete stent dissolution and in a more 
predictable manner from the portion of the stent touching the citric saline 
solution up towards its connection with the anode. This is most likely due to the 
PBS infused tissue conducting in addition to the stent itself, while for tissues 
those stored in 70% ethanol only the stent conducted electricity. 
3.3.2.4 Electrodes and connectors 
Formation of a robust connection between the stent and the anode was found to 
be key to maintaining the electric circuit. Several materials were trialled 
including the central stylet from Mini Trek™ coronary balloon, microelectronic 
clip, tightly coiled spring, spring from propelling pen and fine wire. Initially both 
copper and silver wires were used as they are less reactive than the stent and 
should therefore only electrolyse after the stainless steel stent. However, a firm 
connection between wire and stent could not be maintained. Instead the optimal 
electrode-stent connector was found to be a stainless steel spring from a ball 
point pen, which was itself electrolysed into a sharp shallow point and wedged 
in the end of stent loop. 
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3.3.2.5 Voltage 
Between 3 and 12 Volts were applied from the DC power pack. Twelve Volts 
allowed stent dissolution but excessive heat production caused tissue charring 
and altered staining, Figure 3-20. Below 5 Volts incomplete stent dissolution 
occurred and metallic debris could be seen within tissue sections. Metallic 
fragments tore and distorted tissue architecture, Figure 3-20B and C. Optimum 
stent dissolution was obtained in day 0 and 28 day samples using between 5 and 
8 Volts. 
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Figure 3-20. Optimisation of Stent Electrolysis. A, Charring of tissue around stent strut 
location due to excessive heat from electric circuit. * - stent strut location, Arrow – charred 
area, 40x. B, Incomplete dissolution of stent struts with metallic debris remaining. 
Arrowhead – metallic debris. 20x. C, H&E stained section showing tearing of tissue during 
cutting on microtome due to presence of metal debris 10x. Scale bar = 100 μm. 
Representative sections from n=5. 
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3.3.3 Optimisation of Histochemical and Immunohistochemical 
Staining 
3.3.3.1 Effect of Electrolysis on Tissue Staining 
The electrolysis protocol did not impair tissue staining with either H&E or EVG. 
Error! Reference source not found. and 3-Figure 3-22 show tissue sections from 
an aortic graft harvested at day 28. No difference was observed in staining of 
stented sections, which were subjected to electrolysis, compared to sections 
both proximal and distal to the stent that were not. Similarly tissues harvested 
at day 0 were equally able to take up these standard stains, Figure 3-23. 
Figure 3-23Figure 3-24 andFigure 3-25 demonstrate representative examples of 
staining for a panel of cell markers in stented (electrolysed) sections of the 
aortic graft at day 0 and day 28, respectively. Electrolysis did not inhibit tissues 
undergoing immunohistochemical staining at either time point. The panel of 
antibodies chosen not only assessed the composition of neointima but also 
ensured electrolysis did not alter the ability to stain for cell surface, cytoplasmic 
and nuclear antigens.  
Several observations were noted from immunohistochemistry performed on day 0 
and day 28 tissues. Sections stained for CD31 (an endothelial marker) showed 
there was almost complete endothelial denudation due to balloon and stent 
injury at day 0 and that by day 28 re-endothelialisation was almost complete, 
Figure 3-25. Few macrophages were identified in grafts at day 0 but were 
abundant in the adventitia, media and neointima at day 28. Similarly when 
stained with PCNA, proliferating cells were almost completely absent at day 0 
but easily identified throughout the vessel wall by day 28. 
Sections cut from the vascular anastomosis containing the plastic cuff were also 
examined. This revealed considerable neointimal development with extensive 
cellular infiltration and proliferation within the aorta and around the plastic 
cuff. These cells were confirmed to be VSMCs and macrophages by smooth 
muscle α-actin and MAC2 staining, respectively, Figure 3-9. 
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3.3.3.2 Staining for YM-1 within Tissues 
YM-1, also known as Chitinase 3-like-3 (Chi3L3), is a murine marker of the 
alternatively activated (M2) macrophage (Raes et al., 2002). Expression of YM-1 
is induced by exposure of macrophages to IL-4 or IL-13 both well-known drivers 
of M2 polarisation (Raes et al., 2002, Nair et al., 2003). Identification of M2 
polarised macrophages in tissue sections has not previously been conducted 
within the Baker Laboratory but was achieved using a variety of tissues known to 
contain macrophages in different polarisation states as positive controls. Figure 
3-26 shows YM-1 staining within sections of both mouse spleen and vein graft. 
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Figure 3-21. H&E Staining of Tissues Harvested at Day 28. A, B and C Proximal Graft (H&E 
4x, 10x, 40x). D, E,and F, Stented Graft (H&E 4x, 10x, 40x). G, H and I Distal Graft (H&E 4x, 
10x, 40x). Scale bar = 100 μm. Representative sections from n=5. 
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Figure 3-22. EVG Staining of Tissues Harvested at Day 28. A, B and C Proximal Graft (EVG 
4x, 10x, 40x). D, E,and F, Stented Graft (EVG 4x, 10x, 40x). G, H and I DIstal Graft (EVG 4x, 
10x, 40x). Scale bar = 100 μm. Representative sections from n=5. 
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Figure 3-23. Histochemistry and Immunohistochemistry of stented graft harvested at day 0. 
A and B, H&E (10x, 40x). C and D, EVG (10x, 40x), E and F, SMA (10x, 40x). G and H, SMA 
IgG control (10x, 40x). I and J, PCNA (10x, 40x). K and L, PCNA IgG control (10x, 40x). 
Hatched box, magnified area of interest. Scale bar = 100 μm. Representative sections from 
n=8.  
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Figure 3-24. Immunohistochemistry of stented graft harvested at day 0. A and B, MAC2 (10x, 
40x). C and D, MAC2 IgG control (10x, 40x), E, CD31 staining (10x) and F, CD31 
demonstrating sparse endothelial cells in aortic intima following stenting (arrowhead), 
endothelium intact within blood vessels of vaso vasorum (arrow) (10x, 40x). G and H, CD31 
IgG control (10x, 40x). Hatched box, magnified area of interest. Scale bar = 100 μm. 
Representative sections from n=8. 
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Figure 3-25. Immunohistochemistry of Stented Graft Harvested at Day 28. A and B, SMA 
(10x, 40x). C and D, CD 31 (10x, 40x). E and F, MAC2 (10x, 40x), G and H PCNA (10x, 40x). 
(Inserts-IgG controls). Scale bar = 100 μm. Representative sections from n=5. 
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Figure 3-9 Staining of unstented non-electrolysed portion of graft containing the 
anastomosis forming cuff. A and B, H&E (10x). C and D SMA (10x). E and F, PCNA (10x). G 
and H, MAC2 (10x). Scale bar = 100 μm. Representative sections from n=5. 
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Figure 3-26. YM-1 immunohistochemistry M2 Macrophage staining in different tissues. A & B, Spleen (10x & 40x). C & D, IgG controls (10x & 40x). E & F, 
Vein graft (10x & 40x). G & H, IgG controls(10x & 40x). Scale bar = 100 μm. Representative sections from n=3. 
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3.3.4 C57BL6 Mice Produce a Significant Neointima at Day 28. 
Morphological analysis of stented grafts taken from C57BL6 mice at day 0 and 
day 28 and showed that no significant difference in either total vessel area (0.46 
± 0.03 mm2 vs. 0.53 ± 0.09 mm2) or medial area (0.07 ± 0.005 mm2 vs. 0.08 ±
0.01 mm2) respectively. However, there was a significant difference in medial 
thickness between day 0 and day 28 grafts (0.024 ± 0.002 mm2 vs 0.03 ± 0.002 
mm2, p<0.001, respectively), Table 3-7. This represents the medial compression 
seen at time of stenting and subsequent medial remodelling.  
Luminal area was significantly reduced from day 0 to day 28 (0.38 ± 0.023 mm2 
vs. 0.26 ± 0.018 mm2, p<0.05, respectively). This was paralleled by an increase 
in neointimal area and thickness over the same period. When measured by area 
or thickness neointima was greater than 2 fold larger than the corresponding 
media. In addition significant neointimal coverage of stent struts had developed, 
Table 3-7.  
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Table 3-7. Morphometry from C57BL6 mice at day 0 and 28 following stenting. 
 
 
 
  
C57BL6 Day 0 (n=8) Day28 (n=5) p value
Mean (SEM) Mean (SEM)
Total Vessel Area 
(mm2) 0.46 (0.03) 0.53 (0.09) ns
Luminal Area (mm2) 0.37 (0.07) 0.26 (0.05) <0.05
Medial Area (mm2) 0.07 (0.005) 0.08 (0.01) ns
Neointimal Area 
(mm2) 0 0.17 (0.04) <0.001
N:M Area Ratio - 2.26 (0.29) -
Medial Thickness 
(mm) 0.024 (0.002) 0.03 (0.002) <0.001
Neointimal Thickness 
(mm) 0 0.086 (0.017) <0.001
N:M Thickness Ratio - 2.66 (0.49) -
Strut Depth (mm) 0 0.034 (0.009) <0.001
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The results presented in this chapter demonstrate the refinement of a previously 
developed mouse stenting model. Stented grafts were shown to develop a 
significant neointima and resultant ISR. In addition, successful electrochemical 
dissolution of the metal stent within the vessel wall allowed in situ hybridisation 
to be performed and several immunohistochemical stains to be used, facilitating 
the identification of macrophages, smooth muscle cells and endothelial cells. 
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3.4 Discussion 
The current study successfully replicated the first murine aortic stenting model, 
pioneered by the Channon laboratory and demonstrated the development of ISR 
over a 28 day period. In addition this is the first study in any small animal model 
to utilise electrochemical stent dissolution during tissue processing.  
Small animal air desiccation, wire and cuff injury models been used for decades 
to investigate the effects different genetic mutations and therapies have on 
vascular pathology (Lindner et al., 1993, Moroi et al., 1998). The popularity of 
these models is undoubtedly due to their ease of reproduction, requiring 
minimal surgical skill and low cost. The clinical relevance of such injury models 
is dubious, leading scientists and clinicians to develop both balloon injury models 
simulating the effects of balloon angioplasty in humans and more recently small 
animal models of stenting (Gabeler et al., 2002). Several models of carotid and 
aortic stenting have been published in rats with differing degrees of success and 
vascular access routes (Indolfi et al., 2000, Roks et al., 2002, Lowe et al., 2005). 
However, the inability to manipulate the rat genome has undoubtedly impeded 
their use in the investigation of ISR. 
The first murine model of stenting, replicated here in this study, was based on 
previously published vein graft and aortic allograft models (Dietrich et al., 2000, 
Zou et al., 1998). This allowed Investigators for the first time to demonstrate 
that the use of an over the balloon stent in a C57BL6 mouse produces a 
significantly larger neointimal with a greater inflammatory response than with a 
balloon angioplasty alone (Ali et al., 2007). Investigators were also able to study 
the effect of genetic manipulation on in-stent restenosis. It was shown that the 
atherosclerosis prone ApoE -/- mouse developed a significantly larger neointima 
than a WT mouse from the same genetic background (Ali et al., 2007). Our study 
was also conducted in C57BL6/J mice and produced far larger neointimal lesions 
than those originally observed by Ali et al (Ali et al., 2007). Several reasons may 
account for this, including that while learning the surgical technique grafts were 
subjected to rougher handling and a longer anoxic time. The mice used in our 
study were obtained from a commercial breeder and on arrival we were not able 
to verify they were transported in family groups. Thus while an inbred mouse 
strain was used we were not able to ensure grafting between littermates to 
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minimise any immune mediated allograft vasculopathy. Additionally, although 
we used the same stent as the original study, our balloon catheter was from a 
different manufacturer. Subtle differences in balloon compliance may, through 
differences in the degree of vessel damage, account in part for the discrepancy 
observed in neointimal : media ratio between studies.  
While the use of an over the balloon stent makes the model used in the present 
study more clinically relevant than simpler injury models it is not without 
criticism. A high degree of operator skill is required in order to form two 
vascular anastomoses; with practice the failure rate can be reduced to around 
4%. The requirement of two mice per procedure adds to the number of animals 
required. Concerns have also been noted that disruption of the vaso vasorum will 
produce anoxia within the vessel wall. The vaso vasorum and adventitia has been 
shown to play an important role in vessel remodelling following injury (Gabeler 
et al., 2002). 
Three other mouse models of stenting have been published. Chamberlain et al 
used a single animal procedure with a self-expanding nitinol wire coil stent 
inserted into the infra-renal aorta via the femoral artery (Chamberlain et al., 
2010). Initially, major haemorrhage due to vessel perforation upon stent 
deployment was reduced by the addition of a round bead to the advancing tip of 
the stent. With this tip modification the procedural failure rate was significantly 
reduced to a level similar to our study. However, the lower rate of thrombotic 
stent occlusion in this single animal model may be in part due to absence of 
vascular anastomoses and the use of dual antiplatelet therapy. Temporary or 
permanent hind limb paralysis was observed in over 50% of animals, due to the 
proximity of the femoral nerve and inadvertent damage during femoral artery 
manipulation. In addition while nitinol stents have been trialled in humans 
concerns have been raised regarding cytotoxicity and neither they nor self-
expanding stents are used in routine coronary intervention thus limiting its 
clinical applicability.  
Another murine stenting model described also stented the aorta in situ but 
access was achieved by infra renal aortic incision (Rodriguez-Menocal et al., 
2010). In this model the aorta was predilated prior to stent placement. While a 
clinically relevant over the balloon stent was used, achieving haemostasis proved 
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difficult with a >35% failure rate (Rodriguez-Menocal et al., 2010). In addition 
despite using a stent with the same dimensions as our own the authors 
demonstrated far less neointimal development than both ourselves and Ali et al 
(Rodriguez-Menocal et al., 2010, Ali et al., 2007). While this may be due to 
differences in blood flow between models it may also be in part due to less 
vessel damage from the lower deployment pressures used. We observed that 
lower balloon pressures resulted in incomplete expansion, malaposition of stent 
and a propensity to develop an occlusive thrombus. 
The latest published model of small animal stenting utilised a nitinol self-
expanding coil stent deployed directly into the mouse carotid (Simsekyilmaz et 
al., 2013). While the authors of this model can be commended for their 
technical skill, the massive amount of damage caused by the stent within such a 
small artery gave the investigators difficulty in the accurate identification of IEL 
and EEL during tissue analysis (Simsekyilmaz et al., 2013). The vessels lack of 
vaso vasorum, the type of stent used and the degree of the vessel injury means 
that despite this model being novel is not necessarily more clinically relevant 
than the other published models. 
A key reason that stenting models have not been as popular as simpler injury 
models is due to tissue processing after harvesting. Processing of tissue 
containing metal has traditionally been done by resin embedding tissues 
followed by cutting sections using a diamond tipped saw which can be done to 20 
microns followed by polishing of sections to between 5 and 10 microns (Watt et 
al., 2013). These processes not only require expensive specialist equipment but 
are extremely labour intensive and require considerable operator skill to polish 
sections evenly. Tissue loss during the sawing and grinding process results in far 
fewer sections than would be obtained from paraffin embedding and cutting on a 
standard microtome (Malik et al., 1998). In situ hybridisation is impossible to 
perform on resin embedded tissues and IHC is also limited to a few antibodies 
compared to paraffin embedded tissues (Torgersen et al., 2009). In addition, the 
process of grinding also causes tissue distortion causing difficulty in image 
interpretation (Torgersen et al., 2009, Malik et al., 1998). 
In order to reduce tissue waste and maximise section yield tungsten carbide 
blades mounted on a standard rotary microtome have been used to cut resin 
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embedded tissues into 5 microns thick sections (Rippstein et al., 2006). Another 
benefit of using these blades was a reduction in tissue distortion (Rippstein et 
al., 2006)  
Despite an improvement in preservation of tissue architecture the use of 
tungsten carbide blades are prohibitively expensive and just as time consuming 
as traditional sawing and grinding. Optimisation of electrochemical stent 
dissolution was undertaken to allow tissues to be paraffin embedded and 
sections cut on a standard rotary microtome with stainless steel blades. This 
allowed both IHC and ISH to be conducted with high quality images able to be 
obtained. Electrolysis of coronary stents has been documented previously in 
human tissues but this represents the first time it has been utilised in any small 
animal model (Bradshaw et al., 2009). During the optimisation process it was 
found that the minimal citric acid saline solution to conduct with tissue 
embedded samples was 5% (w/v) this is in concordance previous reports 
(Bradshaw et al., 2009). Also key to complete stent dissolution was for only the 
very end of the stent distal to the anode to be submerged in the citric acid 
saline solution.  
By storing tissues in 70% ethanol rather than PBS almost complete dissolution 
could be achieved. This is most likely as a result of ethanol’s inability to conduct 
electricity. Conversely tissues saturated with PBS would allow conduction not 
only through the stent but also the surrounding tissue thus producing the uneven 
and incomplete stent dissolution observed.  
The development of a suitable connector between anode and stent proved 
difficult. The use of a crocodile clip which had been successful for the larger 
human stents was not appropriate due to size (Bradshaw et al., 2009). Initially 
fine wires of metals less reactive than the stainless steel stent were 
investigated. However, fashioning a robust connection could only be achieved 
with a pen spring due to its rigidity. 
The application of high voltages to the stent (12V) demonstrated the rapid 
production of a visible stream of ions released from the distal stent into 
solution. However, charring due to excess heat production in tissues surrounding 
the stent struts occurred. Optimal results were obtained by gradually increasing 
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the voltage from 3V to between 5 and 8V when both gas bubbles and a 
yellow/brown stream of ions were visible. 
Having optimised stent electrolysis we were able to show it did not interfere 
with a wider range of histological and immunohistochemical stains than has been 
previously documented regardless of antigen location. Some stains such as CD31 
for endothelial cell identification cannot be accomplished on resin embedded 
tissues. In addition this study represents the first time successful ISH (results 
presented in chapter 5) has been documented following electrolysis. 
In summary the results presented in this chapter show the efficient replication 
of a mouse model of stenting with the production of ISR. In addition, the 
efficient electrochemical dissolution of the metal stent to allow cutting of 
paraffin embedded sections on a standard microtome facilitated the 
optimisation of several immunochemical stains within stented sections which 
have not previously been able to be conducted on resin embedded stented 
tissues. 
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4 Investigation of Multiple Strategies to 
Manipulate MicroRNA-21 Expression and the 
Impact on the Development of In-stent 
Restenosis. 
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4.1 Introduction 
Percutaneous Coronary Intervention using stents as a scaffold to hold open a 
diseased and narrowed artery has in many cases superseded the use of balloon 
angioplasty, which was plagued by the issues of acute elastic recoil, vessel 
occlusion and the need for repeat revascularisation (Serruys et al., 1994). 
Indeed, stents have been shown to be a safe and effective treatment for both 
stable coronary artery disease and in the emergency situation of complete vessel 
occlusion during ST elevation myocardial infarction (De Bruyne et al., 2012, 
Andersen et al., 2003). However, the use of stents has been hindered by the 
development of ISR. ISR occurs following stent deployment due to a cascade of 
events as a result of damage to the vessel wall whereby denudation of the 
endothelium and disruption of the elastic lamina and VSMCs results in platelet 
aggregation and leukocyte adhesion (Virmani and Farb, 1999). The release of 
inflammatory cytokines and mitogenic growth factors such as IL-1, IL-6 and 
PDGF-β from a variety of cells in response to stent deployment acts to 
perpetuate inflammation, the proliferation of VSMCs and the deposition of 
connective tissue forming a neointimal layer (Costa and Simon, 2005, Indolfi et 
al., 2003). The resulting encroachment on the vessel lumen limits blood flow and 
results in the return of clinical symptoms (Dangas et al., 2010). 
The development of DES, metal stents coated in a polymer, which is 
impregnated with a cytotoxic drug to limit VSMC proliferation, has been a 
second major advance in PCI, significantly reducing ISR (Bavry and Bhatt, 2008). 
However, DES have been associated with a significantly greater incidence of late 
stent thrombosis (LST) compared to BMS due to delayed arterial healing 
characterised by persistent fibrin around stent struts, incomplete re-
endothelialisation and the presence of eosinophils (McFadden et al., 2004, Joner 
et al., 2006). Evidence from atherectomy specimens isolated from patients with 
LST and from animal models suggest that the non-erodible polymers utilised in 
first generation stents were responsible for the inflammation and 
hypersensitivity reaction rather than the cytotoxic drugs used (Virmani et al., 
2004, Nebeker et al., 2006). 
Despite the development of new generation of polymer-free drug eluting stents 
there is still a need to further elucidate the molecular mechanisms involved in 
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the complex vascular process of ISR. This may in turn lead to the development of 
novel therapies to promote healing and re-endothelialisation following stent 
deployment while inhibiting ISR. The discovery of non-coding RNAs and the 
important roles they play in fine-tuning many biological and pathological 
processes has alerted researchers to a putative role for these molecules in the 
development of ISR (Pauli et al., 2011, Esteller, 2011). MicroRNAs are one class 
of such non-coding RNA, which have yet to be investigated with respect to the 
development of ISR. 
MicroRNAs are short 19-25 nucleotide RNA molecules which upon binding in a 
complementary fashion to the 3’UTR of mRNAs repress their translation (Bartel, 
2009). Over 1000 miRNAs have now been identified within the human genome 
and are thought to regulate around 30% of all protein coding mRNA (Friedman et 
al., 2009). A single miRNA may have numerous mRNA targets at different points 
within multiple biological pathways or act upon a single target to mediate a 
disease phenotype (Aurora et al., 2012, Bang et al., 2014).  
Several miRNAs including miR-133a, miR-143, miR-145, miR-195 and miR-663 
have been studied in the setting of vascular injury with some promoting and 
others inhibiting NIH development and vessel remodelling. Two recent studies 
have been published looking at the role of miRNAs in patients with vascular 
disease. MiR-21 was shown to be up regulated in the intima and serum of 
patients with Arterosclerosis Obliterans (Wang et al., 2011). In addition, the 
Tampere Vascular Study demonstrated miR-21 was up regulated within human 
atherosclerotic plaques (Raitoharju et al., 2011). In humans miR-21 is located on 
chromosome 17q23.1 within the eleventh intron of the TMEM49 gene it is 
transcribed independently by its own promoter (Fujita et al., 2008, Cai et al., 
2004). Its actions have been found to prevent apoptosis, induce cellular growth, 
proliferation and migration (Iliopoulos et al., 2010, Han et al., 2012). The Baker 
laboratory has recently shown that miR-21 can play very important, yet 
distinctly different roles in the vessel wall (White et al., 2014). We 
demonstrated that global loss of miR-21 led to a substantial reduction in 
neointima formation in vivo using a murine vein grafting model and human ex 
vivo specimens (McDonald et al., 2013). Conversely, miR-21 loss in the 
endothelial compartment of small pulmonary vessels led to exacerbation of 
pulmonary hypertension (White et al., 2014). Hence, we therefore sought to 
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understand the expression, location and function of miR-21 in the context of 
vascular stenting, and its role in vessel remodelling, inflammation and 
endothelial damage. 
4.2 Aims 
To investigate the role played by miR-21 on the development of ISR using three 
in vivo strategies: 
1. Genetic deletion,  
2. Pharmacological knock-down,  
3. Genetic over-expression. 
To investigate the role played by miR-21 on VSMC proliferation and migration.   
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4.3 Results 
4.3.1 Effect of Genetic Deletion of microRNA-21 on the 
Development of In-Stent Restenosis   
MicroRNA-21 WT and KO animals underwent isogenic aortic stenting and carotid 
interposition grafting as described previously, chapter 2 (Ali et al., 2007). Mice 
were culled and grafts harvested for analysis at day 0 and day 28 following 
surgery.  
At baseline (day 0) no significant difference was observed between miR-21 WT 
and KO animals, within the stented grafts for any of the parameters measured. 
Table 4-8 summarises all measured parameters for WT and KO grafts at day 0. 
Comparing miR-21 WT grafts at day 0 and day 28 no significant difference was 
seen in total vessel area (0.58 ± 0.09 mm2 vs 0.52 ±0.03 mm2) or medial area 
(0.11 ±0.03 mm2 vs 0.09 ±0.005 mm2). However, luminal area was significantly 
reduced at 28 days compared to day 0, (0.46 ±0.07 mm2 vs 0.22 ±0.02 mm2) as 
a direct consequence of the developing neointima. No neointima was present at 
day 0 but by 28 days one was clearly present. Table 4-9 summarises all measured 
parameters for WT mice at day 0 and day 28.  
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Table 4-8. Baseline (Day 0) Characteristics of Stented Grafts for miR 21 WT and KO mice. 
  
Day 0 WT (n=9) KO (n=3) p value
Mean (SEM) Mean (SEM)
Total Vessel Area 
(mm2) 0.58 (0.09) 0.45 (0.05) ns
Luminal Area (mm2) 0.46 (0.07) 0.39 (0.05) ns
Medial Area (mm2) 0.11 (0.03) 0.06 (0.04) ns
Medial Thickness 
(mm) 0.035 (0.005) 0.025 (0.001) ns
Vessel Injury 
(Schwartz Score) 0.58 (0.15) 0.52 (0.06) ns
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Table 4-9. Characteristics of Stented Grafts for miR 21 WT at Day 0 and Day 28. 
  
WT  Day 0 (n=9) WT Day 28 (n=12) p value
Mean (SEM) Mean (SEM)
Total Vessel Area 
(mm2) 0.58 (0.09) 0.52 (0.03) ns
Luminal Area (mm2) 0.46 (0.07) 0.22 (0.02) <0.01
Medial Area (mm2) 0.11 (0.03) 0.09 (0.005) ns
Neointimal Area 
(mm2) 0 0.18 (0.02) <0.001
N:M Area Ratio - 2.11 (0.17) -
Medial Thickness 
(mm) 0.035 (0.005) 0.038 (0.002) ns
Neointimal Thickness 
(mm) 0 0.092 (0.009) <0.001
N:M Thickness Ratio - 2.51 (0.27) -
Strut Depth (mm) 0 0.072 (0.011) <0.001
Vessel Injury 
(Schwartz Score) 0.58 (0.15) 0.33 (0.14) ns
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Comparing miR-21 WT and KO mice at day 28 no significant difference was 
observed in total vessel area (0.52 ±0.03 mm2 vs. 0.55 ±0.03 mm2, p>0.05, 
respectively). Nor was a significant difference observed between WT and KO 
mice for medial area (0.09 ± 0.005 mm2 vs. 0.08 ± 0.005 mm2, p>0.05, 
respectively) or medial thickness (0.038 ± 0.002 mm vs. 0.036 ± 0.003 mm, 
p>0.05, respectively), Figure 4-27. However, neointimal area was significantly 
larger in the WT than KO mice (0.18 ± 0.02 mm2 vs. 0.12 ± 0.02 mm2, p<0.05, 
respectively) as was neointimal thickness (0.092 ± 0.009 mm vs. 0.057 ± 0.012 
mm, p<0.01, respectively). Neointimal : Media area ratio was significantly 
greater in WT than KO mice, (2.11 ±0.17 vs. 1.37 ±0.18, p<0.05, respectively,) 
this was concordant with Neointimal : Media thickness ratios, Figure 4-27. 
The significantly greater neointima observed within WT vs. KO mice resulted in a 
significantly smaller luminal area (0.22 ±0.02 mm2 vs. 0.30 ±0.02 mm2, 
respectively, p<0.01, respectively) and hence greater percentage stenosis (41.7 
±2.9% vs 24.1 ±2.6%, p<0.01, respectively), Figure 4-27 and Figure 4-28. 
Measurements of strut depth (the thickness of neointima covering each stent 
strut) were concordant with the findings for neointimal area and thickness, with 
greater strut depth found in WT compared to KO grafts (0.072 ±0.011 mm vs 
0.03 ±0.007 mm, p<0.05, respectively), Figure 4-28. Importantly no significant 
difference was observed in Schwartz Injury Score between WT and KO mice (0.33 
±0.14 vs. 0.44 ±0.15, p>0.05, respectively). Figure 4-28 shows representative 
sections from WT and KO grafts at 28 days.  
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Figure 4-27. Characteristics of Stented Grafts from miR 21 WT and KO mice at Day 28. A, 
Total Vessel Area. B, Luminal Area. C, Medial Area. D, Medial Thickness. E, Neointimal Area. 
F, Neointimal Thickness. G, Neointimal:Media Area ratio. H, Neointimal:Media Thickness 
ratio.  WT n=12, KO n=11. *p<0.05, **p<0.01 vs. WT Day 28.  
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Figure 4-28. Further Characteristics of Stented Grafts from miR 21 WT and KO mice at Day 
28. A, Strut Depth. B, Schwartz Injury Score. C, Percentage Stenosis. D and E representative 
H&E sections from WT and KO grafts, respectively. WT n=12, KO n=11. *p<0.05, **p<0.01. 
10x. Scale bar = 100 μm.  
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4.3.2 Comparison of Neointimal Composition between microRNA-
21 WT and KO mice. 
Having identified a significant difference in neointimal size at 28 days, further 
characterisation of neointimal composition was undertaken by staining for a 
variety of cellular markers and connective tissue. 
Examination of neointimal composition revealed more smooth muscle cell α-
actin staining in the WT compared to KO grafts expressed as a percentage of 
neointimal area (28 ±2.4 % vs. 14 ±3.7 %, p<0.01, respectively), Figure 4-29A, 
B and C. Elastin van Geison staining revealed neointima of WT mice had an 
almost two-fold greater elastin content compared to KO mice (21.1 ±1.2 % vs 
11.5 ±3.4 %, p<0.01, respectively). In addition, acellular areas comprised of 
residual fibrin deposits were evident within the neointima formed by miR-21 KO 
mice, Figure 4-29D, E and F.  
Staining for Proliferating Cell Nuclear Antigen (PCNA) was successful but failed 
to demonstrate a significant difference in the number of proliferating cells 
within the neointimal layers of WT and KO mice (3.6 ± 0.8 % vs 3.3 ± 0.7 %, 
respectively), Figure 4-29G, H and I. 
Additionally no significant difference was observed in re-endothelialisation 
between WT and KO groups (91.0 ±3.9 % vs 88.7 ±2.9 %, respectively). Re-
endothelialisation assessed as a percentage of the luminal surface staining 
positive for CD31 (Platelet Endothelial Cell Adhesion Molecule, PECAM), Figure 4-
29J, K and L.  
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Figure 4-29. Neointimal Composition. A, B and C Smooth Muscle Actin Staining. D, E and F 
Elastin van Gieson Staining. G, H and I, Proliferating Cell Nuclear Antigen Staining. J, K, and 
L, CD31 (PECAM) Staining. Inserts IgG control. WT n=12, KO n=11. *p<0.05, **p<0.01. 40x. 
Scale bar = 100 μm. 
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4.3.3 Macrophage Presence and Polarisation within microRNA-21 
WT and KO Grafts 
Identification of macrophages within the neointima was investigated by IHC. In 
addition the polarisation state of macrophages was also investigated. The anti-
inflammatory macrophage marker MAC2 (Galectin3) revealed the majority of 
macrophages were located around the stent struts with lower percentage 
staining observed within the WT than KO grafts (0.79 ± 0.23 % vs. 2.54 ± 0.75% 
p<0.05, respectively), Figure 4-30A, B and C. Further characterisation of 
macrophage polarisation was undertaken by staining for YM-1, a validated 
marker of the alternatively activated (M2) macrophage (Raes et al., 2002). YM-1 
staining demonstrated fewer M2 macrophages were present within WT than KO 
grafts (0.50 ± 0.21 % vs, 1.93 ± 0.54 %, p<0.01, respectively), Figure 4-30D, E and 
F. Both of these stains demonstrate higher levels of anti inflammatory or 
alternatively activated (M2) macrophages are present within the grafts of miR-21 
KO mice.  
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Figure 4-30. Macrophage Staining. A, B, and C Macrophage staining with MAC2 in WT and 
KO grafts 10x. D, E and F, Macrophage staining for YM-1. Inserts IgG control. 40x. WT n=12, 
KO n=11. *p<0.05, **p<0.01. Scale bars = 100 μm. 
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4.3.4 Localisation of microRNA-21 within Graft 
In situ hybridisation for miR-21 was conducted to establish its distribution within 
vascular tissues. In unstented sections of aorta from WT mice MiR-21 was easily 
detected within the media and adventitial layers indicating its expression within 
VSMCs and possibly adventitial fibroblasts, Figure 4-31A-D. Within the stented 
graft miR-21 staining could be identified, indicating that the electrolysis process 
to which it had been subjected prohibited neither IHC nor in situ hybridisation. 
Surprisingly low levels of staining were identified within the media of the 
stented graft compared to unstented aorta. However, within the neointima 
strong miR-21 staining was present around the luminal surface and subluminal 
area in addition to having a marked peri-stent distribution, Figure 4-31. By 
comparing these findings with those from IHC described in sections 4.3.2 and 
4.3.3 it is reasonable to suggest miR-21 is up regulated within endothelium, sub-
luminal VSMCs of the neointima and also within the macrophages surrounding the 
stent struts. 
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Figure 4-31. In situ Hybridisation for miR-21 in WT mice. A and B, Unstented aorta scramble 
probe (10x and 40x respectively). C and D, Unstented aorta miR-21 probe (10x and 40x 
respectively). E, Stented graft scramble probe (10x). F, G and H Stented graft scramble 
probe (40x). I, Stented graft miR-21 probe (10x). J, K, and L Stented graft miR-21 probe (40x). 
hatched boxes represent magnified areas of interest. Scale bars = 100 μm. 
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4.3.5 In vitro Characterisation of miR-21 WT and KO VSMCs 
Proliferative and Migratory Phenotype. 
Having identified a difference in neointimal size and smooth muscle α-actin 
staining between miR-21 WT and KO animals in the model of in-stent restenosis, 
in vitro analysis of aortic VSMCs isolated from both WT and KO mice was 
undertaken. VSMCs are one of the main cell types responsible for the 
development of a neointima due to their proliferation and migration towards the 
vessel lumen following vessel injury (Gabeler et al., 2002).  
4.3.5.1 VSMC Proliferation 
BrdU incorporation assay was used to assess the proliferative response of WT and 
KO aortic VSMCs which had been quiesced for 24 hours prior to use as described 
in Chapter 2. Media containing 0.2% FCS was used as a negative control and BrdU 
incorporation expressed relative to this. 
When cultured in media containing 10% FCS, BrdU incorporation increased over 
two-fold in both WT and KO VSMCs compared to 0.2% FCS, p<0.05 for both, 
Figure 4-32. When exposed to increasing concentrations of PDGF, proliferation 
was significantly greater in WT compared to KO VSMCs at both 20 ng/mL (2.00 ±
0.06 vs. 1.31 ±0.02, p<0.05) and 50 ng/mL, (3.02 ±0.09 vs. 1.40 ±0.02, 
p<0.01), Figure 4-32. Thus genetic deletion of miR-21 appeared to have no 
effect on proliferative response to 10% FCS but resulted in a diminished response 
to PDGF when compared to WT controls. 
4.3.5.2 VSMC Migration 
Assessment of the migratory capacity of cells can be conducted by various 
methods (Liang et al., 2007). Scratch assay is an accepted and well documented 
method of assessing cellular migration by making a linear scratch in a cellular 
monolayer and then observing the movement of cells back into the wound (Liang 
et al., 2007). 
Confluent VSMCs were quiesced in media containing 0.2% FCS for 24 hours prior 
to creating a linear wound in the cellular monolayer. Cells were then either 
maintained in media containing 10% FCS or PDGF 20 ng/mL. Media containing 
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0.2% FCS was used as control. As expected, cells maintained in control media 
containing 0.2% FCS exhibited minimal migration over 24 hours and no significant 
difference was observed between WT and KO VSMCs at 6 hours (42.30 ±9.25 µm 
vs 28.08 ±7.57 µm, respectively), 12 hours (78.46 ±9.25 µm vs. 59.18 ±17.76 
µm, respectively) or 24 hours (140.8 ± 20.3 µm vs. 96.60 ± 14.49 µm, 
respectively), Figure 4-33A. Representative photographs of cellular migration 
under control conditions are presented in Figure 4-33B. 
Cells stimulated with media containing 10% FCS showed marked 
wound closure over 24 hours. However, no difference was observed 
and KO VSMCs at 6 hours (76.27 ±7.19 µm vs 63.85 ±20.68 µm, 
12 hours (136.2 ±5.89 µm vs. 139.7 ±7.10 µm, respectively) or 24 
± 4.9 µm vs. 225.9 ± 32.36 µm, respectively),  
Figure 4-34A. Representative photographs of cellular migration when 
stimulated with 10% FCS are presented in  
Figure 4-34B. 
As with media containing 10% FCS, WT VSMCs stimulated with 20 ng/mL of PDGF 
exhibited profound migration and wound closure. However, the migration of 
VSMCs derived from WT mice was significantly greater than their KO 
counterparts at all time-points, 6 hours (89.61 ±10.01 µm vs 41.66 ±9.86 µm, 
respectively, p <0.01), 12 hours (141.5 ±15.72 µm vs. 101.3 ±4.59 µm, 
respectively, p <0.05) and 24 hours (237.8 ±20.51 µm vs. 163.3 ±0.96 µm, 
respectively, p <0.001), Figure 4-35A. Representative photographs of cell 
migration when stimulated with PDGF 20 ng/mL are presented in Figure 4-35B   
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Figure 4-32. Proliferation Assay. BrdU incorporation within miR-21 WT and KO VSMCs 
relative to 0.2% FCS. n=3. *p<0.05, **p<0.01. 
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Figure 4-33. VSMC Migration Assay. 0.2% FCS. A, distance migrated by miR-21 WT and KO VSMCs in 6, 12 hours and 24 hours. B Representative 
photographs of VSMC migration. Biological triplicate, technical duplicate. Statistics performed on biological triplicate data. Scale bar = 100 μm. 
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Figure 4-34. VSMC Migration Assay. 10% FCS. A distance migrated by miR-21 WT and KO VSMCs in 6, 12 and 24 hours. B Representative photographs of 
VSMC migration. Biological triplicate, technical duplicate. Statistics performed on biological triplicate data. Scale bar = 100 μm 
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Figure 4-35. VSMC Migration Assay. PDGF 20ng/mL. A distance migrated by miR-21 WT and KO VSMCs in 6, 12 and 24 hours. B Representative 
photographs , VSMC migration. Biological triplicate, technical duplicate. Statistics performed on biological triplicate data. Scale bar = 
100μm.*p<0.05,**p<0.01,***p<0.001.
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4.3.6 MicroRNA-21 expression within VSMCs is elevated following 
stimulation. 
In order to determine if the effect of PDGF 20 ng/mL and 10% FCS on VSMC 
proliferation and migration may be mediated by an up-regulation of miR-21, 
expression levels of both miR-21(-5p) and miR-21-3p were determined by RT-
qPCR. VSMCs quiesced in 0.2% FCS were used as control. 
Stimulation of WT VSMCs with 10% FCS resulted in a significant 3.73 (±1.27) fold 
increase in miR-21(-5p), p<0.01. While exposure to PDGF 20 ng/mL also resulted 
in a significant 3.03 (±0.23) fold increase in miR-21(-5p) expression, p<0.05. No 
significant difference was observed in miR-21(-5p) expression comparing 10% FCS 
and PDGF stimulation, Figure 4-36A. No significant difference in miR-21(-5p) 
expression was observed between FCS and PDGF treated VSMCs 
Neither 10% FCS nor PDGF 20 ng/mL had any significant effect on miR-21-3p 
levels found within stimulated VSMCs compared to control (1.04 ±0.15 and 1.18 
±0.89, p>0.05 for both, respectively). However, it was noted that compared to 
miR-21(-5p), miR-21-3p levels were markedly lower, with average cycle 
threshold values of ~25 versus ~35, respectively. 
  170 
 
 
Figure 4-36. miR-21 Expression. WT VSMCs stimulated with 10% FCS or PDGF 20ng/mL 
relative to quiesced cells (0.2% FCS). A, miR-21-5p. B miR-21-3p (miR-21*). vs U6 
housekeeper. Biological triplicate, technical duplicate. Statistics performed on biological 
triplicate data. *p<0.05, **p<0.01 vs 0.2% FCS. RQ = Relative Quantity. 
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4.3.7 Effect of microRNA-21 up-regulation in VSMCs on known 
targets.  
Having shown that miR-21 is up regulated in VSMCs following stimulation with 
10% FCS and PDGF 20 ng/mL further evidence of its role through target 
repression was sought.  
4.3.7.1 Investigation Potential Housekeeing genes in  murine VSMCs  
RT-qPCR was conducted on RNA isolated from VSMCs used during the migration 
assay in section 4.3.5.2. The constant expression of three potential 
housekeeping genes 18S, GAPDH and Tbp were assessed and were found to have 
mean cycle thresholds (±standard deviation) of, 12.48 (±0.71), 20.36 (±0.72), 
28.34 (± 0.46), respectively, Figure 4-37. Tbp had the smallest standard 
deviation (<0.5) and was thus taken forward for use as housekeeper when 
quantifying gene expression in VSMCs from miR-21 WT and KO mice.  
4.3.7.2 Effect of raised microRNA-21 levels on a panel of targets in 
stimulated VSMCs  
RT-qPCR was conducted on a panel of known miR-21 targets validated in various 
cell types including cells present within the cardiovascular system.  
The expression of PDCD4, a miR-21 target validated in VSMCs, was reduced in WT 
VSMCs stimulated with both 10% FCS (0.81 ±0.04, vs quiesced) and PDGF 20 
ng/mL (0.68 ±0.03 vs quiesced, p<0.05). Importantly this reduction in PDCD4 
was not observed in stimulated KO VSMCs. In fact stimulation with 10% FCS and 
PDGF 20 ng/mL induced a significant increase in PDCD4 (1.45 ±0.08 and 1.42 ± 
0.05 vs. quiesced, p<0.01 for both, respectively), Figure 4-38. 
STAT3 expression in WT VSMCs stimulated with PDGF 20 ng/mL was found to be 
significantly decreased (0.51 ± 0.03 vs. quiesced, p<0.001) However, no change 
was observed in WT VSMCs stimulated with 10% FCS, nor was any change seen in 
KO VSMCs, Figure 4-38.  
BMPR2, PPARα, PTEN and TIMP3 did not change significantly upon stimulation 
with 10% FCS or PDGF in miR-21 WT or KO VSMCs. IL-12p35 could not be detected 
in RNA extracted from WT or KO VSMCs, Figure 4-39.  
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Figure 4-37. VSMC Housekeeper gene expression. Average Cycle Threshold (Ct) values for 
three housekeeping genes in miR-21 WT and KO VSMCs. Data presented mean+/-SD. 
Biological n=5, technical duplicates. Tbp, Tata box binding protein.
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Figure 4-38. MiR-21 Target Expression. Relative expression of PDCD4 and STAT3 in miR-21 WT and KO VSMCs stimulated with 10% FCS or PDGF 20ng/mL. 
RQ+/-rqmax (vs. 0.2% FCS). Biological n=5, technical triplicates. Statistics performed on biological data. Scale bar = 100 μm.n=5. *p<0.05, **p<0.01, 
***p<0.001. RQ = Relative Quantity. 
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Figure 4-39. MiR-21 Target Expression. Relative expression of known miR-21 targets which did not significantly change in stimulated miR-21 WT VSMCs. 
RQ +/-rqmax (vs. 0.2% FCS). Biological n=5, technical triplicates. Statistics performed on biological data. RQ = Relative Quantity. 
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4.3.8 Effect of Knockdown of microRNA-21 using AntimiR-21 on 
the Development of In-Stent Restenosis   
C57BL6 mice 15 weeks of age were dosed at 25 mg/kg with antimiR-21 or 
scramble antimiR by subcutaneous injection on a weekly basis for three weeks 
prior to undergoing isogenic aortic stenting and carotid interposition grafting as 
described in Chapter 2. Dose selection was made following the review of 
previously published work by (Patrick et al., 2010). It should be noted that the 
mice used in this experiment are not the same strain as the miR-21 WT and KO 
mice used previously which had been cross bred with S129 mice. Recipient mice 
were given a further dose immediately post operatively and on three further 
occasions at weekly intervals. Mice were culled and grafts harvested for analysis 
at day 28 following surgery. Figure 4-40 outlines the antimiR-21 treatment and 
operating schedule.  
Morphological analysis of antimiR-21 and scramble treated mice at day 28 
showed no significant difference in total vessel area (0.49 ±0.02 mm2 vs. 0.49 ±
0.03 mm2, p>0.05, respectively). Nor was a significant difference observed in 
medial area (0.06 ±0.008 mm2 vs. 0.07 ±0.007 mm2, p>0.05, respectively) or 
medial thickness (0.033 ± 0.004 mm vs. 0.029 ± 0.003 mm, p>0.05, 
respectively), Figure 4-41. Additionally, neointimal area and thickness in the 
antimiR-21 and scramble groups were not significantly different (0.18 ±0.01 
mm2 vs. 0.15 ±0.02 mm2, and 0.085 ±0.006 mm vs. 0.074 ±0.011 mm, p>0.05 
for both, respectively), Figure 4-41. As a consequence neointimal : media area 
and thickness ratios did not differ significantly between antimiR-21 and scramble 
treated groups (2.78 ±0.28 vs. 2.17 ±0.20 and 2.74 ±0.30 vs. 2.58 ±0.32, 
p>0.05 for both, respectively) See Figure 4-41G and H. 
Luminal area and calculated percentage stenosis were concordant with 
previously documented measurements from the grafts of antimiR-21 and 
scramble treated mice with no significant difference observed (0.22 ±0.02 mm2 
vs. 0.24 ± 0.02 mm2 and 41.7 ± 2.9% vs 24.1 ± 2.6%, p>0.05 for both, 
respectively), Figure 4-41 and Figure 4-42. 
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Schwartz injury scores did not differ between antimiR-21 and scramble treated 
mice (0.41 ±0.07 vs. 0.29 ± 0.06, p>0.05, respectively). Figure 4-42 shows 
representative sections from antimiR-21 and scramble grafts. 
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Figure 4-40. AntimiR-21 Dosing and Operation Schedule.  
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Figure 4-41. Morphometry of AntimiR-21 Treated Mice. Characteristics of Stented Grafts 
from antimiR-21 and scramble treated mice at Day 28. A, Total Vessel Area. B, Luminal Area. 
C, Medial Area. D, Medial Thickness. E, Neointimal Area. F, Neointimal Thickness. G, 
Neointimal:Media Area ratio. H, Neointimal:Media Thickness ratio. AntimiR-21 n=11, 
Scramble n=8. 
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Figure 4-42. AntimiR-21 Treated Grafts. Further characterisation of stented grafts for 
antimiR-21 and scramble treated mice at Day 28. A, Percentage Stenosis. B, Schwartz Injury 
Score. C,E and G representative sections from antimiR-21 treated mice. D, F and H 
representative sections from scramble treated mice. Scale bar = 100 µm. AntimiR-21 n=11, 
Scramble n=8. 
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4.3.9 Effect of microRNA-21 over expression on the Development 
of In-Stent Restenosis 
4.3.9.1 miR-21 overexpression within vascular and non-vascular tissues 
Significant overexpression of miR-21 in the CAG-miR-21 containing transgenic 
mouse strain used in this study has been previously confirmed in a variety of 
tissues by both RT-qPCR and Northern blotting (Hatley et al., 2010). However, 
while overexpression has been documented in the heart, expression levels have 
not been previously confirmed in the aorta (Hatley et al., 2010). Therefore, we 
first set out to confirm this prior to using these mice in the stenting model.  
Identification of wild-type (WT +/+) and heterozygous CAG-miR-21 (HET ++/+) 
transgenic mice was first confirmed by conventional PCR for the presence or 
absence of the reporter gene EGFP located within the transgenic construct as 
described in Chapter 2. RT-qPCR was then conducted on RNA isolated from the 
three different tissues: aorta, heart and liver. 
MiR-21(-5p) levels in the aorta, heart and liver were found to be significantly 
elevated in HET ++/+ mice (4.4 ±0.8 fold, 24.4 ±2.6 fold and 4.1 ±0.5 fold vs.  
WT +/+ mice, p<0.01, p<0.0001 and p<0.001, respectively), Figure 4-43. 
In addition miR-21(star)-3p levels in the aorta, heart and liver were also found to 
be elevated in HET ++/+ mice (3.6 ±1.5 fold, 45.7 ±7.9 fold and 4.2 ±1.0 fold 
vs WT +/+ mice, respectively). However, this only reached significance in the 
heart and liver (p<0.001 and p<0.05, respectively), Figure 4-43.  
181 
 
 
Figure 4-43. MicroRNA-21 Expression. MiR-21 expression in aorta, heart and liver samples 
from Transgenic CAG-miR-21 mice and WT littermates. A miR-21-5p. B, miR-21-3p. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 vs WT (+/+). WT +/+ and HET ++/+  biological n=5 for both , 
technical triplicates. Statistics performed on biological data. RQ = Relative Quantity.    
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4.3.10 Morphometry of stented grafts from heterozygous 
miR-21 over expressing mice and wild-type littermates 
Total vessel area was significantly smaller in WT +/+ compared to HET ++/+ mice 
at day 28 (0.49 ±0.03 mm2 vs 0.55 ±0.02 mm2, p<0.05, respectively). No 
significant difference was observed between WT +/+ compared to HET ++/+ for 
medial area (0.08 ±0.01 mm2 vs. 0.08 ±0.01 mm2, p>0.05, respectively) or 
medial thickness (0.037 ± 0.003 mm vs. 0.034 ± 0.002 mm, p>0.05, 
respectively), Figure 4-44. However, neointimal area was significantly smaller in 
the WT +/+ than HET ++/+ group (0.10 ±0.02 mm2 vs. 0.16 ±0.02 mm2, p<0.05, 
respectively), Figure 4-44. Similarly neointimal thickness was less in the WT +/+ 
than HET ++/+ group but this did not reach significance (0.05 ±0.008 mm vs. 
0.08 ± 0.016 mm, respectively). Neointimal : Media area and thickness ratios 
were greater in WT +/+ than HET ++/+ mice but neither reached significance, 
(1.46 ±0.31 vs. 2.15 ±0.30, and 1.48 ± 0.32 vs. 2.55 ± 0.49, respectively), 
Figure 4-44. 
While measurements of strut depth were concordant with the findings for 
neointimal area and thickness, with greater strut depth found in WT +/+ vs HET 
++/+ grafts, this also failed to reach significance (0.03 ± 0.004 mm vs 0.06 ± 
0.018 mm, respectively), Figure 4-45. 
Although WT +/+ had a significantly smaller neointimal area than HET ++/+ mice 
no significant difference was observed in luminal area (0.27 ± 0.02 mm2 vs. 0.25 
±0.03 mm2, respectively, respectively), Figure 4-44. This is likely due to the 
difference in total vessel area. When total vessel area was corrected for, no 
significant difference was noted in percentage stenosis, calculated as: (Area 
within IEL - Luminal Area) / Area within IEL)x100, , (WT +/+ vs. HET ++/+, 24.8 ± 
4.0 % vs 35.5 ± 3.5 %, respectively), Figure 4-45. 
Importantly no significant difference was observed in Schwartz Injury Score 
between WT +/+ and HET ++/+ mice (0.39 ±0.07 vs. 0.34 ± 0.07, respectively), 
Figure 4-45. Representative sections from WT +/+ and HET ++/+ grafts at 28 days 
are shown in Figure 4-45. 
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Figure 4-44. Characteristics of Stented Grafts from WT +/+ and HET ++/+ mice at Day 28. A, 
Total Vessel Area. B, Luminal Area. C, Medial Area. D, Medial Thickness. E, Neointimal Area. 
F, Neointimal Thickness. G, Neointimal:Media Area ratio. H, Neointimal:Media Thickness 
ratio. *p<0.05. WT +/+ n=6, HET ++/+ n=11.  
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Figure 4-45. Further Characteristics of Stented Grafts from WT +/+ and HET ++/+ mice at Day 
28. A, Strut Depth. B, Percentage Stenosis. C, Schwartz Injury Score. D, F and H 
representative sections from WT +/+ mice. E, G and I representative sections from HET ++/+ 
grafts. Scale bar = 100 µm. WT +/+ n=6, HET ++/+ n=11. 
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The data presented above demonstrate that the genetic deletion of miR-21 in a 
mouse model of stenting reduced the formation of neointima and hence the 
development of ISR without affecting re-endothelialisation of the stented 
segments. Reduced proliferative and migratory capacities were observed in 
VSMCs in which miR-21 had been deleted. In addition, an altered macrophage 
polarisation state was observed between miR-21 WT and KO stented grafts. 
Neither pharmacological knockdown nor overexpression of miR-21 significantly 
altered the size of neointima formed.  
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4.4 Discussion 
The results presented within this chapter demonstrate that genetic deletion of 
miR-21 resulted in a significant reduction in neointimal formation and 
importantly in-stent stenosis at 28 days following aortic stenting in this mouse 
model. In addition, loss of the miR-21 stem loop in knockout mice blocked 
neointimal formation through effects on VSMC proliferation and migration but 
had no effect on the re-endothelialisation of grafts. The altered inflammatory 
phenotype with an enhancement of anti-inflammatory (M2) macrophages in 
response to stenting was also evident within grafts from miR-21 KO mice and 
may contribute towards a reduction in the neointima observed.  
This study is the first to investigate the role of microRNAs on the development of 
in-stent stenosis and to document the deleterious effects of miR-21 on the 
development of neointimal hyperplasia following stent placement. We found 
that genetic deletion of miR-21 resulted in a reduction in the development of 
NIH and importantly in-stent stenosis at 28 days following stenting. These results 
are in keeping with our previously published studies of miR-21 in a murine vein 
grafting model where genetic deletion of miR-21 resulted in an 80% reduction in 
NIH (McDonald et al., 2013). Indeed it was also shown that the genetic deletion 
of miR-21 within the vein graft itself was responsible for the reduction in NIH 
rather than presence or absence of miR-21 within the recipient animal as 
evidenced by grafting between genotypes (McDonald et al., 2013). The results 
presented in this chapter are concordant with those from other in vivo models of 
vascular injury. Two independent groups have demonstrated, in rat models of 
carotid and iliac artery balloon injury, inhibition of miR-21 results in a reduction 
in NIH by approximately two thirds. In both of these studies knockdown of miR-
21 was achieved by the local delivery of antagomirs suspended in a poloxamer 
gel (Ji et al., 2007, Wang et al., 2012a). Compared to these balloon injury 
models it is tempting to suggest that the more profound reduction in NIH seen 
within the vein-grafting model is likely to result from the complete absence of 
miR-21 due to its genetic deletion rather than the temporary knockdown of miR-
21. However, within the current study which utilised a miR-21 knockout strategy 
the reduction in NIH was even less than that seen in the knockdown studies 
mentioned above. Thus while the strategy used to inhibit miR-21 may indeed 
play a role in the reduction of NIH observed, accurate conclusions cannot be 
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drawn by comparing such strategies between injury models due to differing type 
and severity of injury as well as the presence of the stent.  
The current study demonstrated up regulation of miR-21 expression by in situ 
hybridisation within the neointima, particularly around the luminal surface and 
subluminal areas. In addition, staining also identified a marked peri-stent 
distribution. Immunohistochemical staining of sequential sections for markers 
such as α-actin, CD31 and MAC2 strongly suggests high miR-21 expression was 
present within the endothelium, neointimal VSMCs, and macrophages 
surrounding stent struts. Our results are not surprising given the findings of other 
studies, which have demonstrated by both in situ hybridisation and RT-qPCR an 
elevated expression of miR-21 not only following vascular injury but also in 
atherosclerotic plaques and in failed human vein grafts (Ji et al., 2007, Wang et 
al., 2012a, Raitoharju et al., 2011). In addition, elevated expression of miR-21 
was identified within samples obtained from patients with Arteriosclerosis 
Obliterans (Wang et al., 2011). Interestingly the greatest expression was not 
found in lesions with the greatest stenosis but within lesions displaying up to 50% 
stenosis, suggesting up regulation of miR-21 may be an early phenomenon (Wang 
et al., 2011). Within a porcine coronary stenting model we have also 
demonstrated, by RT-qPCR, elevated miR-21 expression in the artery wall 
(McDonald et al., 2015). In situ hybridisation confirmed elevated levels of miR-
21 in all three layers of the vessel wall. Interestingly miR-21 expression was 
greatest at 7 days but remained elevated to a lesser degree at 28 days 
(McDonald et al., 2015). Taken together these findings suggest miR-21 induction 
is an early event following vascular injury and may play a role in the 
development of stenotic lesions. 
The mechanisms underpinning miR-21 up regulation following stenting in these 
complex in vivo models is likely to be multifactorial, related to mechanical and 
chemical factors such as hypoxia, oxidative stress and growth factor release. 
Differing from balloon or wire injury models, stent placement against the vessel 
induces a constant rather than transient radial force. In vitro studies have 
identified stretch to be a key stimulus of miR-21 transcription in a variety of cell 
types (Song et al., 2012). Stretch in the form of both unidirectional and 
oscillatory shear stress has been shown to induce up regulation of miR-21 in 
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endothelial cells with the later producing an increase in binding of c-Jun to the 
AP-1 binding site on the miR-21 promoter (Weber et al., 2010); (Zhou et al., 
2011). In human aortic smooth muscle cells cultured in vitro, stretch itself was 
shown to induce miR-21 transcription due to an increase in phosphorylation and 
hence activity of the transcription factor c-Jun, an important component of the 
AP-1 heterodimer (Song et al., 2012). AP-1 has in VSMCs been demonstrated to 
promote proliferation following vascular balloon injury (Yasumoto et al., 2001). 
In vivo models of cardiac pressure overload using trans-aortic constriction which 
increase left ventricular end diastolic pressure have also been shown to induce 
miR-21 expression in cardiac fibroblasts (Thum et al., 2008). 
Local hypoxia due to stent compression and disruption of blood flow within the 
vaso vasorum may also play a role in the modulation of miR-21 within the vessel 
wall. However, the role of hypoxia in modulating miR-21 expression remains 
controversial. While it has been reported that hypoxia induces miR-21 
transcription, others have found the opposite in a hypoxic lung injury model 
(Sarkar et al., 2010, Yang et al., 2012, Caruso et al., 2010). Thus while it is 
conceivable that local hypoxia within the vessel wall due to stent compression 
may play a role in the up regulation of miR-21, confirmation would require 
further investigation in this particular experimental setting. 
In the current study not only did size of neointima differ between miR-21 WT 
and KO mice but neointimal composition also differed significantly. Neointima 
from WT mice were found to contain significantly more smooth muscle cell alpha 
actin than that of KO counterparts. PDGF is a key growth factor released from 
platelets and endothelial cells following vascular injury, promoting VSMC 
proliferation and migration (Jackson et al., 1993). PDGF inhibition has been 
shown to dramatically reduce NIH (Ferns et al., 1991). In vitro analysis 
demonstrated that in response to PDGF stimulation, the reduction in smooth 
muscle staining observed within the neointima of miR-21 KO mice was likely a 
consequence of both reduced VSMC proliferation and migration. These findings 
are not surprising given that upon injury, miR-21 has been shown by several 
groups to induce VSMC proliferation, migration and to protect against apoptosis 
(Ji et al., 2007, Wang et al., 2011, Lin et al., 2009). It has previously been 
shown that miR-21 is a key molecular switch in the signalling pathway of PDGF, 
which increases miR-21 expression indirectly via activation of HIF-1α (Wang et 
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al., 2011). In addition, PDGF stimulation of miR-21 WT VSMCs demonstrated both 
an up regulation of miR-21 and repression PDCD4 and STAT3. PDCD4 is a known 
target of miR-21 previously validated in the setting of vascular injury (Wang et 
al., 2011, Maegdefessel et al., 2012). The results of the current study are in 
keeping with previously published data showing PDCD4 is down regulated 
following both vascular injury and PDGF stimulation (Liu et al., 2010). 
Additionally, over-expression of PDCD4 using an adenoviral vector has been 
shown to attenuate the proliferative response as well as augmenting the 
induction of apoptosis within VSMCs (Liu et al., 2010). Interestingly, within the 
current study PDCD4 was also found to be elevated in VSMCs taken from miR-21 
KO mice adding further weight to the idea that PDCD4 may be a key miR-21 
target involved in the development of ISR. 
Within the current study the apparent discrepancy between the in vivo IHC 
analysis of PCNA staining, which failed to show a difference in proliferation 
between miR-21 WT and KO mice and the in vitro analysis using BrdU could at 
least in part be explained by the fact that a far earlier time point was analysed 
in vitro. Greatest proliferative response is seen immediately following injury and 
quickly reduces to basal levels by 28 days when healing is complete (Touchard 
and Schwartz, 2006). Interestingly, using pharmacological knockdown of miR-21 
in vivo other groups have been able to demonstrate a difference in proliferation 
at 14 days following both balloon injury and within a murine AAA model (Ji et 
al., 2007, Maegdefessel et al., 2012). Thus had the in vivo analysis been 
conducted at an earlier time point following stenting, a difference in 
proliferation may have been observed.  
Following stenting greater elastin deposition was observed within the neointima 
of miR-21 WT mice compared to their KO counterparts. Our results are in 
keeping with other injury models demonstrating that up regulation of miR-21 
following injury induces ECM deposition and sequestration of miR-21 attenuates 
such a response. Thum et al (Thum et al., 2008) demonstrated up regulation of 
miR-21 within cardiac fibroblasts in a trans-aortic constriction model of cardiac 
hypertrophy. This resulted in increased cardiac fibrosis. In addition they showed 
the intravenous administration of antagomir-21 de-repressed SPRY1 protein 
levels, which via a resultant decrease in ERK-MAPK signalling inhibited 
deposition of ECM molecules including collagens (Thum et al., 2008). 
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Interestingly, it has been shown under non-stressed conditions that selective 
deletion of miR-21 from endothelial cells results in both structural and 
functional remodelling of the thoracic aorta with age (Song et al., 2012). In 
particular a reduction in elastin, collagen I and III expression were observed 
within the vessel media compared to WT mice (Song et al., 2012). Song et al 
(Song et al., 2012) attribute these effects to an increase in endothelial cell 
SMAD7 and consequently inhibition of TGFβ1-induced ECM expression. However, 
they fail to demonstrate whether these effects are due to endothelial to 
mesenchymal transition or a paracrine signalling effect on cells classically 
involved in ECM synthesis. Under non-stressed conditions neither the Olsen 
laboratory nor we identified any gross phenotypic vascular abnormality in the 
miR-21 KO mouse used within this study (McDonald et al., 2013, Hatley et al., 
2010). In addition, at baseline no cardiac abnormality could be demonstrated in 
miR-21 KO mice compared to their WT littermates (Patrick et al., 2010).  Further 
work is required to fully understand the differences noted between mice where 
miR-21 has been selectively deleted from ECs and completely removed from all 
cell types.  
Re-endothelialisation following stenting in the model used in the current study 
has been demonstrated to be dependent on both cells originating from bone 
marrow (endothelial progenitor cells) and from those of the adjacent intact 
vasculature (Douglas et al., 2013). Our study did not demonstrate a difference in 
re-endothelialisation between WT and KO mice, which was virtually complete at 
28 days. The complex role of miR-21 in endothelial cell apoptosis, proliferation 
and migration has been extensively investigated. Sabatel et al (Sabatel et al., 
2011) demonstrated that over expression of miR-21 in ECs reduced proliferation, 
migration and tubulogenesis by targeting of RhoB, which has previously been 
implicated in EC migration. Furthermore, up regulation of miR-21 within ECs by 
rapamycin has been shown via RhoB repression to be involved the inhibitory 
effects of this drug on EC proliferation and migration (Jin et al., 2013).  
Concordant with these findings it has also been shown in early passage HUVECs 
that miR-21 overexpression impairs angiogenesis and cell proliferation by 
targeting CDC25A and nuclear factor 1 B-type (Dellago et al., 2013). Down 
regulation of these targets in turn resulted in an increase in the cell cycle 
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inhibitor p21 and a failure to dephosphorylate CDK2 and thus drive the cell 
through the G1/S phase checkpoint (Dellago et al., 2013).  
While the Inflammatory response has been shown to be important to the 
development of NIH in both balloon injury and stenting models, significant 
differences have been identified in the innate immune response to each model. 
Balloon injury induces a transient neutrophil predominant infiltration of the 
vessel wall (Welt et al., 2000) while stenting has been shown to produce a more 
prolonged inflammatory response dominated by macrophages (Horvath et al., 
2002). The majority of the macrophage population originate from bone marrow-
derived circulating monocytes, which infiltrate the tissue via the luminal and 
adventitial surfaces (Tuleta et al., 2008). Significant differences in macrophage 
polarisation were evident with grafts from miR-21 KO mice containing more anti-
inflammatory (M2) macrophages than miR-21 WT mice. These findings are 
concordant with those of other investigators who have independently shown 
miR-21 promotes M1 macrophage polarisation by targeting STAT3 and that 
genetic deletion of miR-21 results in enhanced M2 polarisation in a STAT3 
dependent manner (Wang et al., 2015). M2 or alternatively activated 
macrophages are thought to suppress inflammation, facilitate tissue healing by 
differences in their phagocytic capacity and the cytokines secreted (Murray and 
Wynn, 2011). Lavin et al (Lavin et al., 2014) have recently demonstrated greater 
neointimal lesion formation following balloon injury in NOS3 deficient mice due 
to higher M1:M2 ratios within the vascular wall. They also demonstrated that 
conditioned media from NOS3 deficient endothelial cells could induce 
repolarisation of macrophages from an M2 to an M1 phenotype. In addition, they 
found conditioned media from M1 macrophages induced both greater 
proliferation and migration within VSMCs (Lavin et al., 2014).  
Taken together our findings and those of other groups suggest miR-21 may play 
an important role in modulating the inflammatory response following vascular 
stenting. Thus further experiments were devised to investigate the effect the 
absence of miR-21 has on macrophage biology and in particular the potential 
consequences on neointimal development and are reported in chapter 5.    
Having shown that genetic deletion of miR-21 reduces NIH development, further 
experiments were undertaken to establish if suppression of miR-21 using a knock 
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down strategy would have a similar effect. Unfortunately no significant 
differences were observed between antimiR-21 and scramble treated mice for 
any of the morphological parameters measured. This is in stark contrast to 
several other studies, which have shown the inhibition of miR-21 following 
vascular injury could significantly impact vascular remodelling (Ji et al., 2007, 
Maegdefessel et al., 2012, Wang et al., 2012a). One reason, which may account 
for the current findings may be the model itself. Partial suppression of miR-21 
may not sufficiently de-repress the mRNA targets in order to alter the vascular 
pathology observed within the stenting model.  
Aside from the model itself the method of delivery, dose, dosing schedule and 
chemistry of the antimiR used are all likely to contribute to the results 
observed. The current study used a systemic delivery method in contrast to two 
successful studies, which topically applied antagomir-21 suspended within a 
poloxamer gel to the vessel’s adventitial surface at the time of balloon injury 
(Wang et al., 2012a, Ji et al., 2007). Thus, failure of the antimiR-21 to reach the 
stented graft is a possible explanation in addition to the fact that the majority 
of antimiR is known to be sequestered by the liver. Against this theory is that 
excellent biodistribution of antimiRs have been demonstrated by others 
(Krutzfeldt et al., 2005). With the sole exception being the central nervous 
system, which appears difficult to penetrate following systemic injection 
(Krutzfeldt et al., 2005). In addition within an elastase infusion model, a single 
systemic tail vein injection of antimiR-21 significantly augmented the 
development of AAA by de-repressing PTEN (Maegdefessel et al., 2012). Thus it 
would seem unlikely that the method of delivery would on its own account for 
lack of effect within the current study. 
The dose of antimiR is a further putative explanation for the results observed. 
Indeed the first in vivo antagomir study was conducted in mice to supress miR-
122 within the liver and used three different intravenous doses, 80, 160 and 240 
mg/kg (Krutzfeldt et al., 2005). By using these three doses a dose response 
relationship was observed. While the maximum dose used by Krutzfeldt et al 
(Krutzfeldt et al., 2005) is almost 10 fold greater than the dose of antimiR-21 
used in the current study, a dose of 25 mg/kg has been shown to de-repress 
PDCD4 expression levels within the heart (Patrick et al., 2010). Although others 
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have previously demonstrated it took a dose of 80 mg/kg to alter phenotype 
(Thum et al., 2011). 
The differing chemistries of miR inhibitors have caused great debate regarding 
stability and efficacy in vivo. The earliest oligonucleotides, termed antagomirs 
were similar in length to the mature miR and conjugated to cholesterol at their 
3’ ends to facilitate cellular uptake and in addition contain O-methyl groups 
conjugated to the second oxygen of the ribose sugar within each nucleotide. 
Thum et al (Thum et al., 2008) utilised such antagomirs to inhibit cardiac fibrosis 
following trans-aortic banding. Various other modifications have also been added 
to the 2’-O (Thum et al., 2011, Dangwal et al., 2012). More novel antimiRs have 
been developed between 8 and 15 nucleotides in length with fully lock nucleic 
acids to enhance stability and affinity individual miRs (Montgomery et al., 2011). 
AntimiR-21 and scramble control used within the current study were gifts from 
miRagen™ (Boulder, Colorado USA) the exact chemistry of which is commercially 
sensitive and was not revealed to ourselves. However, it is likely that the gifted 
compounds are similar to those used in the OIsen Laboratory (Patrick et al., 
2010).  
Patrick et al showed maximal target de-repression three weeks following the 
first antimiR-21 dose (Patrick et al., 2010). It should be noted that while they 
demonstrated target de-repression of PDCD4 they failed to show phenotypic 
change. One possible explanation is commencement of trans-aortic banding 6 
weeks before commencement of antimiR-21 resulted in pathological remodelling 
which was irreversible by the time of antimiR delivery. The dosing schedule 
chosen for the current study of weekly antimiR injections commencing 3 weeks 
prior to stenting and continued until harvesting of the graft was devised to 
establish target de-repression prior to stenting and maintain this effect 
throughout the course of the experiment. Due to the requirement for 
histological analysis the current study did not confirm target de-repression 
within the stented graft. 
While every effort was undertaken to optimise the antimiR study protocol it is 
likely that a combination of the above mentioned variables in antimiR delivery, 
dose, regimen and chemistry contributed to the lack of effect observed within 
this study. In addition, other unknown counter-regulatory responses to both 
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antimiR presence and target expression may have contributed to the outcome. 
Further work would be required to investigate this.  
Within VSMCs, over-expression of miR-21 in vitro and in vivo using commercially 
available premiR-21 or lentivirus encoding premiR-21, respectively, have both 
been shown to increase proliferation, vessel wall thickness and reduce apoptosis 
(Maegdefessel et al., 2012). We therefore investigated the effect on ISR 
development in a transgenic mouse overexpressing miR-21. We first confirmed 
that miR-21 was over expressed in different cardiovascular and non-
cardiovascular tissues from heterozygous mice containing CAG-miR-21 gene. An 
increase of 4.4 fold in miR-21 expression was observed within the aorta 
compared to WT mice. This is in keeping with previous reports of miR-21 over 
expression in CAG-miR-21 transgenic mice (Hatley et al., 2010). A small but 
significant increase in neointimal area was observed in heterozygous miR-21 
++/+ mice compared to WT +/+ mice. However, total vessel area was also 
greater in heterozygous miR-21 ++/+ mice and upon correcting for this finding no 
difference was observed in percentage stenosis nor was there a significant 
difference in luminal area. Thus it can be concluded that heterozygous over-
expression of miR-21 in our model did not result in significantly greater ISR than 
WT littermates. It would initially appear reasonable to suggest that had 
homozygote miR-21 ++/++ over-expressing mice been used, a significant 
difference in ISR may have been observed. However, we did not measure 
relative expression in homozygous miR-21 ++/++ mice, nor did we measure miR-
21 expression within the heterozygous miR-21 ++/+ grafts at the end of the study 
period. One putative reason, for the findings presented in this study, is that 
while following stenting there is likely to be up regulation of miR-21 expression 
from native miR-21 alleles, counter regulatory (negative) feedback loops 
involving the AP-1/miR-21/PDCD4 axis may actually suppress increased miR-21 
expression from native alleles within heterozygous miR-21 ++/+ mice (Talotta et 
al., 2009). Consequently the relative difference in miR-21 expression at baseline 
between heterozygous miR-21 ++/+ mice and miR-21 WT mice may be diminished 
following intervention. Interestingly when these over expressing mice were 
studied in the setting of non-small-cell lung cancer miR-21 over-expression alone 
was not enough to induce tumourigenesis. Indeed investigators noted that a 
“second hit” in the form of K-Ras mutation was required to induce tumour 
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progression and metastasis (Hatley et al., 2010). Importantly gain-of-function K-
Ras mutations induce miR-21 by up regulation of AP-1 activity circumventing the 
negative feedback loop involving AP-1/miR-21/PDCD4 (Hatley et al., 2010, 
Talotta et al., 2009). This could explain the lack of effect on ISR in the current 
study but would require further investigation. 
In conclusion, genetic deletion of miR-21 significantly reduces neointimal 
formation but crucially did not impair re-endothelialisation of stent struts. The 
underlying mechanisms are likely to be multifactorial involving a reduced 
migratory and proliferative capacity of miR-21 deficient VSMCs in response to 
de-repression of PDCD4. Mir-21 also appears to alter macrophage polarisation 
within stented arteries and may also play a significant role in modulating the 
development of ISR. The failure of both antimiR-21 and overexpression 
strategies to diminish and augment ISR, respectively are disappointing and 
suggests counter regulatory mechanisms involving miR-21 and its targets are 
complex and robust. Further work is required to develop therapeutically viable 
strategies to mirror the effect of miR-21 deletion. 
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5 Effects of microRNA-21 on macrophage 
polarisation and function in the development of 
in-stent restenosis. 
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5.1 Introduction 
Macrophages are key cellular components of the innate immune system 
functioning in both health and disease (Sica and Mantovani, 2012). One of their 
key roles is to function as part of the host’s defence system against invading 
pathogens including bacteria, viruses, and parasites (Mosser and Edwards, 2008). 
However, they also play important roles in organ development, tissue 
remodelling and repair (Mantovani et al., 2013). In addition the importance of 
macrophages in allergy, metabolism and many cancers has been extensively 
investigated (Biswas and Mantovani, 2010, Robbe et al., 2015). 
In order to accomplish the wide array of tasks required, macrophages exhibit 
extraordinary plasticity to adapt to their local environment (Sica and Mantovani, 
2012, Wolfs et al., 2011). Upon stimulation macrophages polarise to different 
phenotypes by altering their gene expression profile. Classical (M1) activation 
occurs following stimulation with IFNγ or LPS triggering IFN receptor and TLR4 
activation, respectively (Sica and Mantovani, 2012). Through cooperative 
signalling cascades involving NFκB and STAT1 pro-inflammatory cytokines are up 
regulated including IL-1, IL-6, IL-12 and TNFα (Mantovani et al., 2013). M1 
polarised macrophages are predominantly involved in microbial killing and are 
viewed as pro-inflammatory (Mosser and Edwards, 2008). Alternatively activated 
(M2) macrophages are induced by IL-4 or IL-13 stimulation and through STAT6 
signalling up regulate genes such as Retnla, YM-1, PPARγ and IL-10 (Raes et al., 
2002, Odegaard and Chawla, 2011, Szanto et al., 2010). M2 macrophages are 
commonly viewed as anti-inflammatory, functioning to supress inflammation 
while promoting tissue repair (Mantovani et al., 2013). Recently further 
subdivision of M2 macrophages into M2a, M2b and M2c phenotypes has been 
proposed with more subtle but distinct functional characteristics being 
elucidated (Lucas et al., 2010). Polarisation should be viewed as a complex 
phenotypic continuum, which has been shown to be reversible in many 
circumstances upon changing local environmental stimuli (Guiducci et al., 2005).  
The role played by miRs in macrophage polarisation has already been 
investigated. Initial studies demonstrated that following polarisation numerous 
miRs and their passenger stands were up or down regulated. In addition, miR 
expression varied according to polarisation state (Graff et al., 2012). Further 
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work has demonstrated that individual miRs such as miR-125a-5p and let-7c are 
also able to influence initial polarisation as well as drive macrophages from one 
polarisation state to another (Banerjee et al., 2013a, Banerjee et al., 2013b). 
Interestingly, let-7c has also been shown to modulate both phagocytic and 
bactericidal activity of polarised macrophages (Banerjee et al., 2013b).  
Following stent placement macrophages play a far greater role in the 
development of ISR than in NIH following balloon angioplasty (Welt et al., 2000). 
Macrophage presence within the neointima has been positively correlated with 
increasing ISR (Rogers et al., 1996). Conversely, within a rabbit stenting model 
transient depletion of macrophages by the systemic administration of a single 
dose of liposomal alendronate significantly reduced neointimal size (Danenberg 
et al., 2003). Not only do the presence of macrophages contribute to neointimal 
bulk but also the liberation of reactive oxygen species, growth factors and 
cytokines which promote VSMC proliferation and ECM deposition (Chen et al., 
2004). More recently, the polarisation state of macrophages within the 
neointima has been demonstrated to be of considerable importance in the 
generation of NIH. Higher M1 to M2 ratio have been associated with an increase 
in NIH following vascular injury (Lavin et al., 2014). Concordantly, where 
defective M2 polarisation has been induced by genetic manipulation, an increase 
in NIH has also been observed (Lavin et al., 2014).  
The findings presented in chapter 4 demonstrated an altered inflammatory 
phenotype within the stented grafts of miR-21 KO mice. We hypothesised that 
the absence of miR-21 may be responsible for not only the altered inflammatory 
response but consequently the reduction in neointima observed in miR-21 KO 
mice. Therefore, further work was undertaken to elucidate the role played by 
miR-21 in macrophage polarisation and function. 
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5.2 Aims 
Characterise the response to polarisation of macrophages taken from miR-21 WT 
and KO mice.  
Assess the effect of polarisation on the expression of miR-21 and its targets in 
M1 and M2 macrophages.   
Determine any differences in cytokine production and the putative effect on 
other cell types present within the developing neointima.  
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5.3 Methods 
5.3.1 Characterisation of bone marrow derived macrophages from 
miR-21 WT and KO mice. 
Bone marrow derived monocytes were isolated and cultured as described in 
Chapter 2 followed by polarisation into an M1 or M2 state using LPS or IL-4, 
respectively unless otherwise stated. Characterisation of macrophages in 
different polarisation states was undertaken in order to identify differences 
between those macrophages derived from miR-21 WT and KO mice as outlined in 
Figure 5-46, using the following techniques; 
1. Assessment of validated gene expression markers of polarisation by RT-
qPCR.  
2. Determination of cell surface marker expression by flow cytometry. 
3. Assessment of cytokine production. 
4. Effect of conditioned media from macrophages on proliferation of VSMCs. 
5. Assess expression of miR-21 and its targets by RT-qPCR.  
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Figure 5-46. Investigation of miR-21 WT and KO Macrophages. Bone marrow derived 
monocytes were isolated and cultured in presence of M-CSF to produce macrophages. 
Macrophages then polarised to M1 or M2 states with LPS and IL-4, respectively. Cells and 
supernatants assessed by flow cytometry, Luminex assay, and RT-qPCR. 
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5.4 Results 
5.4.1 Assessment of validated gene expression markers of 
polarisation by RT-qPCR.  
No obvious difference was observed by light microscopy between miR-21 WT and 
KO bone marrow derived macrophages in either their unpolarised (M0), M1 or M2 
polarised states, Figure 5-47.  
5.4.1.1 Investigation of Potential Housekeeing genes in murine 
macrophages  
RT-qPCR was conducted on RNA isolated from macrophages cultured from miR-
21 WT and KO mice. The constant expression of three potential housekeeping 
genes: 18S, GAPDH and Tbp were assessed and were found to have mean cycle 
thresholds (+/-standard deviation) of, 11.52 (±0.56), 15.83 (±0.87), 24.75 (±
0.39), respectively, Figure 5-48. GAPDH was more highly expressed in 
macrophages than VSMCs (Ct ~20), see Chapter 4, but had the greatest standard 
deviation. Tbp had the smallest standard deviation (<0.5) and was thus taken 
forward for use as housekeeper when quantifying gene expression in 
macrophages from the miR-21 WT and KO colony, Figure 5-48. 
5.4.1.2 Relative Expression of Macrophage Polarisation Markers 
Successful polarisation of bone marrow derived macrophages to either an M1 or 
M2 state with LPS or IL-4, respectively, was confirmed by the expression of a 
panel of validated markers by RT-qPCR, Figure 5-49. M1 polarised macrophages 
showed appropriate up-regulation of inducible nitric oxide synthase (NOS2) and 
down-regulation of PPARγ, while up-regulation YM-1 and Retnla was observed in 
M2 polarised macrophages, Figure 5-49. 
M0 unstimulated miR-21 KO macrophages had significantly higher PPARγ (M2 
marker) expression than their WT counterparts (2.54 ±0.46 fold higher vs. WT, 
p<0.01), Figure 5-50. 
In addition, a significant difference was observed in the NOS2 : Arginase1 mRNA 
expression ratio, with the ratio in miR-21 WT being significantly greater than 
that in KO macrophages (20.6 ±6.52 fold vs 2.7 ±1.24, p<0.001), Figure 5-50. 
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The significant differences noted at baseline in PPARγ expression levels and in 
NOS2 : Arginase1 ratio in response to LPS indicates miR-21 KO macrophages shift 
towards an M2 polarisation state and are less responsive to traditional stimuli of 
M1 polarisation. This may at least partially account for the preponderance of M2 
macrophages identified within neointima of miR-21 KO stented grafts, see 
Chapter 4.   
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Figure 5-47. miR-21 WT and KO Macrophages. Light microscopy of bone marrow derived 
macrophages cultured for 6 days then stimulated with LPS or IL-4. A and B, Unstimulated 
controls (M0) miR-21 WT and KO respectively. C and D, LPS stimulated (M1) miR-21 WT and 
KO, respectively. E and F, IL-4 stimulated (M2) miR-21 WT and KO, respectively. Scale bar = 
100 μm. 
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Figure 5-48. Macrophage House Keeper Gene RT-qPCR. Average cycle threshold (Ct) values 
for three housekeeping genes in miR-21 WT and KO macrophages. Data presented mean+/-
SD. Tbp, Tata-box binding protein. Biological n=5, technical triplicates. Statistics performed 
on biological data. 
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Figure 5-49. Macrophage Polarisation Markers. A, Relative polarisation marker 
expression following LPS stimulation by RT-qPCR. B, Relative polarisation 
marker expression following IL-4 stimulation by RT-qPCR. RQ = Relative 
Quantity. Biological n=5, technical triplicates. Statistics performed on biological 
data. **p<0.01, vs. WT unstimulated.  
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Figure 5-50. Macrophage Polarisation. A, PPARγ expression in unstimulated macrophages. 
C, NOS2/Arginase1 ratio miR-21 WT and KO macrophages stimulated with LPS. Biological 
n=5, technical triplicates. Statistics performed on biological data. **p<0.01, ***p<0.001 vs. 
WT. 
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5.4.2 Cell Surface Marker Expression on miR-21 WT and KO 
Macrophages Following Polarisation with LPS or IL-4. 
Flow cytometry was used to investigate the expression of a panel of cell surface 
markers commonly associated with M1 and M2 polarisation. Figure 5-51 shows 
the gating strategy used to identify macrophages.  
As with genomic markers detailed in section 5.4.1.2, staining showed 
appropriate changes in cell surface expression according to macrophage 
polarisation state. M1 macrophages up regulated MHC II, the co-stimulatory 
molecule CD86, TLR2, and CD69. M2 macrophages demonstrated elevated 
expression of CD206 and CD11c, with a reduction in TLR2.  
A significant difference in CD69 expression between miR-21 WT and KO polarised 
macrophages was observed, with CD69 being more highly expressed in miR-21 
WT compared to KO M1 macrophages (1.8 fold, p<0.05), see Figure 5-52. 
Interestingly CD69 is an early activation marker induced in macrophages in 
response to TLR signalling by miR-21 (Fabbri et al., 2012). Representative 
scatter plots for CD69 are shown Error! Reference source not found.. 
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Figure 5-51. Macrophage Flow Cytometry Gating Strategy. A, Total events with gate around 
cells of interest. B, Unstained sample. C. Macrophages stained with anti F4/80-APC-Cy7.
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Figure 5-52. CD69 macrophage staining. A. Mean fluorescent intensity of cell surface 
markers on miR-21 WT and KO macrophages. Representative Scatterplots. B and C, 
unstimulated WT and KO, respectively. D and E, LPS stimulated WT and KO, respectively. F 
and G, IL-4 stimulated WT and KO, respectively. *p<0.05 vs LPS. X-axis CD69-PerCP-Cy5.5, 
y-axis F4/80-APC-Cy7. Biological n=9 for both WT and KO groups, technical duplicates. 
Statistics performed on biological data. *p<0.05.  
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5.4.3 Cytokine Production from miR-21 WT and KO Macrophages 
Cytokine levels were measured in media from unstimulated (M0), M1 (LPS 
treated) and M2 (IL-4 treated) macrophages from miR-21 WT and KO mice. 
As expected, the level of many pro-inflammatory cytokines was increased upon 
LPS stimulation including IL-1α"and"β, IL-6, IL-12, IP-10, KC, MCP-1 and TNFα,  
Figure 5-53.  
Several cytokines known to play a role in stimulating fibrosis and VSMC 
proliferation were expressed more highly by LPS treated macrophages from miR-
21 WT than KO mice. IL-1α, IL-1β and MIP-1α"concentrations were greater within 
media from WT compared to KO macrophages (203 ±50 pg/mL vs. 86 ±23 
pg/mL, p<0.01) (111 ±21 vs. 56 ±7.5 pg/mL, p<0.01) and (21556 ±4291 pg/mL 
vs 12056 ±3107 pg/mL, p<0.05),  
Figure 5-53. Interleukin-6, IL-12 and TNFα were also higher from WT than KO 
macrophages (3340 ± 461 pg/mL vs. 2098 ±511 pg/mL, p<0.05), (1323 ±280 
pg/mL vs. 540 ±126 pg/mL, p<0.001), (6772 ±1544 pg/mL vs. 3584 ±821 
pg/mL, p<0.05),  
Figure 5-53. Additionally the IL-12 : IL-10 ratio for LPS-stimulated miR-21 WT 
macrophages was almost double that of KO macrophages (24 vs. 13). 
A statistically significant difference in MIG concentrations between miR-21 WT 
and KO macrophages was also observed (25.3 ±8.0 pg/mL vs. 7.8 ±2.7 pg/mL, 
respectively, p<0.05), in many samples, from both WT and KO macrophages, the 
concentration was below the level of detection and thus its biological 
significance is uncertain. 
Unstimulated macrophages, as well as those stimulated with IL-4, exhibited 
minimal cytokine production with no significant difference noted between 
genotypes, Table 5-10.  
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Figure 5-53. Cytokine production from LPS stimulated macrophages. Measured by Luminex 
assay. Biological n=9 for both WT and KO groups, technical triplicates. Statistics performed 
on biological data.  *p<0.05, **p<0.01, ***p<0.001 vs. WT. 
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Table 5-10. Cytokine Production from WT and KO macrophages 
Cytokine WT 
Untimulated 
KO 
Unstimulated 
WT IL-4 KO IL-4 
IL-1alpha 
IL-1beta 
IL-2 
IL-4 
IL-5 
IL-6 
IL-10 
IL-12 
IL-13 
IL-17 
FGFbasic 
GM-CSF 
IFN-gamma 
IP-10 
KC 
MCP-1 
MIG 
MIP-1alpha 
TNFalpha 
VEGF 
12.9 
10.3 
2.4 
28.4 
12.1 
9.4 
15.9 
4.9 
6.4 
2.4 
84.7 
6.2 
5.3 
14.9 
29.6 
10.2 
3.3 
17.8 
14.7 
4.1 
12.9 
6.9 
2.4 
13.8 
13.9 
9.8 
16.3 
5.0 
8.2 
2.4 
56.7 
6.2 
5.3 
39.9 
26.1 
13.9 
2.7 
14.7 
15.3 
8.0 
12.9 
14.1 
2.4 
2781.6 
77.0 
8.2 
15.9 
19.5 
7.5 
2.4 
85.3 
6.2 
8.5 
14.9 
22.6 
95.5 
3.5 
24.1 
22.8 
1.5 
12.9 
10.2 
2.8 
2255.3 
166.3 
9.8 
20.2 
33.1 
8.2 
2.4 
64.6 
6.2 
6.1 
16.7 
22.6 
204.1 
3.0 
22.3 
17.2 
1.6 
Biological n=9 for both WT and KO groups, technical triplicates. All measurements in 
pg/mL. 
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5.4.4 Effect of conditioned media from cultured miR 21 WT and 
KO macrophages on VSMC 
Quiesced VSMCs from miR-21 WT and KO mice were used to assess the effect of 
conditioned media from polarised WT and KO macrophages on proliferation. 
BrdU incorporation as a surrogate marker of proliferation was conducted as 
described in Chapter 2. 0.2% FCS and 10% FCS were used as negative and positive 
controls, respectively.  
Figure 5-54 shows BrdU incorporation relative to VSMCs quiesced in 0.2% FCS. As 
expected an increase in BrdU incorporation was observed in VSMCs stimulated 
with 10% FCS. Exposure of VSMCs to conditioned macrophage media taken from 
all experimental conditions resulted in poor BrdU incorporation. No significant 
difference in proliferation was observed when comparing conditioned media 
from miR-21 WT and KO macrophages in VSMCs of either genotype,  
Figure 5-54. 
 
  
Figure 5-54. Effect of conditioned media from miR-21 WT and KO macrophages on the 
proliferation of VSMCs. Biological triplicates for both WT and KO groups, technical 
duplicates. Statistics performed on biological data. 
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5.4.5 Effect of macrophage polarisation on miR-21 expression 
The effect of LPS and IL-4 polarisation on miR-21 expression was also studied. 
Relative to unstimulated macrophages, LPS and IL-4 both induced an up-
regulation of miR-21(-5p) (3.00 ±0.23 fold, p<0.05 and 4.74 ±0.13 fold, p<0.01, 
respectively), Figure 5-55. Additionally, relative to untreated macrophages 
significant increases in miR-21-3p was also observed with LPS and IL-4 treatment 
(4.38 ±0.52 fold and 4.88 ±0.43 fold, respectively, p<0.05 for both), Figure 5-
55.  
No difference was observed between LPS or IL-4 treatments for miR-21(-5p) or 
miR-21-3p levels. However, it was noted that compared to miR-21(-5p), miR-21-
3p levels were markedly lower, with average cycle threshold values of ~20 
compared to ~33, respectively. 
  
Figure 5-55. MiR-21 Expression. RT-qPCR for miR-21. A, miR-21(-5p). B, miR-21-3p(star). 
*p<0.05, **p<0.01 vs. unstimulated. Biological triplicates, technical triplicates. Statistics 
performed on biological data.  
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5.4.6 Effect of LPS and IL-4 induced up-regulation of miR-21 in 
macrophages on known targets.  
Having shown that miR-21 is up-regulated in macrophages following LPS and IL-4 
treatment, further evidence of its role in mediating the effects through target 
repression was sought. RT-qPCR was conducted on a panel of known miR-21(-5p) 
targets validated in various cell types. Of these target genes PDCD4, PTEN and 
IL-12p35 have been previously validated in macrophages. Additionally, the 
relative expression of these targets was also evaluated in LPS and IL-4 treated 
macrophages from miR-21 KO mice. 
Upon LPS stimulation, miR-21 WT and KO macrophages demonstrated greater 
than 3700-fold and 1700-fold increases in IL-12p35, respectively. STAT 3 was also 
up regulated by LPS exposure in miR-21 WT and KO macrophages, 4.9-fold and 
3.6-fold, respectively. No significant difference was found between genotype, 
Figure 56. 
While PDCD4 was down-regulated following LPS stimulation in miR-21 WT 
macrophages compared to unstimulated controls, a similar pattern was also 
observed in miR-21 KO macrophages, (88% and 82% reduction, respectively, 
p<0.001 for both), Figure 56. 
Four targets genes BMPR2, PPARα, TIMP3 and PTEN showed no significant change 
in their expression levels despite an increase in miR-21. 
No significant difference in putative target gene expression was observed 
between miR-21 WT and KO macrophages. 
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Figure 56. Macrophage miR-21(-5p) target expression. Unstimulated, LPS stimulated, IL-4 
stimulated miR-21 WT and KO macrophages. A, IL-12p35. B, STAT3. C, PDCD4, Data RQ+/-
rqmax ***p<0.001 vs. WT unstimulated. ###p<0.001 vs. KO unstimulated. Biological n=5, 
technical triplicates for both WT and KO. Statistics performed on biological data. 
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5.4.7 Cell surface marker expression on miR-21 WT and KO 
macrophages following culture in presence of stainless 
steel  
Having assessed cell surface marker expression in M1 and M2 polarised 
macrophages, following exposure to classic polarising stimuli (LPS and IL-4), a 
pilot experiment (n=1, for each, miR-21 WT and KO) was conducted to assess if 
these markers would change in the presence of metal. To mimic, in vitro, the 
effect a bare metal stent may have on macrophage polarisation in vivo, stainless 
steel metal discs were placed in the wells of 6 well plates used during the 
generation of macrophages and during polarisation. M1 polarisation was achieved 
with the addition of LPS (100 ng/mL) and IFNγ (100 units/mL) rather than LPS 
alone. M2 polarisation was conducted as before with IL-4 (2 ng/mL). 
Figure 5-12 shows representative photographs of macrophages at day 4 of 
culture with and without metal discs. Clumping of macrophages around the edge 
of the metal disc was observed. Figure 5-13 shows representative photographs 
from miR-21 WT and KO polarised macrophages at day 7 with and without the 
presence of the metal disc.  
" "
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Figure 5-12. Macrophage culture. Unpolarised macrophages, day 4 in M-CSF, with and 
without presence of stainless steel metal discs. A and B, No metal discs, miR-21 WT and 
KO, respectively. C and D, Metal discs (black), miR-21 WT and KO, respectively. Scale bar = 
100 μm. 
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Figure 5-13. Polarised macrophages with and without presence of stainless steel. A, B and C, miR-21 WT unstimulated, LPS/IFNγ and IL-4, respectively. D, 
E and F miR-21 KO unstimulated, LPS/IFNγ and IL-4, respectively. G, H and I, miR-21 WT with stainless steel, unstimulated, LPS/IFNγ and IL-4, respectively. 
J, K and L, miR-21 KO with stainless steel, unstimulated, LPS/IFNγ and IL-4, respectively. Scale bar = 100 μm.  
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Analysis of cell surface marker expression was undertaken by flow cytometry as 
in section 0.  
Mean fluorescent intensity analysis demonstrated that across polarisation stimuli 
and genotype the presence of metal discs either had little effect on, or 
diminished the expression of CD86, TLR2, MHCII, CD11c and CD69. Using CD69 as 
a representative example, Figure 5-57 demonstrates cell surface marker staining 
in the presence and absence of metal. 
This pilot data would require to be repeated in order to ascertain any effect the 
stainless steel may have on macrophage polarisation. 
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Figure 5-57. CD69 Expression. MFI of cell surface marker on miR-21 WT and KO 
macrophages in presence and absence of stainless steel discs. A, Summary data. B, C and 
D, WT without metal, unstimulated, LPS/IFNγ, and IL-4, respectively. E,F and G KO without 
metal, unstimulated, LPS/IFNγ, and IL-4, respectively. H,I and J, WT with metal, 
unstimulated, LPS/IFNγ, and IL-4, respectively. K,L and M, KO with metal, unstimulated, 
LPS/IFNγ, and IL-4, respectively. X-axis CD69-PerCP-Cy5.5, y-axis F4/80-APC-Cy7. Biological 
n=1 for both WT and KO, technical duplicate. 
  
CD69
WT
 U
ns
tim
ula
ted
KO
 U
ns
tim
ula
ted
WT
 U
ns
tim
ula
ted
 M
eta
l
KO
 U
ns
tim
ula
ted
 M
eta
l
WT
 LP
S/I
FN
ga
mm
a
KO
 LP
S/I
FN
ga
mm
a
WT
 LP
S/I
FN
ga
mm
a M
eta
l
KO
 LP
S/I
FN
ga
mm
a M
eta
l
WT
 IL
-4
KO
 IL
-4
WT
 IL
-4 
Me
tal
KO
 IL
-4 
Me
tal
0
1000
2000
M
FI
WT KO WT%Metal KO%Metal
U
ns
tim
ul
at
ed
IL
44
LP
S/
IF
N
γ
B E H K
C F I L
D G J M
A
223 
 
The results presented above demonstrate that unstimulated miR-21 KO 
macrophages express lower levels of PPARγ than miR-21 WT macrophages. In 
addition, miR-21 WT macrophages stimulated with the classical M1 stimulus LPS 
expressed significantly higher levels of CD69 and several pro-inflammatory 
cytokines including IL-1α"and"β, IL-6, IL-12, IP-10, KC, MCP-1 and TNFα than their 
miR-21 KO counterparts.   
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5.5 Discussion 
The data presented within this chapter show that although stimulation with LPS 
and IL-4 did not significantly alter M1 and M2 polarisation maker expression 
between miR-21 WT and KO, the absence of miR-21 alters the inflammatory 
cytokine response of bone marrow derived macrophages. These findings suggest 
miR-21 modulates macrophage phenotype, its absence directs them away from 
an inflammatory bactericidal role towards an anti-inflammatory (M2) tissue 
healing state.  
Characterisation of unstimulated macrophages demonstrated an increase in 
basal expression of the validated M2 marker PPARγ, in mir-21 KO macrophages 
compared to their WT counterparts. These findings are particularly relevant in 
the setting of inflammatory vascular disease since a number of studies suggest 
that activation of PPARγ can diminish the inflammatory response in both 
macrophages and VSMCs (Jiang et al., 1998, Marx et al., 1998, Shu et al., 2000). 
Activation of PPARγ in human macrophages reduces MMP-9 activity and inhibits 
IL-1β, IL-6, TNFα expression. Furthermore, a number of groups have reported 
that PPAR-γ agonists inhibit the development of atherosclerosis and reduce 
inflammatory markers in ApoE KO mice (Collins et al., 2001, Li et al., 2000). 
Additionally, the response of miR-21 KO macrophages to LPS, a classical (M1) 
inflammatory stimuli is attenuated as evidenced by a reduction in NOS2:Arg1 
ratio. NOS2:Arg1 ratio is a commonly reported parameter of macrophage 
polarisation state and its relative reduction suggests miR-21 KO macrophages 
display a less extreme M1 phenotype upon LPS stimulation. Despite early studies 
showing a direct correlation between macrophage content and neointimal size 
recent evidence suggests macrophages play an important role in the healing 
process and that polarisation state may be as or more important than merely 
their presence. Recently published work has identified key roles played by 
macrophages in EC differentiation and the prevention of thrombosis (Wong et 
al., 2014). It has also been found that M1 macrophages, in particular the 
presence of high M1 to M2 ratios, are likely to contribute to the development of 
larger neointima (Lavin et al., 2014). In addition, investigators determined that 
either defective M2 polarisation or the repolarisation of macrophages from a M2 
to M1 phenotype increased NIH size (Lavin et al., 2014).  
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Cytokine profiling of M1 polarised macrophages following LPS stimulation showed 
a reduced capacity of miR-21 KO macrophages to secrete numerous pro-
inflammatory cytokines including IL-1, IL-6, TNFα and IL-12. These results may 
explain the effect of altered macrophage phenotype between miR-21 WT and KO 
mice and hence differences in NIH development presented in chapter 4. 
Interleukin-1α stimulation of VSMCs has been shown to induce the expression of 
a cascade of proinflammatory cytokines including, IL-6 and TNFα (Clarke et al., 
2010). Interleukin-1β has not only been shown to increase VSMC proliferation but 
also to stimulate the expression of fibronectin, an ECM component known to aid 
the transformation of VSMCs from contractile to synthetic state (Forsyth et al., 
1997). Additionally, IL-6 and TNFα have been shown to stimulate the 
proliferation and migration of VSMCs, respectively (Ikeda et al., 1991, Goetze et 
al., 1999). Thus within the current study the reduction in cytokine release from 
miR-21 KO macrophages is likely to contribute to the reduction in VSMC 
proliferation, ECM deposition and NIH size observed.   
Furthermore, phenotyping of surface receptors from BMDM also demonstrated a 
reduction in the expression of CD69 in miR-21 KO macrophages. It has been 
shown that miRs including miR-21 can activate Toll-like receptors (Fabbri et al., 
2012). TLR7 and its human equivalent TLR8 are intracellular TLRs functioning to 
identify ssRNA which, via NFκB signalling induce the expression of CD69 as well 
as cytokines such as IL-6 and TNFα (Fabbri et al., 2012). Thus the absence of 
miR-21 and hence TLR7/8 activation may account for the reduced CD69 
expression, IL-6 and TNFα observed. In addition, the reduction in CD69 may also 
contribute to the reduction in inflammatory cytokine secretion since previous 
studies have reported that activation of CD69 mediates a number of 
inflammatory processes such as nitric oxide production and release of TNFα from 
murine macrophages and T-cells (Marzio et al., 1997, Santis et al., 1992). 
The use of unconcentrated conditioned media likely containing low absolute 
concentrations of cytokines may have resulted in the poor proliferative response 
observed. Further experiments utilising concentrated media may increase 
proliferation observed. An alternative approach would be to utilise co-culture 
experiments in order to assess the effect of paracrine signalling between 
macrophages and VSMCs with respect to genotype. 
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Both M1 and M2 polarised macrophages demonstrated up regulation of miR-21. 
The work presented in this chapter confirms that of others who have 
demonstrated that LPS stimulation increases miR-21 levels (Sheedy et al., 2010, 
Zhou et al., 2010). It is important to note that only the mature form of miR-21 
was assessed in the current study. While it could be surmised that the increase 
in miR-21 may be as a result of increased transcription from the LPS-induced 
NFκB binding to the miR-21 promoter, an increase in miR-21 due to premir-21 
processing cannot be excluded. In addition, IL-4 stimulation was also found to 
increase miR-21 expression. Taken together these findings suggest miR-21 
expression may be increased upon immune activation rather than polarisation to 
a specific state. 
Despite up regulation of miR-21 upon LPS and IL-4 stimulation no differential 
change in the expression of known targets between miR-21 WT and KO 
macrophages could be demonstrated. This was clearly illustrated in the 
assessment of PDCD4 which, while being significantly down regulated in LPS 
stimulated WT macrophages was also significantly lower in corresponding miR-21 
KO samples. In addition, no reduction in PDCD4 was observed in M2 polarised WT 
macrophages that would have been expected given the increase in miR-21 
expression. Thus within macrophages it is likely that the down regulation of 
PDCD4 by LPS is through a miR-21 independent mechanism. These findings would 
appear to contradict data from previously published studies showing, in both a 
murine macrophage cell line and human peripheral blood mononuclear cells, 
miR-21 was key to down regulation of PDCD4 following LPS stimulation (Sheedy 
et al., 2010). Investigators demonstrated that upon LPS stimulation the addition 
of antimiR-21 increased PDCD4 expression and conversely the addition of a miR-
21 mimic reduced PDCD4 (Sheedy et al., 2010). It would appear LPS can reduce 
PDCD4 expression by both miR-21-dependent and -independent pathways; the 
relative contribution of each may be highly dependent on the cell type and 
setting.  
Strikingly, over a 1000-fold rise in IL-12 RNA of was observed following LPS 
stimulation of both miR-21 WT and KO macrophages. This is concordant with the 
findings of cytokine profiling demonstrating an increase of similar magnitudes at 
a protein level. Thus, while IL-12 has previously been validated as a miR-21 
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target within macrophages in a murine model of asthma it is not one within the 
present model of vascular stenting (Lu et al., 2011). 
The pathophysiological relevance of LPS and IL-4 stimulation strategies to mimic 
the effects on macrophage polarisation in vivo within the murine stenting model 
is questionable and is a significant limitation of this study. Therefore, a pilot 
experiment investigating the effect of a metal stent on macrophage polarisation 
was undertaken. This revealed no obvious morphological differences in 
macrophages following exposure to stainless steel. While much work has been 
published on the effect of metal implants on macrophage cytokine release, little 
data on their effect on cell surface expression markers has been published. 
Investigating the effects of soluble and particulate stainless steel implants on 
innate immunity has been undertaken in the field of orthopaedic prosthetics. It 
has previously been demonstrated that soluble cobalt, chromium, and 
molybdenum (all constituents of stainless steel) induce the production of a 
cascade of pro-inflammatory cytokines through NFκB activation (Lu et al., 2011). 
In addition, careful investigation has shown that within macrophages, metal salts 
as well as cobalt-chromium-molybdenum alloy particles induce reactive oxygen 
species generation, activating the inflammasome, which in turn activates 
caspase-1 and promotes the conversion of pro-IL-1β to IL-1β (Caicedo et al., 
2009). It is likely that the stimulation of macrophages by metal implants is a 
diverse and complex process likely to result in a multitude of different and 
mixed polarisation states dependent on type of metal and tissue involved. It 
should be noted that the data presented in the current study is from a n=1 and 
would require to be repeated if any conclusions are to be drawn. 
In summary, the results presented within this chapter demonstrate that the 
absence of miR-21 results in a propensity for macrophages to polarise towards an 
M2 phenotype. In addition, genetic deletion of miR-21 resulted in a reduction in 
the secretion of several pro-inflammatory cytokines upon classical M1 
polarisation. While it was not possible to demonstrate a direct effect on putative 
target mRNA within macrophages, the effects could at least in part be explained 
by a reduction in intracellular TLR signalling with consequent reduction in IL-6, 
TNFα and CD69 expression due to the absence of miR-21. However, further work 
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would be required to confirm whether these effects are maintained in vivo and 
in the presence of metallic stents. 
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6 General Discussion. 
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This thesis contains research data demonstrating a significant increase in the 
understanding of the development of ISR. Firstly, the refinement of the murine 
stenting model and establishment within the Baker laboratory substantially 
increases our ability to study the development of ISR. In addition, refining the 
stent electrolysis and tissue processing in a small animal stenting model 
facilitates the discovery of novel cellular and molecular mechanisms responsible 
for the development of ISR.  This is the first study to examine the role of 
microRNAs in the development of ISR and using miR-21 KO animals we were able 
to identify a crucial role played by miR-21 in the development ISR. Careful ex 
vivo and in vitro analysis revealed putative mechanisms involving miR-21 in both 
VSMCs and the immune system, which contributed to the differences in ISR 
observed between miR-21 WT and KO animals.  
Despite a significant reduction in its incidence across many western societies IHD 
remains an important cause of morbidity and mortality globally. Indeed within 
the UK IHD continues to place an enormous burden on the NHS. With an aging 
population this burden is only likely to increase (Bhatnagar et al., 2015). The 
two major manifestations of IHD, angina and myocardial infarction are 
commonly treated with a combination of pharmacological therapy and 
revascularisation. Significant changes in the revascularisation strategy adopted 
for many patients now means that far more undergo PCI rather than CABG. 
Indeed, recent figures show that over the last decade the number of CABG 
procedures performed in the UK has fallen by over one third. While over the 
same period PCI procedures have more doubled to over 92,000 per year (BHF, 
2014). This has been due not only to substantial improvements in interventional 
techniques and technologies but also increasing patient age and the presence of 
comorbidities, which have a significant impact on surgical mortality.  
Early interventional procedures were dominated by balloon angioplasty, with the 
use of stents to prevent elastic recoil and acute vessel occlusion more widely 
adopted after the publication of the BENESTENT trial (Serruys et al., 1994). 
However, bare metal stent use appeared only to substitute the problem of 
elastic recoil for that of ISR, which often necessitated target vessel 
revascularisation. The development of drug eluting stents was heralded as a 
major advance in stent technology but their use was complicated by late stent 
thrombosis as a result of delayed and incomplete re-endothelialisation (Joner et 
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al., 2006). In addition, the initial polymers on which the antiproliferative drugs 
were impregnated caused a chronic inflammatory reaction as evidenced by a 
persistent local eosinophilia (Nebeker et al., 2006). Prevention of late stent 
thrombosis was achieved by prolonged dual antiplatelet use at the expense of an 
increased bleeding risk (Joner et al., 2006). Since the introduction TAXUS and 
Cypher first generation DES considerable advances in stent technology have been 
made, including the development of thinner stent struts, new antiproliferative 
medication and improvements in polymer biocompatibility as well as the 
development of biodegradable polymers (Puricel et al., 2015). More recently 
polymer free DESs have been developed (Urban et al., 2013). Taken together 
these improvements have been associated with reduced inflammation, thrombus 
formation and increased re-endothelialisation as well as allowing far shorter 
duration of dual antiplatelet use.  
However, despite the improvements mentioned above ISR remains an important 
clinical problem particularly in those with diabetes (Abizaid et al., 1998). 
Treatment of ISR can be challenging and although several therapies have been 
trialled including cutting balloons, drug eluting balloons and further deployment 
of DES with the original stent no consensus has been reached as to optimal 
therapy (Lee et al., 2015). 
Improved understanding of the pathophysiology of ISR may allow the 
development of novel preventative strategies to reduce its occurrence or 
therapies to treat this iatrogenic problem. It is likely that any such strategy 
would be combined with current DES technology rather than as a standalone 
measure. The use of pre-clinical animal models has already improved our 
understanding of vascular injury but this has not always been translated into 
clinical practice. Numerous reasons for this exist, not least differences between 
humans and animals in healing, inflammation and coagulation cascades 
(Touchard and Schwartz, 2006). Moreover, until now the majority of animal 
models, especially those in small animals have been non-stenting injury models, 
which poorly replicate the clinical problem in humans. The later issue was 
directly addressed in chapter 3 where we refined a mouse model of stenting for 
use within the Baker laboratory. Importantly we used a miniaturised BMS and a 
balloon catheter used in the clinical setting. In addition, the electrochemical 
dissolution of stents led to substantially improved tissue processing, increasing 
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the range of immunohistochemical stains available as well as being able to 
undertake in situ hybridisation for microRNAs. The improvements in model and 
tissue processing allowed further in depth study of ISR development, 
inflammation and re-endothelialisation. Until now assessment of re-
endothelialisation has necessitated transgene use and bone marrow transfer 
studies (Douglas et al., 2013).  
Since the discovery of microRNAs and their role in the coordination of tissue 
development their importance in disease has also been recognised. Indeed, miRs 
have been found to be dysregulated in numerous cardiovascular diseases 
including atherosclerosis, arteriosclerosis obliterans, AAA and following balloon 
angioplasty. Targeting multiple mRNAs and fine-tuning their expression across 
multiple points in biological pathways miRs appear attractive targets for 
therapeutic manipulation in the treatment of disease.  
Given the known role of miR-21 in promoting cellular proliferation and migration 
in many cancers we hypothesised that it is likely to be important in many 
proliferative cardiovascular diseases including ISR (Meng et al., 2007). Within 
chapter 4, miR-21 was demonstrated to be highly expressed in the neointima of 
stented tissue taken from the mouse model used. Within the Baker laboratory 
we have also shown a post stenting increase in miR-21 expression within both a 
large animal model and most importantly within diseased human coronary 
arteries following stenting. These data suggested miR-21 is dysregulated 
following stent injury and that this is conserved across species. Further work was 
undertaken in order to determine if the up regulation of miR-21 played an 
important role in the development of ISR. The use of KO mice demonstrated in 
vivo, that miR-21 has a deleterious effect on the development of ISR with a 
reduction in neointimal size, VSMC and fibrous tissue content observed following 
genetic deletion. In vitro analysis revealed these findings maybe in part due to 
the reduced proliferative and migratory response of miR-21 KO VSMCs to PDGF, a 
key mitogen released from various cell types upon stent deployment (Chaabane 
et al., 2013). Furthermore, investigation revealed that the deleterious effects of 
miR-21 in VSMCs may be due to PDCD4 targeting. 
In addition, in vivo investigation demonstrated the macrophages present within 
miR-21 KO stented tissue had an altered inflammatory state. This finding 
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suggested a potentially novel mechanism by which miR-21 may influence ISR 
development. The data presented within Chapter 5 demonstrated significant 
differences in macrophage cytokine release between miR-21 WT and KO 
macrophages. It is not inconceivable that these differences may be responsible 
for the reduction in ISR observed in KO mice as a result of changes to direct 
macrophage – VSMC interaction and or paracrine signalling mechanisms via 
effects on proliferation, migration and ECM secretion. Adding further weight to 
this immune mediated hypothesis is the work of others within the Baker group 
who have demonstrated significant differences in monocytes, T and B-cells 
between miR-21 WT and KO mice (McDonald et al., 2015). Both T and B-cells 
have been implicated in the development of ISR (Chaabane et al., 2013).  
Despite our initial and unsuccessful attempt to therapeutically manipulate miR-
21 in the setting of ISR, pharmacological manipulation remains an attractive 
therapy for many diseases. Indeed, other researchers have had success in miR 
manipulation within several preclinical models of cardiovascular disease (Ji et 
al., 2007, Maegdefessel et al., 2012, Wang et al., 2011). Several key 
considerations need to be examined when deciding upon the therapeutic 
manipulation of miRs. Firstly, identification of an appropriate miR or miRs which 
are actively involved in the disease process is important. Various strategies can 
be employed to modulate miR levels within tissues. Up regulation of specific 
miRs can be achieved by several methods including the use of miR mimics or 
vectors such as adenovirus and lentivirus containing miR expression cassettes. 
Down regulation of miRs can be achieved by siRNAs, antimiRs (of various 
chemistries) and more recently by the use of miR sponges (van Rooij et al., 
2012).  
Route of delivery is another key consideration in miR modulation and may be 
determined by the ease of access to site or sites required in order to gain a 
therapeutic effect. Local delivery methods have been extensively used in pre-
clinical models and may be clinically relevant in numerous surgical settings. 
Indeed during CABG surgery saphenous veins are harvested and stored for a short 
period prior to grafting, during which miR-modulating therapy could be 
delivered. However, the local delivery methods used in pre-clinical models of 
stenting including the adventitial application of a poloxamer containing antimiR 
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or Adenovirus are not clinically applicable. Instead the use of miR mimics or viral 
vectors conjugated to stents are likely to be necessary to achieve local delivery.   
Systemic delivery either by intravenous, intramuscular or subcutaneous routes 
are possible for miR manipulation. Intravenous administration on antimiR-21 has 
been successful in pre-clinical models of vascular disease (Maegdefessel et al., 
2012). As evidenced in gene therapy trials, these approaches would appear 
particularly useful if trying to target multiple sites, the reticuloendothelial 
system or the liver. However, it is also important to note that systemic delivery 
may require high doses of therapeutic agent and thus risks the development of a 
systemic inflammatory response. 
Another important therapeutic consideration is the potential for off target 
effects following miR manipulation. These include targeting of miRs in 
unintended tissues, which may be more likely following systemic delivery. 
However, local delivery may also result in targeting within unintended cell 
types. This may be very important as individual miRs play multiple roles within 
the body, often having tissue specific effects. Indeed, opposing effects have 
been documented including that of miR-21 in endothelial cells and VSMCs (Lin et 
al., 2009, Sabatel et al., 2011). Other concerns surrounding miR manipulation 
include the alteration of homeostatic mechanisms within non-diseased tissues 
and the unmasking of disease or the acceleration of disease progression such as 
cancer. Even within intended target tissues therapeutic modulation of miRs may 
alter the expression of genes not normally targeted within that tissue, resulting 
in the unintended alteration of bystander biological pathways (van Rooij and 
Olson, 2012).  
Despite the inherent difficulties with the development of miR based 
therapeutics, a recent phase 2 clinical study of antimiR-122 subcutaneously 
administered for the treatment of Hepatitis C has shown considerable promise in 
the reduction of viral load. Importantly the therapeutic regimen appeared to be 
well tolerated with no excess of adverse events noted between antimiR-122 and 
placebo treated groups (Janssen et al., 2013).  
In addition, an on going clinical trial is currently investigating the potential of 
MRX34 in several types of cancer including primary liver cancer, lung cancer and 
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several haematological malignancies (McClure, 2015). Importantly this trial plans 
to recruit those with metastatic disease burden for whom there are often little 
therapeutic options.  MRX34 is a miR-34 mimic formulated within a liposomal 
preparation for intravenous administration (McClure, 2015). Mir-34 has been 
shown to be reduced in several types of cancer and has a dramatic effect on 
many cancers by inducing cell cycle arrest at the G1 checkpoint by targeting 
CDK4/6, cyclin E2 and Bcl-2 (Sun et al., 2008). Interestingly the tumour 
suppressor p53 has been found to induce miR-34 expression and its mutation 
blocks the induction of a positive feedback loop between itself and miR-34 
(Corney et al., 2007). Despite being a phase 1 trial the above study offers some 
hope to those with metastatic cancer. 
MiR-29 has been shown in various settings to through inhibition of TGFβ 
signalling to reduce fibrosis and ECM deposition (Xiao et al., 2012, Chung et al., 
2013). Its potential in the treatment of cutaneous scleroderma is currently being 
investigated in a phase 1 clinical trial using the miR-29 mimic MRG-201 
administered by intradermal injection. This trial is due to report in late 2016 
(Rodman, 2015).  
In summary, the work contained within this thesis demonstrates that miR-21 is 
important in the development of ISR. In addition, genetic deletion of miR-21 
reduced ISR, most likely by affecting the proliferative and migratory response of 
VSMC as well as altering the immune cell function. However, this study is not 
without its limitations. It is important to note the genetic deficiency of miR-21 
was present prior to stenting and may alter the response to injury in these mice. 
In addition, lack of efficacy upon pharmacological knockdown requires further 
investigation including detailed analysis of miR-21 activity and that of mRNA 
targets.
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Appendix 
Reducing In-Stent Restenosis
Therapeutic Manipulation of miRNA in
Vascular Remodeling and Inﬂammation
Robert A. McDonald, PHD,* Crawford A. Halliday, MBCHB,* Ashley M. Miller, PHD,* Louise A. Diver, PHD,*
Rachel S. Dakin, PHD,* Jennifer Montgomery, PHD,* Martin W. McBride, PHD,* Simon Kennedy, PHD,*
John D. McClure, PHD,* Keith E. Robertson, MBCHB,* Gillian Douglas, PHD,y Keith M. Channon, MD,y
Keith G. Oldroyd, MD,z Andrew H. Baker, PHD*
ABSTRACT
BACKGROUND Drug-eluting stents reduce the incidence of in-stent restenosis, but they result in delayed arterial
healing and are associated with a chronic inﬂammatory response and hypersensitivity reactions. Identifying novel in-
terventions to enhance wound healing and reduce the inﬂammatory response may improve long-term clinical outcomes.
Micro–ribonucleic acids (miRNAs) are noncoding small ribonucleic acids that play a prominent role in the initiation and
resolution of inﬂammation after vascular injury.
OBJECTIVES This study sought to identify miRNA regulation and function after implantation of bare-metal and drug-
eluting stents.
METHODS Pig, mouse, and in vitro models were used to investigate the role of miRNA in in-stent restenosis.
RESULTS We documented a subset of inﬂammatory miRNAs activated after stenting in pigs, including the miR-21 stem
loop miRNAs. Genetic ablation of the miR-21 stem loop attenuated neointimal formation in mice post-stenting. This
occurred via enhanced levels of anti-inﬂammatory M2 macrophages coupled with an impaired sensitivity of smooth
muscle cells to respond to vascular activation.
CONCLUSIONS MiR-21 plays a prominent role in promoting vascular inﬂammation and remodeling after stent injury.
MiRNA-mediated modulation of the inﬂammatory response post-stenting may have therapeutic potential to accelerate
wound healing and enhance the clinical efﬁcacy of stenting. (J Am Coll Cardiol 2015;65:2314–27) © 2015 by the
American College of Cardiology Foundation.
C oronary stenting has almost universally su-perseded the use of balloon angioplastyalone for the percutaneous treatment of cor-
onary heart disease. Stenting solves the major prob-
lems of balloon angioplasty, including acute elastic
recoil, occlusive dissection, and the need for repeat
revascularization due to restenosis (1). Stenting is su-
perior to balloon angioplasty alone in the setting of
both stable and unstable coronary artery disease
(2,3). However, the vascular injury caused by stent
implantation provokes neointimal hyperplasia due
to aberrant vascular smooth muscle cell (SMC) prolif-
eration and migration (4). The resulting encroach-
ment on the vessel lumen may be sufﬁcient to cause
in-stent restenosis (ISR), recurrent ischemia, and a
need for repeat revascularization in up to 20% of
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patients treated with bare-metal stents (BMS) at 1
year. The development of metallic drug-eluting
stents (DES) coated with an antiproliferative drug
has substantially reduced ISR (5) but is associated
with a signiﬁcantly greater incidence of late stent
thrombosis compared with BMS due to delayed arte-
rial healing (6,7). Several clinical trials are currently
evaluating fully bioresorbable nonmetallic DES, but
early reports suggest that they may have higher rates
of incomplete strut apposition and strut fracture
(8,9). Collectively, these ﬁndings highlight the need
to further improve our understanding of the events
that control vascular healing responses with both
BMS and DES.
Noncoding ribonucleic acids (RNAs) play a pivotal
role in many physiological and homeostatic processes
(10,11). The best characterized are short, highly
conserved RNA molecules called microRNAs (miR-
NAs), which mediate messenger RNA silencing
through translational degradation or repression after
complementary base pairing (12). More than 1,000
miRNAs are thought to regulate w30% of all protein-
coding messenger RNA (13). Thus, a single miRNA
may have $1 messenger RNA targets at different
points within multiple biological pathways to me-
diate a disease phenotype (14,15). In the setting of
vascular injury, miRNAs are involved in inﬂammatory
cell recruitment and activation and dedifferentiation
of SMCs, key processes that drive the vessel response
to injury. However, there has been no systematic
analysis of miRNA regulation post-stent deployment.
The goal of the present study, therefore, was to
deﬁne the expression pattern and function of miRNAs
after stenting with BMS and DES to identify miRNAs
with the potential to modulate vascular response to
injury.
METHODS
Detailed methods are available in the Online
Appendix. In brief, male Landrace pigs (19 to 26 kg)
were pre-dosed orally with aspirin and clopidogrel
24 h before surgery, and they were maintained on this
dual antiplatelet therapy throughout the study to
reduce the risk of in-stent thrombosis. Vascular ac-
cess was obtained by femoral artery cutdown and the
insertion of a 6-F transradial sheath (Arrow Interna-
tional, Reading, Pennsylvania). Coronary angiog-
raphy was performed before the deployment of
either BMS (Gazelle, Biosensors Europe SA, Morges,
Switzerland) or Biolimus A9 eluting stents (BioMatrix
Flex, Biosensors Europe SA) to achieve a target ratio
of stent to artery diameter of 1.2:1. Animals
were euthanized after 7 or 28 days.
In the murine model, a stainless steel stent
(5-cell, 2.5 mm ! 0.8 mm; strut thickness
0.06 mm; Cambus Medical, Galway, Ireland)
was crimped onto a 1.20-mm ! 8-mm Mini-
Trek balloon angioplasty catheter (Abbott
Vascular, Abbott Park, Illinois) and deployed
(10 atm for 30 s) into the thoracic aorta before
engraftment into a recipient mouse. Mice
were allowed to recover in heated chambers
for 24 h and were returned to normal housing
conditions, where they were maintained on
aspirin-supplemented water and a normal
chow diet for another 28 days before being
killed. Murine aortas were harvested from
male mice 8 to 12 weeks of age, and vascular
SMCs were isolated and cultured. Cell
migration was assessed via scratch assay.
Bone marrow–derived macrophages (BMDM)
were generated and bone marrow cells iso-
lated from femurs and tibiae of wild-type
(WT) and miR-21 knockout (KO) mice. Flow
cytometry was performed by using a BD FACSCanto II
or LSR II (BD Biosciences, San Jose, California).
Global proﬁling for miRNAs in the control unsten-
ted arteries and stented porcine coronary arteries was
performed with miRNA quantiﬁcation by using real-
time polymerase chain reaction. For analysis, fold
changes for each miRNA were normalized to U6
because this miRNA was the most suitable endo-
genous miRNA in porcine tissue. Data analysis
was performed by using SDS software version 2.3
(Applied Biosystems, Carlsbad, California), and the
baseline and threshold were automatically set. Data
were normalized and then analyzed to identify miR-
NAs differentially expressed between the control
(unstented) arteries and arteries subjected to stenting
for 7 or 28 days. Data were analyzed by using Data-
Assist software version 3 (Applied Biosystems).
All data are mean " SEM. Visual assessment was
used to check for any lack of normality; because there
was no evidence of this, 1-way analysis of variance
followed by a Tukey multiple comparison test (for
comparison of >2 groups) or Student t test (for
comparison of 2 groups) were conducted. For all
the quantitative polymerase chain reaction experi-
ments, values are expressed as fold-change. All sta-
tistical analyses were conducted by using Prism
version 4 (GraphPad Software, San Diego, California).
The microRNA array data were analyzed in DataAssist
software. Comparisons of in vitro SMC proliferation
and migration were performed by using 2-way anal-
ysis of variance and Bonferroni post-hoc tests.
SEE PAGE 2328
AB BR E V I A T I O N S
AND ACRONYM S
BMDM = bone marrow–derived
macrophages
BMS = bare-metal stent(s)
CD = cluster of differentiation
DES = drug-eluting stent(s)
IL = interleukin
ISR = in-stent restenosis
KO = knockout
LPS = lipopolysaccharide
miRNA = micro–ribonucleic
acid
PDCD4 = programmed cell
death protein 4
PDGF = platelet-derived
growth factor
PPAR = peroxisome
proliferator–activated receptor
RNA = ribonucleic acid
SMC = smooth muscle cell
WT = wild-type
J A C C V O L . 6 5 , N O . 2 1 , 2 0 1 5 McDonald et al.
J U N E 2 , 2 0 1 5 : 2 3 1 4 – 2 7 Inﬂammatory miRNAs and In-Stent Restenosis
2315
Downloaded From: http://content.onlinejacc.org/ on 01/05/2016
All animal procedures were performed in accor-
dance with the United KingdomHome Ofﬁce Guidance
on the operation of the Animals (Scientiﬁc Procedures)
Act 1986 and institutional ethical approval.
RESULTS
The effects of BMS and DES on ISR were assessed in
pig coronary arteries by using optical coherence to-
mography imaging (Figures 1A to 1D). The DES
reduced neointima formation by 33% compared with
BMS at 28 days (Figure 1A), leading to a signiﬁcantly
larger luminal area (Figure 1B) with no difference in
stent expansion (Figure 1C).
We sought to identify aberrantly expressed
miRNAs. At 7 days post-stenting, 116 miRNAs were
differentially regulated in the BMS group, with 23
miRNAs remaining dysregulated at 28 days. At
7 days, multiple miRNAs associated with inﬂamma-
tory cell inﬁltration and activation were altered
(Online Table 1, Online Figure 1). Of note, miR-21-3p
was substantially up-regulated in both BMS- and
DES-treated arteries at 7 days, suggesting that the
miR-21 stem loop (i.e., both lead and “passenger”
strands) may be important post-stenting. The
expression proﬁle of miR-21-3p and miR-21-5p were
validated, and this revealed that miR-21-5p was
signiﬁcantly up-regulated in stented arteries at 7 days
regardless of stent type and remained up-regulated at
28 days compared with unstented control arteries
(Figure 2A). MiR-21-3p was also up-regulated at 7 and
28 days post-stenting in both groups (Figure 2B). We
then identiﬁed the localization of expression of the
miR-21 axis in the vessel wall after stenting, focusing
on miR-21-5p (because the absolute levels of miR-21-
3p are lower and below the detection threshold for
in situ hybridization). In control coronary arteries,
miR-21-5p was detected within the media (Figure 2C).
In injured vessels 28 days post-stenting, increased
signal intensity was observed in the medial layer and
developing neointima, particularly around stent
struts. To determine if this expression pattern is
maintained in the clinical setting, in situ hybridiza-
tion was performed in human coronary arteries 14
days post-stenting from tissue obtained from a heart
transplant patient. In concordance with the staining
pattern in porcine arteries, abundant miR-21 expres-
sion was observed in the developing neointima
and inﬁltrating inﬂammatory cells (Figure 2D,
Online Figure 2). Taken together, these ﬁndings
FIGURE 1 ISR Assessment: Porcine Stent Model
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Porcine coronary arteries were stented with bare-metal stents (BMS) or Biolimus A9 drug-eluting stents (DES). Measurements of in-stent
restenosis (ISR), including (A) percent diameter stenosis, (B) luminal diameter, and (C) stent expansion, were analyzed at 7 and 28 days post-
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FIGURE 2 Regulation of miR-21-5p and -3p During ISR
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suggest that miR-21-5p and miR-21-3p may be
important in the development of post-stent patho-
physiological responses to injury.
We used a murine interpositional graft model of
stenting. In situ hybridization conﬁrmed abundant
miR-21-5p staining around the stent struts and
developing neointima (Figure 3), consistent with the
porcinedata.Morphometric analysis found thatmiR-21
KO mice stent grafts had a reduced neointimal
area, neointimal thickness, and neointima-to-medial
ratio compared with WT controls (1.37 ! 0.18 [n ¼ 8]
vs. 2.11 ! 0.17 [n ¼ 9]; p < 0.05) (Figures 4A and 4B,
Online Table 2). Measurements of strut depth were
concordant with greater strut depth in WT-stented
grafts than in KO-stented grafts. A signiﬁcant
reduction in luminal area in WT mice compared with
miR-21 KO mice was also observed (Figures 4C and 4D,
Online Table 2). There were no apparent differences
in luminal, media, or total vessel area between WT
and miR-21 KO mice at baseline (before stent injury),
although an increased sample size would be need-
ed to conﬁrm this observation (Online Table 3).
Furthermore, the total vessel area did not differ
signiﬁcantly at 28 days (Figure 4E), and no differences
were observed in unstented vessels at baseline
(Online Table 3).
The neointimal lesions from miR-21 KO mice
contained signiﬁcantly less a-actin–positive SMCs
(28 ! 2.4% [n ¼ 8] vs. 14 ! 3.7% [n ¼ 9]; p < 0.01)
(Figures 5A and 5B). Lesions in WT mice contained
50% more elastin than in KO mice (Figures 5C and 5D,
Online Table 2). No difference in cell proliferation was
observed after quantiﬁcation of cells in the neointima
(Figures 5E and 5F, Online Table 2). We assessed vessel
reendothelialization and, importantly, found no sig-
niﬁcant difference between miR-21 KO and WT mice
(91.0 ! 3.9% vs. 88.7 ! 2.9%, respectively) (Figures 5G
and 5H). No differences were observed at baseline
(i.e., unstented vessels) (Online Table 3).
To explore the mechanisms responsible for the
reduction in neointima formation in miR-21 KO mice,
proliferation and wound healing assays were per-
formed. The proliferative response of miR-21 KO SMC
was dramatically attenuated in response to platelet-
derived growth factor (PDGF) (Figure 6A), as was
migration in response to PDGF (Figures 6B and 6C).
To identify potential targets responsible for these
effects, we stimulated aortic SMC from miR-21 WT
and KO mice with PDGF (n ¼ 5) to elevate miR-21
levels (3.03 ! 0.23-fold vs. controls; p < 0.01)
(Figure 6D). The messenger RNA levels of known
miR-21 targets with deﬁned roles in SMC prolifera-
tion and migration were proﬁled. The expression of
programmed cell death protein 4 (PDCD4) and signal
transducer and activator of transcription 3 were
signiﬁcantly reduced in aortic SMC from WT mice
after PDGF stimulation. These changes were not
observed in miR-21 KO cells stimulated with PDGF
(Figures 6E and 6F); however, further experiments
are required to determine whether repression of
these genes is direct or indirect via miR-21 regulation
in this setting.
MiR-21 KO mice contained greater numbers of
galactin-3þ (MAC-2) macrophages in the neointima
comparedwithWTmice (0.79!0.23%vs. 2.54!0.75%;
p < 0.05) (Figures 7A and 7B) and enhanced levels
of YM-1–positive macrophages, a validated murine
marker of the alternatively activated (M2) macro-
phage (1.93 ! 0.54% vs. 0.50 ! 0.21%; p < 0.01)
FIGURE 3 In Situ Hybridization for miR-21
Scramble probe at (A) low magniﬁcation and (C and E) areas under enhanced magniﬁcation
corresponding to regions highlighted by the hatched areas are seen in murine stented
grafts 28 days post-implantation, as are (B) MiR-21 probe and (D and F) areas under
enhanced magniﬁcation corresponding to regions highlighted by the hatched areas.
Scale bar ¼ 100 mm.
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(Figures 7C and 7D). Thus, loss of miR-21 results in
altered inﬂammatory cell phenotype within injured
vessels. To investigate whether these effects were
derived from any hematological defect, before cell
recruitment to the vessel wall, the populations of
immune cells in both bone marrow and blood of WT
and miR-21 KO mice were examined (16). In bone
marrow, the percentage of cluster of differentiation
(CD) 3þ T cells was signiﬁcantly reduced in miR-21 KO
mice, but neutrophils, monocytes, B cells, CD4þ, and
CD8þ T cells did not differ (Online Figures 3A and 3B).
In blood, miR-21 KO mice exhibited a signiﬁcantly
reduced percentage of circulating Ly6cþhi monocytes
and CD3þ T cells (Figures 7E and 7F), potentially
indicating a reduced capacity to develop proin-
ﬂammatory responses.
To investigate whether the absence of miR-21 leads
to altered macrophage differentiation, BMDMs from
WT and miR-21 KO mice were generated and treated
with either lipopolysaccharide (LPS) or interleukin
(IL)-4 in vitro to induce M1 and M2 polarization,
respectively. Both LPS and IL-4 signiﬁcantly
up-regulated the expression of miR-21-3p and
miR-21-5p in WT macrophages (3.00 " 0.23-fold,
4.38 " 0.91-fold, 4.74 " 0.13-fold, and 4.88 " 0.7-fold,
respectively; p < 0.05), indicating that inﬂammatory
mediators can modulate the expression of miR-21
(Figure 8A). At baseline, unstimulated (M0, non-
polarized) miR-21 KO macrophages had signiﬁcantly
higher levels of peroxisome proliferator–activated
receptor (PPAR)-g expression (M2 polarization
marker) than WT cells (p < 0.01) (Figure 8B). After
activation with LPS, expression of nitric oxide syn-
thase (an M1 marker) was signiﬁcantly reduced in
miR-21 KO versus WT macrophages (Figure 8C). In
addition, the ratio of messenger RNA expression of
nitric oxide synthase, compared with arginase 1 (an
M2 marker), was signiﬁcantly higher in WT than miR-
21 KO macrophages treated with LPS (20.6 " 6.52-fold
vs. 2.7 " 1.24-fold; p < 0.001) (Figure 8D). Flow
cytometric analysis demonstrated that after activa-
tion with LPS, CD69 was signiﬁcantly reduced in miR-
21 KO versus WT LPS-treated macrophages (1.8-fold;
p < 0.05) (Figure 8E). However, all other markers
examined by using ﬂow cytometry (major histocom-
patibility complex-II, CD11c, CD86, CD206, and Toll-
like receptor-2) were not signiﬁcantly different in
either LPS- or IL-4–treated WT or miR-21 KO BMDM
(Online Figure 4). The levels of several proin-
ﬂammatory mediators were signiﬁcantly reduced
from LPS-stimulated macrophages of miR-21 KO
compared with WT mice: IL-1a, IL-1b, IL-6, IL-12, tu-
mor necrosis factor-a, and macrophage inﬂammatory
protein-1a (Figure 8F). In addition, the IL-12/IL-10
ratio for LPS-stimulated miR-21 macrophages was
almost double that of KO macrophages (24 vs. 13).
To address whether miR-21 KO macrophages had
a reduced capacity to inﬁltrate and migrate into
vascular lesions after injury, we studied BMDM
migration through Matrigel-coated transwell inserts
containing 8-mm pores (Sigma, United Kingdom).
These experiments showed that both BMDM iso-
lated from WT and miR-21 KO mice had the same
capacity to migrate through a matrix membrane in
response to monocyte chemoattractant protein-1
(Figure 8G).
FIGURE 4 Effect of miR-21 Ablation on Neointimal Formation and ISR
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FIGURE 5 Cellular Analysis of Murine Lesions
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DISCUSSION
We report for the ﬁrst time miRNA patterns associated
with delayed arterial healing and neointima forma-
tion after stenting (Central Illustration). Aberrantly
expressed miRNA lead and “passenger” strands asso-
ciated with 7- and 28-day time points were identiﬁed.
Of particular interest, the stem loop of miR-21,
including lead (miR-21-5p) and passenger (miR-21-3p)
strands, was up-regulated in both the BMS and
DES groups compared with controls. Further experi-
ments highlighted that loss of the miR-21 stem
loop in KO mice blocked neointimal formation
through effects on SMC proliferation and migration,
FIGURE 6 In Vitro Analysis of miR-21 SMC
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FIGURE 7 Inﬂammatory Cells in Neointimal Lesions and Blood of miR-21 KO Mice
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FIGURE 8 In Vitro Altered Inﬂammatory Response in miR-21–Deﬁcient Macrophages
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macrophage polarization, and inﬂammatory activa-
tion. A causal network analysis was performed of miR-
21-3p and miR-21-5p targets to determine whether
these miRNAs affect the inﬂammatory networks
associated with vascular injury. Despite a relatively
small overlap of predicted genes, pathways associated
with tumor necrosis factor-a and IL-1 were 1 of the
top-ranking regulatory networks (Online Figure 5);
this ﬁnding may be relevant because both of these
cytokines play prominent roles in neointima forma-
tion (17,18).
MiR-21 KO mice exhibited reduced SMC deposi-
tion, neointima formation, and an altered inﬂam-
matory phenotype, resulting in enhanced levels of
anti-inﬂammatory M2 macrophages in response to
vascular injury and stenting, with no effect on
endothelial regeneration. Subsequent proﬁling of
immune cell populations in the blood of miR-21 KO
mice demonstrated reduced numbers of Ly6cþhi
cells, a cell type that can differentiate into M1 mac-
rophages after tissue inﬁltration. This ﬁnding sug-
gests that miR-21 KO mice have a reduced capacity to
develop an M1 inﬂammatory phenotype in response
to injury. We also found reduced total CD3þ T-cell
counts in the bone marrow and blood of the miR-21
KO. Recently, it has been reported that miR-21 can
modulate T-cell responses, including alterations in
cytokine production and apoptosis rates (19–21).
T cells are already known to contribute to the in-
ﬂammatory response after coronary artery stenting
(22); thus, the absence of miR-21 in T cells likely
contributes to the altered inﬂammatory responses
and reduced in-stent stenosis seen in miR-21 KO.
In support of the altered inﬂammatory responses
in vivo, our BMDM experiments revealed that miR-21
KO macrophages contain enhanced baseline levels of
PPAR-g, a well-characterized M2 macrophage marker,
and a reduced ratio of nitric oxide synthase/arginase
CENTRAL ILLUSTRATION Role of miRNA in ISR
McDonald, R.A. et al. J Am Coll Cardiol. 2015; 65(21):2314–27.
Although drug-eluting stents (DES) reduce the incidence of in-stent restenosis (ISR), they delay vascular healing and are associated with a chronic inﬂammatory
response, which involves micro–ribonucleic acids (miRNAs). In pig, mouse, and in vitro models, miR-21 promotes vascular inﬂammation and remodeling after stenting
and may be a therapeutic target to enhance wound healing after vascular injury. BMS ¼ bare-metal stent(s); FACS ¼ ﬂuorescence-activated cell sorting; IL ¼ interleukin;
KO ¼ knockout; LPS ¼ lipopolysaccharide; PDGF ¼ platelet-derived growth factor; RT-PCR ¼ real-time polymerase chain reaction; SMC ¼ smooth muscle cell;
TNF ¼ tumor necrosis factor; WT ¼ wild type.
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1 (M1/M2 markers). These ﬁndings are particularly
relevant in the setting of inﬂammatory vascular dis-
ease because numerous studies suggest that PPAR-g
activation can curtail the inﬂammatory response.
Activation of PPAR-g in human macrophages reduces
matrix metallopeptidase 9 activity and inhibits ex-
pression of IL-1b, IL-6, and tumor necrosis factor-a
(23–25). Furthermore, several groups have reported
that PPAR-g agonists inhibit atherosclerosis devel-
opment and reduce inﬂammatory markers in apoli-
poprotein E KO mice (26,27). Furthermore, miR-21
KO macrophages exhibited a reduced capacity to
secrete proinﬂammatory mediators such as IL-1,
tumor necrosis factor-a, macrophage inﬂammatory
protein-1, IL-6, and IL-12 in response to LPS, a
substance known to stimulate the inﬂammatory
M1 macrophage phenotype. However, a defective
response to LPS does not necessarily mean altered
polarization and may simply reﬂect, for example,
defective CD14 expression. Further phenotyping of
surface receptors from BMDM also showed reduced
expression of CD69 in miR-21 KO mice. A CD69
deﬁciency may contribute to reduced inﬂammatory
cytokine secretion, as previous studies have reported
that CD69 activation mediates numerous inﬂamma-
tory processes such as nitric oxide production and
release of tumor necrosis factor-a from murine
macrophages and T cells (28,29). Thus, loss of miR-21
may accelerate wound healing and resolution of
the inﬂammatory response after vascular injury and
stenting, events that could reduce the incidence of
late stent thrombosis.
It is important to note that we used human arrays
in the porcine samples to identify miRNAs that would
extrapolate to the pathology in the clinical setting. It
is possible that a proportion of miRNAs may be un-
derrepresented due to the sequence variation or
chromosomal locations between pig and human.
We identiﬁed an almost 20-fold up-regulation of miR-
21-3p after stenting with BMS and DES. Our subse-
quent experiments in BMDM demonstrated that both
miR-21-3p and miR-21-5p were up-regulated in
response to LPS, which induces classical macrophage
polarization (M1). In combination with reduced
inﬂammatory cytokine release from miR-21 KO mac-
rophages, these results suggest that miR-21-3p and
miR-21-5p may both play a pathological role in
macrophage activation in response to inﬂammatory
stimuli.
Currently available DES directly target SMC pro-
liferation to prevent neointima formation. We
observed that miR-21 plays a prominent role in SMC
proliferation and migration in response to vascular
injury, consistent with other studies (30,31). Aortic
SMC isolated from miR-21 KO mice had a reduced
capacity to migrate and proliferate in response to
PDGF, an important observation because novel DES
must retain the antiproliferative effect on SMC accu-
mulation to maintain their clinical efﬁcacy. These
ﬁndings are consistent with previous reports
demonstrating that pharmacological or genetic
knockdown of miR-21 reduces SMC proliferation and
neointima formation after balloon injury or vein
grafting (30–33). Several of these reports suggest that
miR-21 mediates a beneﬁcial effect on SMC prolifer-
ation and neointima, at least in part, via inhibition of
phosphatase and tensin homolog.
We also found that the levels of PDCD4 were sup-
pressed after PDGF exposure in WT mice. Impor-
tantly, the levels of PDCD4 were increased in miR-21
KO mice, suggesting that PDCD4 is modulated after
exposure to PDGF and plays a role in SMC prolifera-
tion and migration, effects repressed in miR-21 KO
SMCs. In concordance with these ﬁndings, previous
studies suggest that PDCD4 is down-regulated after
vascular injury, and overexpression of PDCD4 with
adenoviral vectors increases apoptosis and reduces
SMC proliferation (34).
STUDY LIMITATIONS. Although the present study
demonstrates that miR-21 play a prominent role in the
pathology of in-stent restenosis, it is important to
note that these studies are based on data from pre-
clinical animal models of restenosis. Although our
results in miR-21 knockout mice demonstrate that
loss of miR-21 reduces in-stent restenosis and in-
ﬂammatory cell function, it is important to note that
these defects are present before vascular injury, these
deﬁciencies may alter the response to injury in these
mice. In order to demonstrate that these ﬁnding have
efﬁcacy in the clinic, further studies are required to
demonstrate that pharmacological knockdown ofmiR-
21 or miR-21 targets can inhibit neointimal formation
and vessel inﬂammation from current drug-eluting
stent platforms. Furthermore, detailed pharmacoki-
netic proﬁling would be needed to demonstrate an
effect elution proﬁle of antimiR-21 therapy, without
any off-target effect.
CONCLUSIONS
The miR-21 stem loop plays an important role in
SMC and macrophage activation after vascular
injury. Our ﬁndings in the murine model of ISR
revealed that loss of miR-21 attenuates neointima
formation and macrophage activation, resulting in
a less inﬂammatory phenotype. These ﬁndings sug-
gest that miR-21 modulation could enhance wound
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healing and resolve the inﬂammatory response,
effects that could improve the clinical efﬁcacy
of currently available DES. The miR-21 axis warr-
ants further investigation as a therapeutic target in
the setting of stent-induced inﬂammatory vascular
disease. Lineage-restricted knockouts maybe re-
quired to unravel the complex role of miR-21 in this
setting.
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